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ABSTRACT 
In recent years, the adeno-associated virus (AAV) gained considerable 
attention mainly due to the approval of the first AAV-based gene therapy 
treatment in the Western hemisphere in 2012, named Glybera®. It not only 
conveyed the feasibility of utilizing this parvovirus to introduce healthy gene 
copies but simultaneously reinforced further interest in developing more 
specific and efficient synthetic vectors by capsid engineering approaches such 
as DNA family shuffling or random peptide display. However, the 
characterization of lead candidates resulting from these directed evolution 
strategies is labor-intensive and therefore excludes the possibility to validate 
multiple promising variants. 
Therefore, a comprehensive high-throughput capsid validation pipeline 
was established in this work adapting a previously reported approach in 
which a DNA barcode-comprising AAV genome is assigned to a chosen capsid 
variant during virus production. Thus, the identification of the respective 
capsid in the complex physiological environment of living animals is enabled 
by solely detecting the barcode sequence via next generation sequencing. The 
principle was further improved by placing the barcode into the 3’UTR of a 
CMV promoter-driven eyfp transgene permitting tracking on the DNA and 
RNA level. Hence, next to information about transduction efficiency, the 
especially crucial transcriptional activity in a certain tissue was measured. 
Using this design, three barcoded AAV libraries were generated comprising up 
to 157 variants including 12 commonly used serotypes, >70 peptide-displaying 
mutants based on these naturally occurring wild types and several published 
benchmarks such as AAVDJ, AAV9_PHP.B and AAVAnc80L65. After 
intravenously injecting the library into C57BL/6J mice and analyzing the RNA 
and DNA data from >20 collected tissues, prior observations for the literature 
variants could be confirmed thus validating the workflow. Most impressively, 
a peptide display mutant previously created in our laboratory exhibited 
drastically improved efficiencies in the diaphragm, heart and skeletal muscles 
in comparison to AAV9wt on the cDNA and protein level while in addition 
demonstrating pronounced muscle specificity.  
In conclusion, in the course of this PhD thesis a highly robust barcode-based 
capsid screening pipeline was established that facilitates and accelerates the 
identification of promising candidates for gene therapies, best exemplified by 
the discovery of the muscle-tropism of our lead candidate. 
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ZUSAMMENFASSUNG 
In den letzten Jahren erfuhr das Adeno-assoziierte Virus (AAV) viel 
Aufmerksamkeit, insbesondere im Jahr 2012 durch die Zulassung von 
Glybera®, der ersten AAV-basierten Gentherapie in der westlichen 
Hämisphere. Dadurch wurde nicht nur die erfolgreiche Verwendung dieser 
Parvoviren zur Einführung gesunder Genkopien demonstriert, sondern auch 
das Interesse an der Entwicklung spezifischerer und effizienterer Vektoren 
durch Modifizierung des Kapsides verstärkt. Allerdings ist die 
Charakterisierung von einzelnen aussichtsreichen Kandidaten besonders 
arbeitsintensiv, was die Validierung mehrerer Viren erschwert. 
Demzufolge wurde in dieser Arbeit ein umfassendes Hochdurchsatz-
Kapsid-Validierungssystem etabliert, welches einen zuvor beschriebenen 
Ansatz adaptiert, bei dem ein DNA-barcodiertes AAV-Genom während der 
Virusproduktion einem ausgewählten Kapsid zugewiesen wird. Somit wird 
die Identifizierung des jeweiligen Kapsides in der komplexen physiologischen 
Umgebung lebender Tiere ermöglicht, indem lediglich die Barcode-Sequenz 
über Next-Generation Sequenzierung detektiert wird. Durch die Integrierung 
des Barcodes in die 3‘-UTR eines CMV-Promotor-gesteuerten eyfp -Transgens 
wurde der Ansatz weiter verbessert, was eine Detektion auf DNA- und RNA-
Ebene ermöglichte. Neben der Transduktionseffizienz wird dadurch zudem 
die äußerst wichtige Transkriptionsaktivität in einem bestimmten Gewebe 
gemessen. Unter Verwendung dieses Designs wurden drei barcodierte AAV-
Bibliotheken mit bis zu 157 Varianten generiert einschließlich 12 häufig 
verwendeter Serotypen, >70 Peptid-präsentierender Mutanten auf Basis dieser 
natürlich vorkommenden Wildtypen und mehrerer veröffentlichter Viren wie 
AAVDJ, AAV9_PHP.B und AAVAnc80L65. Nach intravenöser Injektion der 
Bibliothek in C57BL/6J-Mäuse und Analyse der RNA- und DNA-Daten von 
>20 isolierten Geweben konnten vorherige Beobachtungen für die 
Literaturvarianten bestätigt werden, wodurch das System validiert wurde. 
Eine Peptid-präsentierende Mutante unseres Labors zeigte eindrucksvoll eine 
drastisch verbesserte Effizienz im Vergleich zu AAV9wt in der Zwerchfell-, 
Herz- und Skelettmuskulatur auf cDNA- und Proteinebene und gleichzeitig 
eine ausgeprägte Muskelspezifität. 
Zusammenfassend wurde im Rahmen dieser Dissertation ein äußerst 
robustes Barcode-basierendes Kapsid-Validierungssystem etabliert, welches 
vielversprechende Kandidaten für Gentherapien identifizieren kann, am 
besten verdeutlicht durch die Entdeckung unseres Muskelkandidaten. 
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 1 INTRODUCTION 
Genetic disorders such as hemophilia, cystic fibrosis and Parkinson’s 
disease pose a serious problem for the affected patients. Unlike other 
reversible, temporary diseases, e.g. many viral or bacterial infections, the 
malfunction manifests itself in the genome of our cells making the search for a 
permanent cure highly challenging. Nevertheless, researchers across the world 
tackled the issue and started to develop treatment strategies commonly 
referred to as gene therapy approaches. These methods aim to alter or 
circumvent the genetic mutation by introducing DNA sequences comprising a 
healthy gene copy or tools required for genome modifications. Various ways to 
penetrate the nonpolar cell membrane were tested for the delivery, and each of 
them showed advantages and disadvantages.  
One possibility is the use of cationic liposomes possessing a positively-
charged head for interaction with the negatively-charged DNA and a 
hydrophobic lipid tail inducing the formation of particles1,2. Liposomes are 
then capable of entering the cells by endocytosis3. The principle of condensing 
the DNA can also be applied when using cationic polymers such as poly-L-
lysine or polyethylenimine4,5. Next to chemical methods, successful DNA 
delivery to various cell types was shown for procedures relying on physical 
mechanisms, e.g. electroporation6,7, sonoporation8–10, gene guns11 and 
hydrodynamic gene transfer12–14. In general, all the aforementioned strategies 
lack efficiency, especially regarding in vivo delivery. This is due to the manifold 
challenges that are faced prior to nuclear transcription, for instance, passing 
the endothelium and cell membrane, escaping the endosome, trafficking 
through the cytoplasm and finally entering the nucleus15–17. The design of 
synthetic delivery tools has to be adapted to overcome these roadblocks that 
hamper overall efficiency.  
Next to nonviral approaches, viruses are nowadays the preferred delivery 
vector since they have already been optimized by nature for successful cell 
infection and processing of their cargo. Notable examples are altered 
retroviruses as they are capable of undergoing reverse transcription and DNA 
integration. Modifications to their genome and the producer cell line were 
made to generate replication-incompetent vectors that display an increased 
safety profile18,19. Gammaretrovirus is a genus in the Retroviridae family and 
was proved to transduce hematopoietic stem cells20,21 and primary T-
lymphocytes22,23. This has eventually led to the approval of an ex vivo stem cell 
gene therapy treatment called Strimvelis®24. The latter is aimed at curing the 
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very rare disease Severe Combined Immunodeficiency due to Adenosine 
Deaminase deficiency which is impairing the development of the immune 
system in children. Another member of the Retroviridae family, the lentivirus, is 
able to carry larger gene cassettes and integrates into coding regions of genes 
in contrast to the gammaretrovirus which is targeting the 5’-untranslated 
region25. The latter poses a greater risk of causing oncogenic mutagenesis in 
respective cells26,27. Hence, lentiviral vectors have increasingly attracted 
considerable attention best exemplified by the development of chimeric 
antigen receptor T-cell therapies (CAR-T). To this end, lentiviruses and, to a 
lesser extent, gammaretroviruses are used to stably express receptors on T cells 
directed against antigens on the surface of cancer cells28–31. One of the most 
studied viral vectors are adenoviruses (Ad) owing to their robust transduction 
profile, especially in the liver. However, gene correction with Ad led to the 
tragic death of an 18-year-old patient after systemic inflammatory response 
syndrome, triggered by the virus itself32. Although further modifications were 
performed helping to target other tissues next to the liver and evading host 
immune system responses33, arguably the most promising virus for gene 
therapy is the adeno-associated virus (AAV). Due to its dependence on a 
helper virus for replication, AAV's safety profile is already naturally 
advantageous and can be further enhanced by omitting the encapsidation of 
wild type AAV genes preventing genome integrations. On top, AAV possesses 
the ability to transduce multiple cell and tissue types, which makes it highly 
interesting for the therapy of many diseases. The first AAV-based treatment, 
Glybera®, developed by uniQure, was approved in 2012 for the European 
market and aimed to restore the rare genetic disease lipoprotein lipase 
deficiency34. Yet, in October 2017, after injecting only one patient, the license of 
Glybera® was not renewed since the treatment expenses per person amount to 
one million euros making the enterprise unprofitable. Nevertheless, uniQure 
has led the way by proving the feasibility of an AAV gene therapy. In 
December 2017, Spark Therapeutics released LUXTURNA™ to treat RPE65 
mutation-associated retinal dystrophy35 and despite the again striking price tag 
of ~$450,000 per eye, a steadily growing number of clinical trials involving 
AAV-based solutions have been registered increasing the chances for the 
approval of treatment options for genetic diseases in the future. 
1.1 ADENO-ASSOCIATED VIRUS (AAV) 
The discovery of the non-enveloped adeno-associated virus dates back over 
50 years to 1965 when it was first described as a contamination of adenovirus 
stocks. The publication of Atchison et al. moreover reported a replication 
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deficiency when adenovirus was absent36. Today the replication dependency of 
AAV on helper viruses such as the already mentioned adenovirus, herpes 
simplex virus37 or human papilloma virus38 is commonly known, justifying the 
assignment of AAV to the dependoparvovirus genus within the Parvoviridae 
family. AAV is one of the smallest known viruses with a capsid diameter of 
only ~22 nm, sterically limiting its genome size to ~4.7 kb. The genome itself 
was identified as single-stranded DNA back in 196939. Important for gene 
therapy applications, AAV is to date considered to be in principle non-
pathogenic, although debatable evidence has been found suggesting AAV 
integration to cause hepatocellular carcinoma40–42. Over the years, hundreds of 
isolates could be identified in various species, and some of them were 
classified as novel serotypes. AAV1 and the very extensively studied AAV2 
were the first to be discovered43 followed by AAV444, AAV545, AAV6 and 
AAV3b46, AAV7 and AAV847, AAV9 and AAVrh1048, AAV1249 and finally 
AAVpo150. Regarding the amino acid sequence of their respective capsid 
proteins, AAV serotypes are largely homologous to each other (Figure 1).  
 
Figure 1: Phylogenetic tree of popular AAV serotypes 
Phylogenetic tree of the respective VP1 amino acid sequences of the primarily used 
serotypes in our laboratory AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, 
AAV9, AAVrh10, AAVpo1 and AAV12. Additional members of the respective groups with 
a common ancestor (clades) are not shown.  
The highest relatedness is observed for the non-human primate isolate 
AAV1 and the human variant AAV6 that vary in only six amino acids (99% 
homology). Two pairs in the phylogenetic tree, AAV4 and AAV12 as well as 
AAV5 and AAVpo1 are substantially more different compared to serotypes 
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from clade A, B, D, E and F (Table 1). The homology of the remaining AAV1, 
AAV2, AAV3b, AAV6, AAV7, AAV8, AAV9 and AAVrh10 is around ~85%. 
Table 1: Homologya of AAV serotypes 
AAV 1 2 3b 4 5 6 7 8 9 rh10 po1 12 
1 100            
2 83 100           
3b 87 88 100          
4 64 61 64 100         
5 59 58 59 53 100        
6 99 83 87 64 59 100       
7 85 82 85 64 59 85 100      
8 84 83 86 64 58 84 88 100     
9 83 82 84 63 57 82 81 85 100    
rh10 85 84 86 64 58 85 89 94 86 100   
po1 59 58 59 53 86 59 59 58 57 57 100  
12 61 60 62 79 53 61 62 62 60 61 52 100 
aDescribes the VP1 homology in %. 
1.1.1 GENOME ORGANIZATION AND TRANSCRIPTOME 
The 4.7 kb-long AAV genome harbors two genes, rep and cap, flanked by 
145 bp-long inverted terminal repeats (ITR) (Figure 2). A palindromic sequence 
within the ITR forms a T-shaped hairpin structure51. Furthermore, the ITR 
contains cis-elements required for replication and packaging of the genome 52. 
Between the 5’ and 3’ ITR, the internal promoters p5 and p19 govern the 
transcription of transcripts coding for Rep78 and Rep68 as well as Rep52 and 
Rep40, respectively53. The resulting proteins are involved in various steps of 
the AAV infection cycle (1.1.3). The third promoter, p40, is driving the 
transcription of mRNAs encoding the three capsid proteins, VP1, VP2, VP3 and 
the assembly-activating protein (AAP)54–56. All primary transcripts utilize the 
same polyadenylation signal downstream of cap and carry an intron positioned 
between rep and cap. The donor site D and the two acceptor sites A1 and A2 
surrounding the intron allow alternative splicing of the Rep and VP mRNAs 
(Figure 2). Unspliced transcripts of the p5 and p19 promoter lead to expression 
of Rep78 and Rep52, respectively. Splicing with either A1 or A2 as an acceptor 
site results in Rep68 for the p5 transcript or Rep40 for the p19 mRNA53. A1-
splicing for p40-driven transcripts enables VP1 expression by using a regular 
AUG start codon. VP2 and VP3 are both encoded on the same A2-spliced 
mRNA but differ in their start codon. VP2 translation starts with the unusual 
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and inefficient ACG codon whereas VP3 utilizes AUG55,57. The discrepancy of 
the start codons and the fact that A1-splicing occurs less frequently than A2-
splicing explains the VP1:VP2:VP3 ratio of 1:1:1058. AAP expression is enabled 
by exploiting an alternative open reading frame (ORF) of cap and the highly 
uncommon initiation codon CUG between VP2 and VP356. The resulting 
protein is required for the formation of the capsid and is currently studied 
extensively56,59–63. 
 
Figure 2: AAV genome organization and transcriptome 
Depicted is the AAV genome with rep and cap genes flanked by ITRs. Promoters (arrows) p5 
and p19 are driving the transcription of mRNAs encoding Rep78/Rep68 and Rep52/Rep40, 
respectively. The mRNA for the capsid proteins VP1, VP2 and VP3 as well as AAP is 
generated by p40 activity. All intron-containing transcripts can be unspliced or spliced 
either with the A1 or A2 acceptor site and the common splice donor (D). Translation of 
capsid proteins is controlled by splicing efficiencies and unconventional start codons in the 
case of VP2 and AAP. On top, AAP is using an alternative open reading frame in cap. 
1.1.2 CAPSID STRUCTURE AND RECEPTORS 
Over the years, the use of X-ray crystallography and cryo-reconstruction 
has led to the identification of the ~3900 kDa large capsid structures of AAV164, 
AAV265,66, AAV3b67, AAV468,69, AAV570, AAV671, AAV772, AAV873 and 
AAV974,75. Comparison of the individual structures revealed that the VP core 
contains an eight-stranded anti-parallel β-barrel motif, βB to βI, as well as an α-
helix, αA (Figure 3A). The loop structures connecting the β-strands, named 
after the flanking β-strands, appear on the surface of the assembled capsid and 
comprise the variable regions, VRI to VRIX69.  
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Figure 3: AAV VP3 and 
capsid structure 
(A) VP3 monomer of AAV1 
with the variable regions VRI 
to VRIX as well as the various 
symmetry axes. The β-barrels 
(βB to βI), the connecting 
loops (DE, HI) and the α-helix 
(αA) form the core of the 
protein. N, N-terminus; C, C-
terminus. (B) Depiction of an 
assembled icosahedral AAV2 
particle comprising 60 
monomeric VPs. Two-, three- 
and five-fold axes are 
indicated. The pore at the five-
fold axis is connecting the 
inside to the outside. The 
three-fold axis shows the 
crucial protrusions for 
receptor binding. Color code 
as in (A). Taken from Tseng 
and Mc-Kenna, 201476. 
Sixty copies of VP proteins finally assemble to form the T = 1 icosahedral 
capsid via two-, three-, and five-fold symmetry-related interactions (Figure 3B). 
These interactions form the typical surface area of the particle with cylindrical 
channels at the five-fold axis surrounded by a depression, protrusions 
enclosing a depression at the three-fold axis and depressions at the two-fold 
axis76. The DE loop, linking βD and βE, forms the cylindrical channel at the 
five-fold axis, which is a pore separating the inside from the outside of the 
capsid. AAV genome-bound Rep proteins can attach to the capsid leading to 
the encapsidation of the DNA strand77. Since VP proteins derive from the same 
ORF, they share a common 534 aa-long C-terminus. However, start codon 
usage and alternative splicing lead to shorter N-termini of VP2 and VP3 as 
compared to VP1, whose additional amino acids encoding a phospholipase A2 
(PLA2) domain required for virus infectivity78 (1.1.3). This unique N-terminus 
as well as the truncated N-terminus of VP2 are involved in forming globules 
inside the capsid79. Upon conformational change, the VP1 N-terminus is 
released through the five-fold axis-channels exposing the PLA2 domain79,80 and 
additional nuclear localization signals (NLS)81. Although VP1 carries important 
domains for infectivity and intra-cellular trafficking, particle formation is 
possible with solely VP182, VP282,83 or VP356,59. To make VP3-only particles, 
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AAP has to be complemented in trans since the VP3-encoding mRNA lacks the 
start codon and first amino acids of AAP56. 
The capsid surface-exposed variable regions differ predominantly between 
the serotypes due to the fact that these areas are not involved in the essential 
core structure of the particle, leaving room for evolutionary adaptation. They 
play a major role in receptor binding and antibody recognition. The former 
was first discovered for AAV2, which is naturally able to interact with heparan 
sulfate proteoglycan (HSPG)84. In general, most AAV serotypes interact with 
glycan structures on the cell surface for primary attachment. HSPG are utilized 
for AAV2, AAV3b and AAV6; N- or O-linked sialic acid (SA) for AAV1, AAV4, 
AAV5 and AAV6; and N-linked galactose for AAV9 (Table 2).  
Table 2: AAV receptors 
Serotype Glycan receptors Additional receptors 
AAV1 α2,3/ α2,6 N-linked SA85,86  AAVR87,  
AAV2 HSPG84 AAVR87, FGFR188, HGFR89, LamR90, 
CD991, integrin92,93 
AAV3b HSPG94 AAVR87, FGFR195, HGFR96, LamR90 
AAV4 α2,3 O-linked SA97 unknown 
AAV5 α2,3 N-linked SA97,98 AAVR87, PDGFR99 
AAV6 α2,3/ α2,6 N-linked SA85, 
HSPG86 
AAVR87, EGFR100 
AAV7 unknown unknown 
AAV8 unknown AAVR87, LamR90 
AAV9 N-linked galactose101,102 AAVR87, LamR90 
AAVrh10 unknown AAVR103 
AAVpo1 unknown unknown 
AAV12 unknown unknown 
Abbreviations: AAV = adeno-associated virus, AAVR = AAV receptor, CD9 = tetraspanin, 
EGFR = epidermal growth factor receptor, FGFR1 = fibroblast growth factor receptor 1, 
HGFR = hepatocyte growth factor receptor, HSPG = heparan sulfate proteoglycan, LamR = 
laminin receptor, PDGFR = platelet-derived growth factor receptor, SA = sialic acid. 
After attaching to the cell, internalization and trafficking are believed to be 
mediated by secondary proteinaceous receptors such as, in the case of AAV2, 
fibroblast growth factor receptor 1 (FGFR1), hepatocyte growth factor receptor 
(HGFR), laminin receptor (LamR), CD9 tetraspanin and αVβ5/α5β1 integrin. 
However, knockout studies for FGRF1 and HGFR demonstrated in several cell 
lines an unconvincing effect of those receptors87 questioning their crucial role 
in this multifactorial procedure. In 2016, one noteworthy publication of Pillay 
et al. caught the attention of the AAV field by reporting the discovery of an 
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essential AAV receptor, consequently called AAVR87. In this work, AAVR 
dependency was shown for AAV1, AAV2, AAV3b, AAV5, AAV6, AAV8 and 
AAV9. A follow-up study could prove AAVR-mediated internalization of even 
more AAVs, including AAVrh10, but revealed receptor independence in the 
case of AAV4 and a closely related AAVrh32.33103, suggesting an alternative 
entry route for these viruses. Interestingly, a viral overlay assay performed in 
another study demonstrated that AAVR and a 150 kDa large glycoprotein, 
originally discovered over 20 years ago104, are identical105. 
Especially relevant for gene therapy applications in humans is that the 
assembled viral AAV particle offers extensive contact areas for neutralizing 
antibody interactions. As mentioned above, the variable regions are crucial for 
receptor binding making an antibody-induced impairment at this position 
particularly disruptive. The antigen-binding fragment (Fab) of the antibodies 
were shown to cover the protrusions surrounding the three-fold axis in AAV1, 
AAV2 and AAV6106 and bind to specific surface epitopes on the capsid107. In 
general, the neutralization can occur prior to or post attachment to cellular 
receptors, in both cases preventing successful transduction. A major problem 
for the use of AAV in gene therapy is the high anti-AAV antibody prevalence 
in humans of 67%, 72%, 40%, 46%, 38% and 47% for AAV1, AAV2, AAV5, 
AAV6, AAV8 and AAV9, respectively108. Hence, the highest antibody 
abundance in our society is observed for AAV2, as further validated by 
analyzing 888 human serum samples from donors around the world109. 
Although the serotypes differ in their respective variable regions, cross-
reactivity has been documented e.g. between AAV2 and AAV3110, and even 
very weakly between AAV1 and AAV5111 that share a low sequence homology 
(59%). The complex antibody-capsid interplay is not only biologically 
interesting but has major implications in clinical trials where appropriate 
solutions, such as generation of immune-evasive capsids, have to be found and 
applied. 
1.1.3 INFECTION CYCLE 
The life cycle of AAV is a multi-step process including virus binding to its 
receptor, internalization, endosomal trafficking, import to the nucleus, genome 
replication and gene expression. The different serotypes possess variable 
interaction partners on the cell surface (Table 2) but the initial membrane 
attachment is typically facilitated by glycan receptor binding. Subsequent 
invagination of the cellular membrane forms a vesicle around the receptor-
bound AAV, a process whose mechanistic details remain elusive. Dependency 
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on dynamin- and clathrin-mediated endocytosis has been described for this 
process112,113. However, drug-induced inhibition of clathrin-coated vesicles 
showed an independency of AAV2 of this particular route, and alternative 
pathways such as the GPI-anchored-protein-enriched endosomal compartment 
as well as the clathrin-independent carriers were suggested instead114. After 
internalization, the AAV particle has to traffic to the nucleus, which was 
demonstrated to be a rate-limiting hurdle for the outcome of the infection115. 
The majority of internalized virions accumulate in the perinuclear region and 
only a fraction ends up in the nucleus after passing through early, late and 
recycling endosomes including the crossing of the Golgi complex and the 
endoplasmic reticulum113,116,117. The confinement in the endosomes is 
eventually circumvented by a pH-induced conformational change in the capsid 
structure of the AAV particle, leading to the translocation of the internal 
VP1/VP2 N-terminal region to the capsid surface79,80. This region comprises the 
PLA2 domain that plays a major role in endosome escape and therefore the 
release of the virus into the cytoplasm78,118. Next to the PLA2 domain, the 
externalized parts of VP1/VP2 additionally contain essential NLS mediating a 
translocation into the nucleus in a still poorly characterized process81,119,120. A 
recent study showed that AAV2 is transported through the nuclear pore 
complex (NPC) indicating yet another physiological barrier that the virus has 
to overcome121 but at the same time implying intact particle transport across 
the NPC. Thus, it is assumed that genome uncoating occurs in the nucleus, 
albeit details of this process remain to be elucidated.  
Once uncoated, the faith of the single-stranded AAV genome is dependent 
on the presence or absence of a helper virus. In the absence of a helper virus, 
the genome preferentially integrates into the AAVS1 locus on chromosome 19 
to establish latency122,123. The region in close proximity to the locus contains 
Rep binding sites (RBS) for the Rep78 and Rep68 proteins which can tether the 
AAV genome to the chromosome by simultaneously interacting with RBS 
motifs in the ITRs124–126. The mechanism of integration is proposed to be non-
homologous end joining (NHEJ) due to weak homology between the AAV 
genome and the AAVS1 locus127. This is further supported by the detection of 
several Rep-interacting DNA repair proteins by pull-down assays128. In the 
presence of a helper virus, the integrated AAV genome is activated to initiate 
replication and transcription. In a first step, the single-stranded AAV genome 
is converted to a double-stranded DNA by utilizing a strand displacement 
mechanism129. Therefore, the partially self-complementary ITR forms a 
secondary structure with an exposed 3’ hydroxyl group serving as a replication 
primer. Next, the host replication machinery is facilitating unidirectional 
synthesis of the complementary strand until reaching the 5’ end of the genome. 
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Subsequent binding of Rep78 and Rep68 to the Rep binding element (RBE) and 
RBS within the 3’ ITR leads to a conformational change and cleavage at the 
terminal resolution site (trs)130. This process is induced by the endonuclease, 
helicase and ATPase enzymatic activities of the Rep proteins and allows the 
replication of the 3’ ITR. Separation of the newly-generated double-stranded 
genome yields two DNA strands with a free 3’ hydroxyl group for further 
iteration. In parallel, the AAV promoters p5 and p19 are activated by the 
helper virus leading to the expression of the Rep proteins Rep78, Rep68, Rep52 
and Rep40 which are fostering replication, expression and, in absence of a 
helper virus, integration. Expression of the essential structural components 
VP1, VP2 and VP3 as well as the assembly-activating protein (AAP) is driven 
by the p40 promoter. With the exception of AAV4 and AAV5, capsid assembly 
of all studied AAV serotypes is dependent on AAP60,61. The detailed 
mechanism of AAP-assisted particle formation is still unclear; however, a role 
as a scaffold or chaperone has been suggested61–63 The encapsidation of one 
single-stranded genome through the five-fold symmetry pore is facilitated by 
the binding of the large Rep proteins to the ITRs and the VPs77,131. The 
translocation is assisted by the helicase domains of the smaller Rep proteins 
Rep52 and Rep40132. Infectious particles are then mostly released from the cell 
upon helper virus-induced cell lysis. 
1.1.4 RECOMBINANT AAVS 
Arguably one of the biggest advantages of AAV is the easy manipulation of 
its genome by replacing rep and cap with foreign DNA, such as a promoter and 
transgene of choice. Despite the size restrictions of ~4.7 kb, AAV leaves 
sufficient room for delivering intact gene copies, transcriptional regulators or 
gene editing tools. The only requirement for the production of such a 
recombinant AAV (rAAV) are cis-acting ITRs flanking the synthetic cargo as 
well as the supply of rep and cap in trans133. This offers the possibility to freely 
select a genome-capsid combination that is best suited for the individual task. 
To mimic an adenovirus infection needed for rAAV particle generation, a 
plasmid containing important adenoviral genes, namely E2A, E4 and VA RNA 
genes, is mandatory134. The fact that viral genes are solely present during virus 
production dramatically enhances the safety profile of rAAV. In contrast to the 
integration capability of rep/cap-bearing AAVs, recombinant vector sequences 
could not be detected in the AAVS1 locus due to the missing Rep proteins135. 
Instead it was demonstrated that the genome persists preferentially 
episomally136, guaranteeing a stable expression over years in mice137, rats138, 
monkeys138,139 and humans140. Although random integration is not fully 
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abolished141, no oncogenic effects could be detected in mice for a recombinant 
AAV2 in an extensive study by Li et al.142. 
Genome engineering led to the development of self-complementary AAV 
vectors (scAAV) with the aim to circumvent the rate-limiting step of the second 
strand generation143,144. A mutation in the trs within the ITR prevents Rep-
induced nicking of the DNA, leading to a double-stranded genome that can 
directly serve as a template for transcription145,146. Initial tests in vitro revealed 
dramatic effects of up to 140-fold increased transduction efficiency147. 
Additionally, superior transduction of muscle and liver tissue was shown in 
vivo145. The downside of these scAAVs is that the already limited packaging 
capacity is cut in half to ~2.2 kb, restricting the design of expression cassettes. 
Solutions to enhance the extent of available genetic information include 
splitting the cis-acting sequence elements in half, to later reunite the two 
fragments by either homologous recombination or RNA splicing148–151. In 
conclusion, the favorable characteristics of single-stranded and self-
complementary rAAV led to the initiation of dozens of clinical trials for 
recessive monogenic disorders over the past decades, further illustrating the 
potential impact of basic AAV biology research for future applications152. 
1.2 CAPSID ENGINEERING 
Although AAV exhibits many advantageous characteristics for successful 
use in gene therapy, concerns persist about insufficient tissue specificity and 
clearance by the host immune system. Due to the simple nature of this virus, 
the exposed capsid epitopes are directly interacting with cellular receptors and 
antibodies, promoting the search for beneficial variations in these regions. To 
address these needs, several approaches exist. For instance, the Wilson group 
is mining for natural AAV isolates in different species and thus assembling a 
comprehenisve collection of novel capsids. However, it has been shown that 
most AAV serotypes preferentially transduce the liver153, leaving room for 
improvement by utilizing technologies for the design of synthetic capsids, 
commonly referred to as capsid engineering.  
One possibility is the introduction of mutations into the cap gene in a 
random fashion by error-prone PCR. It has previously been demonstrated that 
already a single amino acid change can restore defective AAV isolates154, 
providing the rationale to screen libraries consisting of AAV mutants. Perabo et 
al. and, in the following year, Maheshri et al. made use of an AAV2-based 
mutant collection and reported evidence for an improved immune 
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evasion155,156. Since crystal structures exist for most of the commonly used AAV 
serotypes, the approach can be fine-tuned by limiting the random mutagenesis 
to regions which are important for receptor or antibody binding157,158. 
Furthermore, detailed knowledge about particle structures allows rational 
mutagenesis to, for instance, mediate immune evasion or improve capsid 
stability by masking of proteasome-associated tyrosine residues159–164. As an 
example of how beneficial a single point mutation can be, the change of 
phenylalanine to leucine in AAV6 resulted in a capsid termed AAV6.2 that 
showed enhanced transduction of murine lung tissue and human airway 
epithelium165. 
Two studies published in 2015 by the groups of Vandenberghe and Schaffer 
took a highly innovative approach to capsid engineering by aiming to discover 
ancestral AAVs through computational analysis. Both groups phylogenetically 
compared naturally occurring AAV isolates to predict common amino acids of 
putative ancestors. For positions where no clear prediction could be made, a 
library comprising the potential residues was generated and subsequently 
screened in cell lines. The most promising candidates demonstrated increased 
expression in muscle tissue for AAVC7166 and enhanced transduction of liver, 
muscle and retina for AAVAnc80L65167. The latter was studied more 
extensively in follow-up publications illustrating its great potency in the inner 
ear. AAVAnc80L65 was able to transduce all inner hair cells and the majority 
of outer hair cells in an adult murine cochlea168. Additionally, the ancestral 
vector showed a superior GFP expression in comparison to AAV1, AAV2, 
AAV6, AAV8 and AAV9 in organotypic cochlea explants169 and could rescue 
mice with Usher syndrome type 1c170. 
1.2.1 DNA FAMILY SHUFFLING 
In 1994, DNA family shuffling was introduced for the first time171 and 
eventually adapted for the AAV field by Grimm et al. in 2008172 as well as later 
in the same year by the groups of Samulski173 and Schaffer174. The technique 
facilitates the directed evolution of novel synthetic AAV capsids in a high-
throughput manner by exploiting the high homology of over 50% between the 
naturally occurring AAV serotypes (Table 1). In a first step, parental capsid 
genes undergo DNase-mediated fragmentation and subsequent primer-free 
PCR amplification. The ~300 bp-large pieces of the cap genes are capable of 
priming themselves in the elongation reaction, ultimately leading to the 
restoration of a chimeric full-length capsid sequence. Due to the shuffling of 
several parental sequences, the recombination possibilities are virtually 
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unlimited and and vastly exceed the typical library diversities of up to 107 
variants172. Cloning of the chimeric sequences into an ITR- and rep-bearing 
plasmid allows production of the viral library that can then be utilized to 
screen for chimeras with enhanced efficiency or specificity in vivo or in vitro. By 
systematically rescuing AAV genomes by PCR from the cells or organs of 
interest, chimeras with increased capability to selectively transduce these 
targets are favored. Iterative rounds further boost chances to enrich promising 
variants.  
The enormous potential of this approach was demonstrated by the isolation 
of AAVDJ in 2008, a chimera based on AAV2, AAV8 and AAV9, and by its 
high efficiency in the liver and additional cell types172. Subsequent to this work, 
several laboratories expanded the knowledge about the variant by testing its 
application in various tissues as well as by eventually solving its crystal 
structure175–178. Sparked by the success of AAVDJ, numerous groups adopted 
the technique to select novel variants in various tissues179–188. A noteworthy 
example is AAVM41, a chimera isolated after only two selection rounds from 
murine skeletal muscle that exhibits pronounced liver-detargeting as well as 
superior muscle efficiency compared to AAV6189. In 2016, Choudhury et al. 
identified a new capsid that efficiently transduces the central nervous system, 
AAVB1, and that is also more efficient than AAV9 in muscle, pancreas and 
lung190. The Kay group recently published two studies using a xenograft mouse 
model with implanted human hepatocytes for selection of clinically more 
relevant AAV chimeras. The rationale for this approach is the poor 
transduction of human hepatocytes by AAV8, despite its high potency in the 
murine liver. AAVLK03 was presented in the first publication as a promising 
variant for selective targeting of human cells and concurrent detargeting from 
murine hepatocytes191. The same vector was then outperformed in the more 
recent study by their lead candidate AAVNP59, which was 3-fold more 
efficient in human hepatocytes as compared to AAVLK03192. 
1.2.2 PEPTIDE DISPLAY 
Another approach to engineer novel AAV capsids is peptide display, 
whereby small, mostly 7-9 amino acid-long peptides are integrated into 
exposed regions of the VP proteins by modification of the cap gene. Unlike 
DNA family shuffling, this technology is not restricted to the domains 
provided by the naturally occurring serotypes but allows introducing motifs 
that are entirely new in the context of AAV. This was demonstrated for the first 
time in 1999 by inserting an integrin-targeting peptide into different putative 
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loop structures of the AAV2 capsid proteins. One mutant managed to 
successfully infect AAV2-resistant cell lines, proving the feasibility to retarget 
the vector193. Many follow-up studies were carried out afterwards that 
similarly attempted to use peptides previously isolated by phage display to 
increase AAV transduction efficiency in various cell types or tissues (Table 3).  
Table 3: AAV variants generated by rational peptide display 
Target  Serotype Insertiona  Peptide Source 
integrin AAV2 587 AGTFALRGDNPQG 193 
CD13 AAV2 588 NGRAHA 194 
HUVEC AAV2 587 SIGYPLP 195 
integrin AAV2 588 TGCDCRGDCFC 196 
SMC AAV2 587 EYHHYNK 197 
HUVEC AAV2 587 SMTPFPTSNEANLGGGS 198 
Brain AAV2 587 QPEHSST 199 
Lung AAV2 587 VNTANST 199 
MT1-MMP AAV2 587 CNHRYMQMC 200 
Muscle AAV2 587 TGASSLNIAGLS 201 
Astrocytes AAV9 588 GRGDLGLSA 202 
aInsertion describes the amino acid position after which the peptide was inserted. 
Abbreviations: AAV = adeno-associated virus, CD13 = alanyl aminopeptidase, HUVEC = 
human umbilical vein endothelial cell, MT1-MMP = membrane type 1 metalloprotease, SMC 
= vascular smooth muscle cell. 
The altered behavior of these viruses is thought to be explained by the 
disruption of the HSPG motif203,204. A peptide insertion into position 587 or 588 
of the AAV2 capsid protein is separating the essential arginines 585 and 588, 
which typically results in HSPG binding-deficient variants. Hence, detargeted 
vectors are subsequently able to utilize alternative pathways for cellular entry. 
In most cases, rationally designed variants possess limited chances to excel in 
specificity or efficiency, since the pre-selected peptides face different steric 
constraints when incorporated, for the first time, into AAV particles. Similarly, 
this was even shown for peptides selected in the context of AAV2 when 
displayed on AAV8 and AAV9205. To allow a peptide selection directly in the 
context of AAV, Perabo et al. and Müller et al. constructed random peptide 
display libraries to screen for promising peptide motifs by directed 
evolution206,207. Following the same principle as for DNA family shuffling 
(1.2.1), iterative selection rounds in the tissue or cells of interest favor 
candidates with peptide-induced transduction benefits. To monitor the 
enrichment of certain amino acid configurations, next-generation sequencing 
of the unselected and final library can nowadays be performed208. Since 2003, 
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numerous groups have adopted this technique and isolated novel, mainly 
AAV2-based vectors (Table 4). 
Table 4: AAV variants generated by random peptide display 
Target  Serotype Insertiona  Peptide Source 
Mec1 AAV2 587 AAAGENQARSAA 206 
M-07e AAV2 587 AAARGDAVGVAA 206 
HCAEC AAV2 588 GNDVRAVSA 207 
HCAEC AAV2 588 GNSSRDLGA 207 
Calu6 AAV2 588 GVTAGRAPA 209 
PC3 AAV2 588 GDLSNLTRA 209 
HSaVEC AAV2 588 GNDVRSANA 209 
HSaVEC AAV2 588 GNDVRAVSA 209 
Kasumi-1 AAV2 588 GNQVGSWSA 210 
K562 AAV2 588 GEARVRPPA 211 
CD34+ PBPC AAV2 588 GNRTWEQQA 212 
Lung AAVDJ 588 GMVNNFEWA 172 
Lung AAVDJ 588 GNSSRDLGA 172 
PymT AAV2 588 GESGLSQSA 213 
PymT AAV2 588 GDLGSARAA 213 
Lung AAV2 588 GPRSTSDPA 213 
PymT AAV2 588 GRGDLGLSA 213 
Heart AAV2 588 GVNSTRLPA 214 
HCAEC AAV9 589 GSLRSPPSA 215 
HCAEC AAV9 589 GRGDLRVSA 215 
Retina AAV2 587 LALGETTRPA 186 
Keratinocytes AAV2 587 AAAPRGDLAPAA 216 
Retina AAV8 586 unknown 217 
Lung AAV2 588 GESGHGYFA 208 
Brain AAV2 588 GNRGTEWDA 218 
Brain AAV9 588 TLAVPFK 219 
Brain AAV9 588 YTLSQGW 219 
Brain AAV9 588 QAVRTSL 220 
aInsertion describes the amino acid position after which the peptide was inserted. 
Abbreviations: AAV = adeno-associated virus, Calu6 = mouse lung carcinoma cell line, 
CD34+ PBPC = primary human CD34-positive peripheral blood progenitor cells, HCAEC = 
human coronary artery endothelial cells, K562 = human myelogenous leukemia cell line, 
Kasumi-1 = human acute myeloid leukemia cell line, M-07e = human acute 
megakaryoblastic leukemia cell line, Mec1 = human B-cell chronic lymphocytic leukemia cell 
line, PC3 = human prostate carcinoma cell line, PymT = polyoma middle T antigen-induced 
breast cancer cells. 
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Of note, Grimm et al. made use of their newly-discovered AAVDJ as 
backbone for peptide insertions instead of the less efficient (in vivo) AAV2 in 
order to target the lung172. Varadi and colleagues likewise replaced AAV2 by 
the highly potent AAV9 and succeeded at improving its efficiency in 
endothelial cells by 40-fold when using a GSLRSPPSA or GRGDLRVSA 
peptide215. In 2016, two publications proved that AAV2 still remains a vital 
serotype for directed capsid evolution by random peptide display. The most 
promising peptide in the respective screenings, that has been isolated after five 
selection rounds, dramatically changed the tropism of the parental virus to the 
lung208 and the brain218, indicating a bigger influence of the peptide itself 
compared to the serotype. The findings reported in another 2016 study caught 
particular attention of many in the AAV field. Deverman et al. established a 
novel random peptide screening pipeline by using a Cre recombinase-
transgenic mice strain specifically driving transgene expression of loxP site-
comprising AAV genomes in astrocytes. The isolated lead candidate was able 
to robustly transduce the brain of C57BL/6J mice with superior efficiency as 
compared to the benchmark AAV9219. One year later, a slightly modified 
version of the peptide proved to further enhance the efficiency in the brain220. 
In conclusion, in peptide display, only little changes are made to the cap 
gene in contrast to the broader alterions caused by DNA family shuffling. 
Nevertheless, the observation that even these subtle modifications can result in 
significant retargeting also make this technology highly interesting for the 
development of tailored AAV vectors. 
1.3 BARCODED AAVS 
Synthetic AAV vectors isolated from capsid selection strategies such as 
mutagenesis, DNA family shuffling or peptide display exemplify the 
enormous potency of these techniques to enhance efficiency and specificity. 
However, even after several selection rounds in the target tissue or cell, 
hundreds or thousands of interesting candidates often remain and, complicate 
the final decision for a single variant. Illumina or PacBio221 next generation 
sequencing nowadays facilitate this choice by offering the possibility to 
monitor the enrichment of certain favorable patterns. Based on this 
information, few lead candidates are usually selected and validated by 
individually testing them in the target of interest. Ideally, such validation 
experiments include essential benchmarks from the literature as controls 
concurrently increasing the required time, costs and amounts of animals.  
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A solution for these issues was presented by Adachi et al. in 2014 who 
introduced a barcode-based parallel screening system for novel AAV 
variants222. To this end, DNA barcodes were integrated into the AAV genome 
after the rep and cap genes enabling a tracking of the cognate capsids in vivo by 
detecting the capsid-assigned barcodes in the tissues. A screening of such 
barcoded AAV libraries dramatically cuts down animal numbers and 
downstream processing of massive sample amounts, while permitting a 
concurrent head-to-head comparison of all candidates in the same organism. 
By utilizing this approach, the group could identify amino acids in the AAV 
capsid that are important for receptor binding, tropism and neutralization. 
Later that year, Marsic and colleagues published a highly similar strategy that 
deviated in the construct design. Rather than incorporating the barcode into a 
wild type genome, it was placed into a recombinant AAV comprising a 
ubiquitously-expressing CBA promoter driving a luciferase and mApple 
reporter gene223. Next to the sequencing-based tracking of the barcode and thus 
capsid, this allows a simultaneous detection of the bioluminescence and 
fluorescence as functional readouts. The power of this adapted technique was 
exemplified in a separate paper in 2015 by the same group224. Moreover, the 
Björklund group presented a high-throughput approach where a collection of 
random barcode sequences can be linked to a plasmid library consisting of cis-
regulatory elements (CRE). Ultimately, this generates libraries with several 
million unique barcodes placed in the 3’UTR of the gene cassette, therefore also 
permitting tracking of the viral transcripts. By sequencing the initial library, a 
link between the barcode sequence (unknown until this point) and the CRE can 
be established, facilitating subsequent identification in the tissues225. 
1.4 AIM OF THE THESIS 
The aim of this work was to establish a pipeline for the parallel in vivo 
screening of novel pre-selected capsid variants in a high-throughput manner, 
by exploiting barcode-based tracking of the individual candidates in mice. 
Based on the knowledge provided by the literature (chapter 1.3) the barcode 
was placed into the 3’UTR of a reporter cassette enabling concomitant 
detection of the capsid on the cDNA and DNA level. Furthermore, the goal 
was to set up a comprehensive normalization strategy for the next generation 
sequencing data, to quantitatively and simultaneously characterize capsid 
behavior in terms of specificity and efficiency. The collection of variants to be 
screened comprised over 70 novel peptide-modified derivatives of natural 
AAV isolates that had already been studied extensively in our group in vitro. 
Exposing these capsids to the complex physiological environment of living 
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animals would ideally identify tissue-tropic or highly active vectors for 
potential use in clinical applications. Importantly, to improve the stringency of 
this screening and the results, the most popular benchmarks from the literature 
were included, such as AAVDJ, AAVLK03, AAVAnc80L65 and many others. 
This promised the possibilities to not only validate the pipeline by reproducing 
published results, but to potentially also identify and characterize superior 
candidates from our own pool. 
 
 2 MATERIALS 
2.1 LABORATORY EQUIPMENT 
Table 5: Laboratory equipment 
Name Vendor 
4K15C Merck KGaA 
Accu-jet® pro BRAND GmbH & Co. KG 
Allegra X-12 Beckman Coulter 
Aqualine AL 12 LAUDA 
Aqualine AL 5 LAUDA 
Avanti J-26 XP Beckman Coulter 
Axio Imager.A2 Carl Zeiss AG 
Axio Scan.Z1 Carl Zeiss AG 
Axiocam 503 color Carl Zeiss AG 
Basic Meter PB-11 Sartorius AG 
CanoScan LiDE 70 Canon Inc. 
Captair bio erlab 
CE Module Bio-Rad Laboratories, Inc. 
Centrifuge 5415R Eppendorf AG 
Centrifuge 5417R Eppendorf AG 
Centrifuge 5424R Eppendorf AG 
Centrifuge 5430R Eppendorf AG 
Centrifuge 5810R Eppendorf AG 
CKX41SF Olympus Corporation 
Countess Invitrogen AG 
Cryostar™ NX70 Thermo Fisher Scientific 
Cytation 5 imaging reader BioTek Instruments, Inc. 
Cytomics FC 500 MPL Beckman Coulter 
E1-ClipTip 12.5, 200, 300, 1250 Thermo Fisher Scientific 
E835 Consort 
E-H2 Febikon Labortechnik GmbH 
epMotion® 96 Eppendorf AG 
FlexCycler Analytik Jena AG 
Forma -86 °C ULT Freezer Thermo Fisher Scientific 
Fragment Analyzer™ Advanced Analytical Technologies, Inc. 
Function Line Thermo Fisher Scientific 
Galaxy MiniStar VWR International 
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Gel Doc XR Bio-Rad Laboratories, Inc 
GenePulser Xcell™ Bio-Rad Laboratories, Inc. 
HB-202 Biozym Scientific GmbH 
HERAcell 150 Thermo Fisher Scientific 
HERAsafe KS12 Thermo Fisher Scientific 
HXP 120V Carl Zeiss AG 
KB 650-2NM KERN & SOHN GmbH 
MagMAX™ Express 96 Thermo Fisher Scientific 
Mastercycler Eppendorf AG 
Mastercycler gradient Eppendorf AG 
Mastercycler pro S Eppendorf AG 
MF 22 Scotsman 
Microlab STAR Hamilton Robotics GmbH 
Microwave oven Sharp Electronics 
Mixing Block MB-102 BIOER Technology 
MPS C1000 Labnet International, Inc. 
MSH basic yellow line IKA-WERKE GmbH &Co. KG 
Multitron INFORS-HT 
NANODROP 2000 Thermo Fisher Scientific 
NextSeq™ 500 Illumina, Inc. 
Optima L-90K Ultracentrifuge Beckman Coulter 
Owl EasyCast B1 Thermo Fisher Scientific 
P2, P10, P20, P200, P1000 Gilson, Inc. 
P93D Mitsubishi Electric Corporation 
PC Module Bio-Rad Laboratories, Inc. 
PCR Plate Spinner VWR International 
peqSTAR 96 Universal VWR International 
Precellys 24-Dual Bertin Instruments 
Premium Freezer -20 °C Liebherr-International AG 
Premium Fridge 4 °C Liebherr-International AG 
QuantStudio™ 6 Flex Real-Time 
PCR System 
Thermo Fisher Scientific 
Refractometer Model RMI Exacta + Optech 
RG-6000 Corbett Research 
Rotor 70.1TI Beckman Coulter 
Rotor 70TI Beckman Coulter 
Shaker DOS-10L neoLab Migge GmbH 
Sonorex Super RK31 BANDELIN electronic GmbH & Co. KG 
Sprout Mini Centrifuge Heathrow Scientific 
StepOnePlus Applied Biosystems 
Synergy™ HT BioTek Instruments, Inc. 
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Tube Sealer 342428 Beckman Coulter 
TW12 water bath Julabo GmbH 
Ultraviolet Sterilizing PCR 
Workstation 
VWR International 
U-RFL-T Olympus Corporation 
UST-30M-8E Biostep GmbH 
UVT-S-AR Grant Instruments 
Vac-Man® Promega GmbH 
Veriti 96 Well Thermal Cycler Thermo Fisher Scientific 
Vortex-Genie 2 Scientific Industries, Inc. 
2.2 LABORATORY MATERIAL 
Table 6: Laboratory material 
Name Vendor Catalog# 
0.2ml 8-Strip PCR Tube STARLAB International 
GmbH 
I1402-2900 
0.2ml 8-Strip PCR Tube STARLAB International 
GmbH 
A1402-3700 
1.5 ml tube STARLAB International 
GmbH 
E1415-2230 
500ml Centrifuge Tube Corning, Inc. 431123 
5PRIME Phase Lock Gel Quantabio 2302830 
96 Well Cell Culture Plate Greiner Bio One 655180 
Amicon Ultra-15 Merck KGaA UFC910008 
Biosphere® Fil. Tip 10 µl Sarstedt AG & Co. KG 70.1130.210 
Biosphere® Fil. Tip 100 µl Sarstedt AG & Co. KG 70.760.212 
Biosphere® Fil. Tip 1000 µl Sarstedt AG & Co. KG 70.762.211 
Biosphere® Fil. Tip 20 µl Sarstedt AG & Co. KG 70.760.213 
Biosphere® Fil. Tip 200 µl Sarstedt AG & Co. KG 70.760.211 
Cell Culture Flask 550 ml Greiner Bio One 660175 
Cell lifter Corning, Inc. CLS3008 
CELLSTAR® 15 ml Greiner Bio One 188271 
Centricon Plus-70 Merck KGaA UFC710008 
CK28 2 ml Bertin Instruments P000911-LYSK0-A 
CK28 7 ml Bertin Instruments P000935-LYSK0-A 
Combitips advanced® 0.5 ml Eppendorf AG 0030089421 
Combitips advanced® 1.0 ml Eppendorf AG 0030089430 
Combitips advanced® 10 ml Eppendorf AG 00300089464 
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Combitips advanced® 2.5 ml Eppendorf AG 0030089448 
Combitips advanced® 5.0 ml Eppendorf AG 0030089456 
Costar Stripette 25 ml Corning, Inc. CLS4489 
Costar Stripette 50 ml Corning, Inc. CLS4490 
Countess™ cell counting 
chamber slides 
Thermo Fisher Scientific C10283 
Disposable Scalpel FEATHER Safety Razor 
Co., Ltd. 
02.001.30.010 
Easystrainer 70 µm Greiner Bio One 
International GmbH 
542070 
Electroporation cuvettes Biozym Biotech Trading 
GmbH 
748050 
Falcon™ 50 ml Corning, Inc. 352070 
Inoculation Loop Greiner Bio One 731170 
Luer-Lok™ 3ml Syringe BD Biosciences 309658 
Luer-Lok™ 5ml Syringe BD Biosciences 309649 
Micro tube 0.5ml Sarstedt AG & Co. KG 72.699 
Micro tube 1.5ml Sarstedt AG & Co. KG 72.690.001 
Micro-Fine™ + Demi BD Biosciences 324826 
Microlance 3™ BD Biosciences 301500 
Nunclon™ Delta Surface Thermo Fisher Scientific 168381 
Optiseal Polypropylene 
Centrifuge Tubes 
Beckman Coulter 361625 
Pasteur pipette BRAND GmbH & Co. 
KG 
747720 
Petri Dish Greiner Bio One 633180 
Pierce Protein Concentrator Thermo Fisher Scientific 88537 
Pipette 10 ml Greiner Bio One 607180 
Pipette 5 ml Sarstedt AG & Co. KG 86.1253.001 
Pipette Tips 10-200 µl Greiner Bio One 739290 
Pipette Tips 200-1000 µl Greiner Bio One 740290 
QiaShredder Qiagen N.V. 79654 
Quali-Pipette tips 10 µl Kisker Biotech GmbH & 
Co. KG 
GC.TIPS.B 
Quick-Seal Centrifuge Tubes Beckman Coulter Z51218SCA 
Re-Seal™ Polyallomer 
Centrifuge Tubes 
Seton Scientific Corp. 9041 
SafeSeal micro tube 2ml Sarstedt AG & Co. KG 72.695.500 
SafeSeal tube 1.5ml Sarstedt AG & Co. KG 72.706 
Slyde-A-Lyzer™ G2 Dialyse 
Cassettes 
Thermo Fisher Scientific 87736 
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Strip Tubes and Caps, 0.1 ml Qiagen N.V. 981103 
Superfrost Ultra Plus® Thermo Fisher Scientific J4800AMNZ 
TissueTek® Cryomold® Sakura Finetek Europe 
B.V. KvK 
4557 
VacConnectors Qiagen N.V. 19407 
2.3 CHEMICALS 
Table 7: Chemicals 
Name Vendor Catalog# 
Acetic acid Merck KGaA 33209 
Adenosine triphosphate (ATP) Merck KGaA A2383 
Agarose Biozym Biotech Trading GmbH 840004 
Ampicillin Carl Roth GmbH + Co. KG K029.2 
Aqua ad injectabilia B. Braun Melsungen AG - 
Bacto™ agar BD Biosciences 214010 
Bacto™ tryptone BD Biosciences 211705 
Bacto™ yeast extract BD Biosciences 212750 
Bovine serum albumin (BSA) Carl Roth GmbH + Co. KG 8076 
Calcium chloride (CaCl2) Carl Roth GmbH + Co. KG HN04.3 
Cesium chloride (CsCl2) Carl Roth GmbH + Co. KG 8627.2 
DEPC-Treated Water Thermo Fisher Scientific AM9916 
Dimethyl sulfoxide (DMSO) Thermo Fisher Scientific F515 
Disodium phosphate 
(Na2HPO4) 
AppliChem GmbH A3567 
Dithiothreitol (DTT) Thermo Fisher Scientific 15508013 
Ethanol (EtOH) VWR International 20821-330 
Ethidium bromide Merck KGaA E1510 
Ethylenediaminetetraacetic 
acid 0.1 M (EDTA) 
Honeywell International Inc. 34550 
Glucose Merck KGaA 1.08342 
Glycerol VWR International 24388.260 
HEPES AppliChem GmbH A3268 
Hydrochloric acid (HCl) Merck KGaA 35328 
Isopropanol Different manufacturer - 
Magnesium chloride (MgCl2) AppliChem GmbH A3618 
Magnesium sulfate (MgSO4) Merck KGaA 1.05886 
Monopotassium phosphate 
(KH2PO4) 
AppliChem GmbH A3620 
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Nuclease-Free Water Qiagen N.V. 1039498 
OptiPrep™ PROGEN Biotechnik GmbH 1114542 
Phenol red Merck KGaA 1.07241 
Polyethylene glycol (PEG) Merck KGaA 81260 
Polyethylenimine (PEI) Polysciences, Inc. 23966-2 
Potassium chloride (KCl) AppliChem GmbH A3582 
Sodium chloride (NaCl) Merck KGaA 31434 
Sodium hydroxide (NaOH) Merck KGaA 35256 
Sucrose Carl Roth GmbH + Co. KG 4661 
TRIS Carl Roth GmbH + Co. KG 4855.2 
TWEEN®20 Merck KGaA P9416 
β-Mercaptoethanol (β-ME) Merck KGaA M3148 
2.4 BUFFERS AND SOLUTIONS 
Table 8: Commercial buffers and solutions 
Name Vendor Catalog# 
1 Kb Plus DNA Ladder Thermo Fisher Scientific 10787018 
Agencourt AMPure XP Beckman Coulter A63882 
Agencourt RNAClean XP Beckman Coulter A63987 
Buffer RLT Qiagen N.V 79216 
CD11b MicroBeads Miltenyi Biotec 130-049-601 
CD11c MicroBeads 
UltraPure 
Miltenyi Biotec 130-108-338 
CD19 MicroBeads Miltenyi Biotec 130-052-201 
CD3ε MicroBead Kit Miltenyi Biotec 130-094-973 
Chloroform:Isoamyl alcohol Merck KGaA 25666 
CutSmart® Buffer New England Biolabs B7204S 
DPBS Thermo Fisher Scientific 14190 
DMEM Thermo Fisher Scientific 61965 
dNTP Mix Thermo Fisher Scientific R0193 
Fetal bovine serum Merck KGaA F7524 
GAPDH Primer/Probe Mix 
(60X) 
Thermo Fisher Scientific Mm00186825_cn 
Gel loading dye Purple (6X) New England Biolabs B7024S 
Illumina Resuspension 
Buffer 
Illumina, Inc. 15026770 
NEBuffer 2 New England Biolabs B7002S 
Penicillin-Streptomycin Thermo Fisher Scientific 15140-122 
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Phenol-chloroform-isoamyl 
alcohol mixture 
Merck KGaA 77617 
Phusion HF buffer (5X) Thermo Fisher Scientific F518L 
POLR2A Primer/Probe Mix 
(20X) 
Thermo Fisher Scientific Mm00839502_m1 
ProLong™ Gold antifade 
reagent with DAPI 
Thermo Fisher Scientific P36935 
Red Blood Cell Lysis 
Solution 
Miltenyi Biotec 130-094-183 
RNAlater Qiagen N.V 76106 
RPMI Thermo Fisher Scientific 61870 
T4 DNA Ligase Reaction 
buffer 
New England Biolabs B0202S 
Tango Buffer (10X) Thermo Fisher Scientific BY5 
TE Buffer Thermo Fisher Scientific 12090015 
TissueTek® O.C.T 
Compound 
Sakura Finetek Europe 
B.V. KvK 
4583 
Trypan Blue stain 0.4% Thermo Fisher Scientific T10282 
Trypsin-EDTA (0.25%) Thermo Fisher Scientific 25200-056 
4% PFA Solution in PBS Booster Biological 
Technology 
AR1068 
 
Table 9: Self-made buffers and solutions 
Name Composition  
15% Iodixanol 25% (v/v) OptiPrep™ 
 75% (v/v) PBS-MK-NaCl 
25% Iodixanol 41.56% (v/v) OptiPrep™ 
 58.19% (v/v) PBS-MK 
 0.25% (v/v) Phenol red stock solution 
40% Iodixanol 66.67% (v/v) OptiPrep™ 
 33.33% (v/v) PBS-MK 
60% Iodixanol 99.75% (v/v) OptiPrep™ 
 0.25% (v/v) Phenol red stock solution 
Benzonase Buffer 150 mM NaCl 
 50 mM TRIS-HCl (pH 8.5) 
 2 mM MgCl2 
Lysogeny broth (LB) agar 1.5% (w/v) Bacto™ agar 
 1% (w/v) NaCl 
 1% (w/v) Bacto™ tryptone 
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 0.5% (w/v) Bacto™ yeast extract 
Lysogeny broth (LB) media 1% (w/v) NaCl 
 1% (w/v) Bacto™ tryptone 
 0.5% (w/v) Bacto™ yeast extract 
MACS buffer (pH 7.2) solvent PBS (1X) 
 0.5% (w/v) BSA 
 2 mM EDTA 
Na-HEPES resuspension buffer 150 mM NaCl 
 50 mM HEPES 
 25 mM EDTA 
PBS (1X) 137 mM NaCl 
 10 mM Na2HPO4 
 3 mM KCl 
 2 mM KH2PO4 
PBS-MK solvent PBS (1X) 
 2.5 mM KCl 
 1 mM MgCl2 
PBS-MK-NaCl solvent PBS-MK 
 1 M NaCl 
PEG-NaCl solution 40% (w/v) PEG 
 1.915 M NaCl 
Phenol red stock solution 0.5% Phenol red 
SOB media 2% (w/v) Bacto™ tryptone 
 0.5% (w/v) Bacto™ yeast extract 
 0.05% (w/v) NaCl 
 10 mM MgSO4 
 10 mM MgCl2 
 2.5 mM KCl 
SOC media solvent SOB media 
 20 mM Glucose 
Sucrose solution (30%) solvent DPBS 
 30% (w/v) Sucrose 
TAE Buffer 5.71% (v/v) Acetic acid 
 2 M TRIS 
 50 mM EDTA 
Topping solution solvent Na-HEPES resuspension 
buffer 
 3.27 M CsCl (0.55 g/ml) 
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2.5 ENZYMES 
Table 10: Enzymes 
Name Vendor Catalog# 
Antarctic Phosphatase New England Biolabs M0289S 
Benzonase Merck KGaA 1.01695.0001 
BsaI-HF New England Biolabs R3535S 
ClaI New England Biolabs R0197S 
Esp3I Thermo Fisher Scientific ER0451 
HindIII-HF New England Biolabs R3104S 
NotI-HF New England Biolabs R3189S 
NsiI New England Biolabs R0127S 
OneTaq® Quick-Load MM New England Biolabs M0486S 
Phusion Polymerase HF Thermo Fisher Scientific F530L 
Phusion Polymerase HS Thermo Fisher Scientific F549L 
PstI-HF New England Biolabs R3140S 
QuantiFast PCR Master Mix Qiagen N.V. 1044234 
SfiI New England Biolabs R0123S 
SpeI New England Biolabs R0133S 
T4 DNA Ligase New England Biolabs M202L 
XmaI New England Biolabs R0180S 
XmnI New England Biolabs R0194S 
2.6 KITS 
Table 11: Kits 
Name Vendor Catalog# 
Allprep DNA/RNA 96 Kit Qiagen N.V 80311 
DNA Clean & Concentrator™ Zymo Research D4013 
High-Capacity cDNA Reverse 
Transcription Kit 
Thermo Fisher Scientific 4368813 
MinElute PCR Purification Kit Qiagen N.V. 28006 
NextSeq 500/550 High Output 
Kit v2 (75 cycles) 
Illumina, Inc. FC-404-2005 
NucleoBond® Xtra Maxi Macherey-Nagel GmbH & 
Co. KG 
740414.100 
NucleoSpin Plasmid Miniprep 
Kit 
Macherey-Nagel GmbH & 
Co. KG 
740588.250 
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Ovation Low Complexity 
Sequencing System 
NuGEN Technologies, Inc. 9092-256 
Pure Yield Plasmid Midiprep 
System 
Promega GmbH A2495 
PureLink HiPure Plasmid 
Gigaprep Kit 
Thermo Fisher Scientific K210009 
Qiaprep Spin Miniprep Kit Qiagen N.V. 27106 
QIAquick Gel Extraction Kit Qiagen N.V 28706 
QIAquick PCR Purification Kit Qiagen N.V 28104 
Quant-iT™ PicoGreen™ 
dsDNA Assay Kit 
Thermo Fisher Scientific P7589 
RNase-free DNase Set Qiagen N.V 79254 
SensiMix™ II Probe Kit Bioline Bio-83020 
Standard Sensitivity NGS 
Fragment Analysis Kit 
Advanced Analytical 
Technologies, Inc. 
DNF-473 
TOPO™ TA Cloning™ Kit Thermo Fisher Scientific 450641 
2.7 LABORATORY ANIMALS 
The inbred strain C57BL/6J (Janvier Labs) was used for in vivo experiments. 
Mice were kept and handled in accordance with the animal proposal G-126/14 
and G-89/16. 
2.8 BACTERIAL STRAINS 
Table 12: Bacterial strains 
Name Vendor Catalog# 
5-alpha Competent E.coli New England Biolabs C2987H 
MAX Efficiency™ DH5α™ 
Competent Cells 
Thermo Fisher Scientific 18258012 
MegaX DH10B™ T1R 
Electrocomp™ Cells 
Thermo Fisher Scientific C640003 
One Shot® ccdB Survival™ 2 T1R 
Competent Cells 
Thermo Fisher Scientific A10460 
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2.9 DNA  
2.9.1 PEPTIDE OLIGONUCLEOTIDES 
Oligonucleotides listed in Table 13 were used for oligonucleotide annealing 
and subsequent peptide insertion cloning (3.2.2). Lowercase letters indicate 
overhangs. 
Table 13: Peptide oligonucleotides 
Name Sequence (5’ to 3’) 
A1_fw AGGCATGCCATTAGGAGCGGCAGGCGCCCagg 
A1_rev GGGCGCCTGCCGCTCCTAATGGCATGCCTctc 
A2_fw AGGCAACTACTCCAGAGGAGTGGACGCCCagg 
A2_rev GGGCGTCCACTCCTCTGGAGTAGTTGCCTctc 
A6_fw AGGCAACGAGGCGCGGGTCCGGGAGGCCCagg 
A6_rev GGGCCTCCCGGACCCGCGCCTCGTTGCCTctc 
BR1_fw AGGCAATAGGGGGACGGAGTGGGACGCCCagg 
BR1_rev GGGCGTCCCACTCCGTCCCCCTATTGCCTctc 
L1_fw AGGCGAGTCAGGACATGGATATTTTGCCCagg 
L1_rev GGGCAAAATATCCATGTCCTGACTCGCCTctc 
P2_fw TGGCTGCGATTGCCGCGGCGATTGCTTTTGCGCCCagg 
P2_rev GGGCGCAAAAGCAATCGCCGCGGCAATCGCAGCCActc 
P4_fw TGGCAACGATGTGCGCAGCGCGAACGCCCagg 
P4_rev GGGCGTTCGCGCTGCGCACATCGTTGCCActc 
P5_fw TGGCAACGATGTGCGCGCGGTGAGCGCCCagg 
P5_rev GGGCGCTCACCGCGCGCACATCGTTGCCActc 
2.9.2 OLIGONUCLEOTIDES 
Table 14 shows the oligonucleotides which were used for overlap extension 
PCR, sequencing, golden gate cloning and regular PCR. Uppercase letters 
indicate binding regions, lowercase letters visualize overhangs. Restriction 
digest sites are marked by an underscore. 
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Table 14: Oligonucleotides 
Name Sequence (5’ to 3’) 
#1310_AAV cap 4 
correct pos.1630 fw 
CTTTGCGGGGCCTAAACAGAACGGCAAC 
#1311_AAV cap 4 
correct pos.1630 rev 
GTTGCCGTTCTGTTTAGGCCCCGCAAAG 
#1318_Rep2 rev 
primer pos. 1827 
TCATCCAAATCCACATTGAC 
#1319_Rep2 rev 
primer pos. 944 
CGTGGCCCATCCCAGAAAG 
#1424_M13 Rev CAGGAAACAGCTATGAC 
#178_DJrev (real) GTCGCAAAACACTCACGTGACCTC 
#36_Pos680For13689 GAAATTGGCATTGCGATTCC 
#37_Pos682For45 GATTGGCATTGCGATTCCAC 
#412_CMV rv ccgttaattaaGGCTGGATCGGTCCCGGTGTCTTC 
#651_13_eGFPrev TCCTCCTTGAAGTCGATGC 
#652_14_eGFPfw ATCTTCTTCAAGGACGACG 
#653_15-
CMVrevCTR 
TTGATGTACTGCCAAGTGG 
#678_pos. 1990 Amp 
Rev 
GCCTCACTGATTAAGCATTGG 
#679_pos. 1205 rep 
Rev 
GCCTATGGAAAAACGCCAGCAAC 
#680_E4 Rev pos. 
35156 Ad 2 
CCTGTTGTAAGACAGGCTTC 
#682_E2A-1 Rev pos. 
22320 
GGCTGCGGAAGTAGGGCGAG 
#683_E2A-2 pos. 
26966 
CAAAGCAGGGGCCAAGAAC 
#684_E2A-3 For CCAACTCCATGCTTAACAGTC 
#685_E2A-end For GAAGATTTGAGGAAGTTGTGG 
#686_Rep upstr. GAGTTTGATTAAGGTACGGTG 
#688_E4-3 Rev CAGTTTGCCTTTTGGAAGCC 
#703_E2A-4 For CACTTAAGCTCGCCTTCGATCTCAG 
#704_E2A-5 For GACAGCCTAACCGCCCCCTTTG 
#705_E2A-6 For CAGTTGGCGATGAGCAGCTG 
#706_E2A-7 For GTGGACGTCGGCTTACCTTC 
#707_E4-4 For GATGATCCATGGTTACGAGTCC 
#708_bla For GGTCTGACGCTCAGTGGAACG 
#792_pEGFP_C2_FP GATCACATGGTCCTGCTG 
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#822_LSeqFor GATCTGGTCAATGTGGATTTG 
#828_M13Rev GGAAACAGCTATGACCATG 
#833_Rep2for AGACGCGGAAGCTTCGATCAA 
#835_CMV-F CGCAAATGGGCGGTAGGCGTG 
AAV2-MTP_fw acaggagcttcctccctcaacatcgccggattaagtAGACAAGCAG
CTACCGCAGATG 
AAV2-MTP_rev acttaatccggcgatgttgagggaggaagctcctgtGTTGCCTCTCT
GGAGGTTGG 
AAV9_K1_fw gccaagcaggcagtttgcgatccccgccatccgcccaggcggccACCG
GCTGGGTTCAAAACC 
AAV9_K1_rev ggccgcctgggcggatggcggggatcgcaaactgcctgcttggcCACT
CTGGTGGTTTGTGGCC 
AAV9_K3_fw gccaagcaggccgaggtgacctcagggtatccgcccaggcggccACCG
GCTGGGTTCAAAACC 
AAV9_K3_rev ggccgcctgggcggataccctgaggtcacctcggcctgcttggcCACTC
TGGTGGTTTGTGGCC 
AAV9_LD_fw GAATTTGCTTGGGCTGCAGCTTCTTCTTGG 
AAV9_LD_rev CCAAGAAGAAGCTGCAGCCCAAGCAAATTC 
AAV9_PHP. eB _rev cttaaaaggcaccgccaaagtcccatcACTCTGGTGGTTTGTGG
CCAC 
AAV9_PHP. S _rev caaagacgtcctaaccgcctgTTGGGCACTCTGGTGGTTTGT
G 
AAV9_PHP.A_fw tatactttgtcgcagggttggGCACAGGCGCAGACCGG 
AAV9_PHP.A_rev ccaaccctgcgacaaagtataTTGGGCACTCTGGTGGTTTGT
G 
AAV9_PHP.eB_fw gatgggactttggcggtgccttttaagGCACAGGCGCAGACCG
G 
AAV9_PHP.S_fw caggcggttaggacgtctttgGCACAGGCGCAGACCGG 
Barcode #2 TGACGTCTCTGCTCNNNNNNNNNNNNNNNCAG
GCGAGACGTGACACTGC 
Barcode #2_rv GCAGTGTCACGTCTCGCCTG 
EGFP_fw cgtatgcggccgcACCGGTCGCCACCATGG 
EGFP_rev agctgcatcgatTTACTTGTACAGCTCGTCCATGCCG 
NGS_Fw4 ATCACTCTCGGCATGGACGAGC 
NGS_Rev3 GGCTGGCAACTAGAAGGCACA 
qPCR_EGFP_fw GAGCGCACCATCTTCTTCAAG 
qPCR_EGFP_rev TGTCGCCCTCGAACTTCAC 
qPCR_EYFP_fw GAGCGCACCATCTTCTTCAAG 
qPCR_EYFP_rev TGTCGCCCTCGAACTTCAC 
Rep2_front_rev GGGAGCAAGTAATTGGGGATG 
WHc1_NISrepair_fw GGGACCGTGGCAGTCAATTTCCAGGGC 
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WHc1_NISrepair_rev GCCCTGGAAATTGACTGCCACGGTCCC 
WHc12_repair_fw CAAGTACAACCACGCCGACGCCGAGTTCC 
WHc12_repair_rev GGAACTCGGCGTCGGCGTGGTTGTACTTG 
2.9.3 PROBES 
Table 15: Probes 
Name Sequence (5’ to 3’) 
EYFP_Probe FAM-ACGACGGCAACTACA-NFQ 
EGFP_Probe FAM-ACGACGGCAACTACA-BHQ1 
2.9.4 CAPSID HELPER 
Table 16: Capsid helper 
Plasmid# Name Source 
#0193 WH-Rep2-CapDJ Eike Kienle 
#0827 WH-Rep2-Cap9_P1 Eike Kienle 
#0829 WH-Rep2-Cap9_P3 Eike Kienle 
#1539 WH-Rep2-CapLK03 Marc Kay 
#1610 WH-Rep2-Cap2NIS Eike Kienle 
#1611 WH-Rep2-Cap3NIS Eike Kienle 
#1612 WH-Rep2-Cap4mutNIS Eike Kienle 
#1613 WH-Rep2-Cap5NIS Eike Kienle 
#1614 WH-Rep2-Cap6NIS Eike Kienle 
#1615 WH-Rep2-Cappo1NIS Eike Kienle 
#1729 WH-Rep2-Cap1wt Eike Kienle 
#1730 WH-Rep2-Cap1_P2 This thesis 
#1731 WH-Rep2-Cap1_P4 This thesis 
#1732 WH-Rep2-Cap1_P5 This thesis 
#1733 WH-Rep2-Cap1_A1 This thesis 
#1734 WH-Rep2-Cap1_A2 This thesis 
#1735 WH-Rep2-Cap1_A6 This thesis 
#1736 WH-Rep2-Cap2wt Eike Kienle 
#1737 WH-Rep2-Cap2_P2 Eike Kienle 
#1738 WH-Rep2-Cap2_P4 Eike Kienle 
#1739 WH-Rep2-Cap2_P5 This thesis 
#1740 WH-Rep2-Cap2_A1 This thesis 
#1741 WH-Rep2-Cap2_A2 This thesis 
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#1742 WH-Rep2-Cap2_A6 This thesis 
#1743 WH-Rep2-Cap3bwt Eike Kienle 
#1744 WH-Rep2-Cap3b_P2 Eike Kienle 
#1745 WH-Rep2-Cap3b_P4 Eike Kienle 
#1746 WH-Rep2-Cap3b_P5 This thesis 
#1747 WH-Rep2-Cap3b_A1 This thesis 
#1748 WH-Rep2-Cap3b_A2 This thesis 
#1749 WH-Rep2-Cap3b_A6 This thesis 
#1750 WH-Rep2-Cap4wt Stefanie Große 
#1751 WH-Rep2-Cap4_P2 This thesis 
#1752 WH-Rep2-Cap4_P4 This thesis 
#1753 WH-Rep2-Cap4_P5 This thesis 
#1754 WH-Rep2-Cap4_A1 This thesis 
#1755 WH-Rep2-Cap4_A2 This thesis 
#1756 WH-Rep2-Cap4_A6 This thesis 
#1757 WH-Rep2-Cap5wt Eike Kienle 
#1758 WH-Rep2-Cap5_P2 Eike Kienle 
#1759 WH-Rep2-Cap5_P4 Eike Kienle 
#1760 WH-Rep2-Cap5_P5 This thesis 
#1761 WH-Rep2-Cap5_A1 This thesis 
#1762 WH-Rep2-Cap5_A2 This thesis 
#1763 WH-Rep2-Cap5_A6 This thesis 
#1764 WH-Rep2-Cap6wt Eike Kienle 
#1765 WH-Rep2-Cap6_P2 Eike Kienle 
#1766 WH-Rep2-Cap6_P4 Eike Kienle 
#1767 WH-Rep2-Cap6_P5 This thesis 
#1768 WH-Rep2-Cap6_A1 This thesis 
#1769 WH-Rep2-Cap6_A2 This thesis 
#1770 WH-Rep2-Cap6_A6 This thesis 
#1771 WH-Rep2-Cap7wt Eike Kienle 
#1772 WH-Rep2-Cap7_P2 Eike Kienle 
#1773 WH-Rep2-Cap7_P4 Eike Kienle 
#1774 WH-Rep2-Cap7_P5 Eike Kienle 
#1775 WH-Rep2-Cap7_A1 Eike Kienle 
#1776 WH-Rep2-Cap7_A2 Eike Kienle 
#1777 WH-Rep2-Cap7_A6 Eike Kienle 
#1778 WH-Rep2-Cap8wt Eike Kienle 
#1779 WH-Rep2-Cap8_P2 Eike Kienle 
#1780 WH-Rep2-Cap8_P4 Eike Kienle 
#1781 WH-Rep2-Cap8_P5 Eike Kienle 
#1782 WH-Rep2-Cap8_A1 Eike Kienle 
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#1783 WH-Rep2-Cap8_A2 Eike Kienle 
#1784 WH-Rep2-Cap8_A6 Eike Kienle 
#1785 WH-Rep2-Cap9wt Eike Kienle 
#1786 WH-Rep2-Cap9_P2 Eike Kienle 
#1787 WH-Rep2-Cap9_P4 Eike Kienle 
#1788 WH-Rep2-Cap9_P5 Eike Kienle 
#1789 WH-Rep2-Cap9_A1 Eike Kienle 
#1790 WH-Rep2-Cap9_A2 Eike Kienle 
#1791 WH-Rep2-Cap9_A6 Eike Kienle 
#1792 WH-Rep2-Caprh10wt Eike Kienle 
#1793 WH-Rep2-Caprh10_P2 Eike Kienle 
#1794 WH-Rep2-Caprh10_P4 Eike Kienle 
#1795 WH-Rep2-Caprh10_P5 Eike Kienle 
#1796 WH-Rep2-Caprh10_A1 Eike Kienle 
#1797 WH-Rep2-Caprh10_A2 Eike Kienle 
#1798 WH-Rep2-Caprh10_A6 Eike Kienle 
#1799 WH-Rep2-Cappo1wt Eike Kienle 
#1800 WH-Rep2-Cappo1_P2 Eike Kienle 
#1801 WH-Rep2-Cappo1_P4 Eike Kienle 
#1802 WH-Rep2-Cappo1_P5 This thesis 
#1803 WH-Rep2-Cappo1_A1 This thesis 
#1804 WH-Rep2-Cappo1_A2 This thesis 
#1805 WH-Rep2-Cappo1_A6 This thesis 
#1806 WH-Rep2-Cap12wt Stefanie Große 
#1807 WH-Rep2-Cap12_P2 This thesis 
#1808 WH-Rep2-Cap12_P4 This thesis 
#1809 WH-Rep2-Cap12_P5 This thesis 
#1810 WH-Rep2-Cap12_A1 This thesis 
#1811 WH-Rep2-Cap12_A2 This thesis 
#1812 WH-Rep2-Cap12_A6 This thesis 
#1813 WH-Rep2-Cap4mutwt Eike Kienle 
#1814 WH-Rep2-Cap4mut_P2 Eike Kienle 
#1815 WH-Rep2-Cap4mut_P4 Eike Kienle 
#1816 WH-Rep2-Cap4mut_P5 This thesis 
#1817 WH-Rep2-Cap4mut_A1 This thesis 
#1818 WH-Rep2-Cap4mut_A2 This thesis 
#1819 WH-Rep2-Cap4mut_A6 This thesis 
#1820 WH-Rep2-Cap1NIS This thesis 
#1821 WH-Rep2-Cap4NIS This thesis 
#1822 WH-Rep2-Cap12NIS This thesis 
#1925 WH-Rep2-Cap9LD This thesis 
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#1926 WH-Rep2-Cap9K449R_PHP.eB This thesis 
#1927 WH-Rep2-Cap9K449R_PHP.S This thesis 
#1928 WH-Rep2-Cap2_MTP This thesis 
#1929 pGG-Rep2-B1 Addgene 
#1930 pAnc80L65 Addgene 
#1933 pAAV-Rep2-cap2_7m8 Boehringer Ingelheim 
#1934 pAAV-Rep2-cap2_BR1 Boehringer Ingelheim 
#1935 pAAV-Rep2-cap2_L1 Boehringer Ingelheim 
#1936 pAAV-Rep2-Cap6ShH10 Boehringer Ingelheim 
#1937 pAAV_AAV6.2 Boehringer Ingelheim 
#1938 pAAV-Rep2-Cap9BI Boehringer Ingelheim 
#1939 pAAV-Rep2-cap2HBKO Boehringer Ingelheim 
#1940 pAAV-Rep2-Cap9K449R_PHP.B Boehringer Ingelheim 
#2004 WH-Rep2-CapAH3-5 Anne-Kathrin Herrmann 
#2047 WH-Rep2-Cap9_K1 This thesis 
#2048 WH-Rep2-Cap9_K3 This thesis 
#2049 WH-Rep2-Cap9K449R_PHP.A This thesis 
#2050 WH-Rep2-Cap9LD_P1 This thesis 
#2051 WH-Rep2-CapM41 This thesis 
#2052 WH-Rep2-Cap9_BR1 This thesis 
#2053 WH-Rep2-Cap4_L1 This thesis 
2.9.5 BARCODED REPORTER PLASMIDS 
All plasmids listed in Table 17 are based on Plasmid#552 and were cloned 
during this thesis as described in 3.2.3. 
Table 17: Barcoded reporter plasmids 
Plasmid# Name Barcode sequence 
#2056 pJW1-CMV-EYFP-BC#A2 AGACTCGTTGTATAT 
#2057 pJW2-CMV-EYFP-BC#A3 TAGAGATTTAAACCG 
#2058 pJW3-CMV-EYFP-BC#A4 CGTGACAGCGGATGG 
#2059 pJW4-CMV-EYFP-BC#A5 TGGGCGGTCAGGGTC 
#2060 pJW5-CMV-EYFP-BC#A6 TTGCCGTCCTTCGAG 
#2061 pJW6-CMV-EYFP-BC#A8 TTCAGCGGACGGGCC 
#2062 pJW7-CMV-EYFP-BC#A9 GTCAGTCCGCTCTTT 
#2063 pJW8-CMV-EYFP-BC#A11 TTAAGATCCTGGTCG 
#2064 pJW9-CMV-EYFP-BC#A13 TCAACATGGGCAACG 
#2065 pJW10-CMV-EYFP-BC#A14 CTTGATCGACGCCCA 
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#2066 pJW11-CMV-EYFP-BC#A15 TACGCTATTCAATCT 
#2067 pJW12-CMV-EYFP-BC#A18 GTGCTTCTGGCGGAT 
#2068 pJW13-CMV-EYFP-BC#A21 CGGCTGTCGGTCGCC 
#2069 pJW14-CMV-EYFP-BC#A22 ATCGTACGTTACTGA 
#2070 pJW15-CMV-EYFP-BC#A23 GATTCGAAAGCATAG 
#2071 pJW16-CMV-EYFP-BC#A24 CGTATCGGGTCCGGA 
#2072 pJW17-CMV-EYFP-BC#A25 TGGTTGGGTTTGTGG 
#2073 pJW18-CMV-EYFP-BC#A26 TCGTTGTAACGGTAC 
#2074 pJW19-CMV-EYFP-BC#A29 TAACGTTGGGTTGCC 
#2075 pJW20-CMV-EYFP-BC#A30 GACCACTAGAAGGGC 
#2076 pJW21-CMV-EYFP-BC#A32 CTGCATGGCGGAGTT 
#2077 pJW22-CMV-EYFP-BC#A33 TCAACGATTGTCTGG 
#2078 pJW23-CMV-EYFP-BC#A34 TGGTAGGTTCGAAAT 
#2079 pJW24-CMV-EYFP-BC#A35 ACGTCGCACCGTTTG 
#2080 pJW25-CMV-EYFP-BC#A37 CAGGCTTAACGCGGG 
#2081 pJW26-CMV-EYFP-BC#A38 ACCATAGCGCCACGA 
#2082 pJW27-CMV-EYFP-BC#A39 GTCCCGACTAGGACT 
#2083 pJW28-CMV-EYFP-BC#A40 GTCTTGATTGCTTCG 
#2084 pJW29-CMV-EYFP-BC#A41 ATTTGGCACAGGATG 
#2085 pJW30-CMV-EYFP-BC#A42 GGCCACCGTGTGTGA 
#2086 pJW31-CMV-EYFP-BC#A43 ATGAGCAGCGAATGA 
#2087 pJW32-CMV-EYFP-BC#A44 ATGTTTAACGGCATA 
#2088 pJW33-CMV-EYFP-BC#A45 TTGGACTCACAGATG 
#2089 pJW34-CMV-EYFP-BC#A47 AAGGTGACCTAGTGT 
#2090 pJW35-CMV-EYFP-BC#A48 CCCTCATGAGGTCCG 
#2091 pJW36-CMV-EYFP-BC#A49 ATGACAATGTGCAGG 
#2092 pJW37-CMV-EYFP-BC#A50 GCGAGGTCGTTAGTT 
#2093 pJW38-CMV-EYFP-BC#A51 TAAGACTGTTCCGGG 
#2094 pJW39-CMV-EYFP-BC#A52 GTTTGTAATCTCTAC 
#2095 pJW40-CMV-EYFP-BC#A53 GTTAACGCGGCCATT 
#2096 pJW41-CMV-EYFP-BC#A55 AGCGGCGTTTATCGT 
#2097 pJW42-CMV-EYFP-BC#A56 TTGGTATGTGTCAAT 
#2098 pJW43-CMV-EYFP-BC#A58 GTCGACTTCATGGCA 
#2099 pJW44-CMV-EYFP-BC#A61 GAGCGTAATTGTGAG 
#2100 pJW45-CMV-EYFP-BC#A62 CGTTAACCCGAAAGC 
#2101 pJW46-CMV-EYFP-BC#A63 GTGACATGCAGGTAG 
#2102 pJW47-CMV-EYFP-BC#A65 ACGATCGTACGTCTT 
#2103 pJW48-CMV-EYFP-BC#A67 GTTCAGGTCAGGTCT 
#2104 pJW49-CMV-EYFP-BC#A68 TAAGGAGGGCTGTAG 
#2105 pJW50-CMV-EYFP-BC#A69 TATCAAGCTAACGTT 
#2106 pJW51-CMV-EYFP-BC#A70 GCTCTGGATGTAGTA 
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#2107 pJW52-CMV-EYFP-BC#A71 TAGATGTGGCGGACA 
#2108 pJW53-CMV-EYFP-BC#A74 GTCAACATCGTTACA 
#2109 pJW54-CMV-EYFP-BC#A75 GGGCCCTAGCGCGTG 
#2110 pJW55-CMV-EYFP-BC#A76 GATAGGCTGGTCCAA 
#2111 pJW56-CMV-EYFP-BC#A77 TATTTGTGTCGTTCC 
#2112 pJW57-CMV-EYFP-BC#A79 AGTTAGGGCGCTGCG 
#2113 pJW58-CMV-EYFP-BC#A80 GCGGAACATAGGCGG 
#2114 pJW59-CMV-EYFP-BC#A81 GCCCTTCAGTCAGCT 
#2115 pJW60-CMV-EYFP-BC#A82 CGGTCGCGTGACGTG 
#2116 pJW61-CMV-EYFP-BC#A83 GCCGGAGTCCCGGTA 
#2117 pJW62-CMV-EYFP-BC#A84 CGAGTCGTATGTGGC 
#2118 pJW63-CMV-EYFP-BC#A85 AGTAATTGGTCTTGG 
#2119 pJW64-CMV-EYFP-BC#A86 GGTCTTTGCTCGGTG 
#2120 pJW65-CMV-EYFP-BC#A87 GACTTGGTTGTGACG 
#2121 pJW66-CMV-EYFP-BC#A90 TTGTTGTATGAGCAG 
#2122 pJW67-CMV-EYFP-BC#A91 TCCACGGAGGCTGCG 
#2123 pJW68-CMV-EYFP-BC#A94 CTACCTATTTACTCT 
#2124 pJW69-CMV-EYFP-BC#A97 ACCGGGCGTTGAGGC 
#2125 pJW70-CMV-EYFP-BC#A99 ACTGTGATGGGTTAG 
#2126 pJW71-CMV-EYFP-BC#A100 TGGTTTACAAATTAT 
#2127 pJW72-CMV-EYFP-BC#A101 TGTCCGGAAAGGACA 
#2128 pJW73-CMV-EYFP-BC#A102 GTTGTGCCCTGAGTG 
#2129 pJW74-CMV-EYFP-BC#A104 ACCGTATCTCTCCGG 
#2130 pJW75-CMV-EYFP-BC#A107 TTGGAACGTGGGCTT 
#2131 pJW76-CMV-EYFP-BC#A109 AGATTCAAAGCTGCG 
#2132 pJW77-CMV-EYFP-BC#A110 TGTTGGAAGGTATCA 
#2133 pJW78-CMV-EYFP-BC#A111 GTAGCTGAGGTTGGT 
#2134 pJW79-CMV-EYFP-BC#A114 AGCCTAATCTTTGAC 
#2135 pJW80-CMV-EYFP-BC#A115 AAGCACTAAAGAACA 
#2136 pJW81-CMV-EYFP-BC#A116 GGTATGGCCTGCCGC 
#2137 pJW82-CMV-EYFP-BC#A117 TGTTTAGGTGAGCCT 
#2138 pJW83-CMV-EYFP-BC#A118 TGTGGTGTGACTCAG 
#2139 pJW84-CMV-EYFP-BC#A119 TCGGGTTGGTCTTTG 
#2140 pJW85-CMV-EYFP-BC#A120 ACATTGTGGTCATAG 
#2141 pJW86-CMV-EYFP-BC#A121 AGACTTGGCGTTATG 
#2142 pJW87-CMV-EYFP-BC#A122 ACGTGTCGTAGTAAG 
#2143 pJW88-CMV-EYFP-BC#A124 TATATTGAGGCGTGT 
#2144 pJW89-CMV-EYFP-BC#A126 TGAGAGTCATCCAAG 
#2145 pJW90-CMV-EYFP-BC#A127 CCTAATCTCAGGCGG 
#2146 pJW91-CMV-EYFP-BC#A129 CGTGACCCAGGAAGT 
#2147 pJW92-CMV-EYFP-BC#A132 TCGTTAGTAGCGATC 
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#2148 pJW93-CMV-EYFP-BC#A135 GAGGTCCAGAGGAAG 
#2149 pJW94-CMV-EYFP-BC#A138 ATGATCAGCGATATC 
#2150 pJW95-CMV-EYFP-BC#A139 GGTGCCGGACAGCTC 
#2151 pJW96-CMV-EYFP-BC#A141 TATAACTTAGCTGAT 
#2152 pJW97-CMV-EYFP-BC#A142 CTTCTTCAGGCAACC 
#2153 pJW98-CMV-EYFP-BC#A144 CCACTAGGATCCGGA 
#2154 pJW99-CMV-EYFP-BC#A145 CAAGGCTTTCTGATC 
#2155 pJW100-CMV-EYFP-BC#A146 ATCTCGAAGCGCGTA 
#2156 pJW101-CMV-EYFP-BC#A147 GCAATTATCATAGTC 
#2157 pJW102-CMV-EYFP-BC#A149 GACCTGCGCCTTACA 
#2158 pJW103-CMV-EYFP-BC#A150 CGTCCGTCTAATGAA 
#2159 pJW104-CMV-EYFP-BC#A151 GGTTGACAGTGGGCT 
#2160 pJW105-CMV-EYFP-BC#A152 AGTTTAGGACAGGCA 
#2161 pJW106-CMV-EYFP-BC#A155 TTCATCGGCCGCTAA 
#2162 pJW107-CMV-EYFP-BC#A157 TACGTATCGCGTGAT 
#2163 pJW108-CMV-EYFP-BC#A158 CTAGGCAGGACACCG 
#2164 pJW109-CMV-EYFP-BC#A160 TTGGCAGAGGATCAC 
#2165 pJW110-CMV-EYFP-BC#A161 TCGGCTCTGTTCTAG 
#2166 pJW111-CMV-EYFP-BC#A162 TTTAGGCGCGGCTTG 
#2167 pJW112-CMV-EYFP-BC#A163 CGTCCTGTAAGGAGT 
#2168 pJW113-CMV-EYFP-BC#A164 TAGAGTATGAGTGGT 
#2169 pJW114-CMV-EYFP-BC#A166 GAGCGGGCAGACGAT 
#2170 pJW115-CMV-EYFP-BC#A169 GTGCGCAGGTTAGTG 
#2171 pJW116-CMV-EYFP-BC#A171 CTCGCGGCCTGAGGG 
#2172 pJW117-CMV-EYFP-BC#A172 CTAGATAAATGCGGT 
#2173 pJW118-CMV-EYFP-BC#A173 ACCTGAGTTTGGTGG 
#2174 pJW119-CMV-EYFP-BC#A175 CCGTCGAAGAAGGGA 
#2175 pJW120-CMV-EYFP-BC#A179 GGCAGCGGACACGTG 
#2176 pJW121-CMV-EYFP-BC#A180 ATCCTCTCCGCTACC 
#2177 pJW122-CMV-EYFP-BC#A181 TAGCACCATTTACGG 
#2178 pJW123-CMV-EYFP-BC#A184 CATGCCATGTGTATC 
#2179 pJW124-CMV-EYFP-BC#A187 ACCAACCGGTGTGGG 
#2180 pJW125-CMV-EYFP-BC#A189 GGTACAGGACGCAGG 
#2181 pJW126-CMV-EYFP-BC#A190 GACCACTTATCGCCA 
#2182 pJW127-CMV-EYFP-BC#A195 TCGGCGTGGCGGTCG 
#2183 pJW128-CMV-EYFP-BC#A197 GACTTTGACATGTCA 
#2184 pJW129-CMV-EYFP-BC#A198 TACATTTAACTGAAG 
#2185 pJW130-CMV-EYFP-BC#A199 GGTCAGGACCATTGG 
#2186 pJW131-CMV-EYFP-BC#A201 TGGGTTTCGGCATCA 
#2187 pJW132-CMV-EYFP-BC#A202 TTACCTTCTAAGGGC 
#2188 pJW133-CMV-EYFP-BC#A203 TGGTCGGCGAGTTTG 
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#2189 pJW134-CMV-EYFP-BC#A205 GGTTGGTTAGGCTGT 
#2190 pJW135-CMV-EYFP-BC#A207 ACCGGCAATCCTAGC 
#2191 pJW136-CMV-EYFP-BC#A208 GTGTGTTACCTAACA 
#2192 pJW137-CMV-EYFP-BC#A209 TCATCTAGCATCGGG 
#2193 pJW138-CMV-EYFP-BC#A210 GCCACAGGCATCGTG 
#2194 pJW139-CMV-EYFP-BC#A211 CTTATGTGAAGAGAT 
#2195 pJW140-CMV-EYFP-BC#A212 TAGTTTATCGCAGGG 
#2196 pJW141-CMV-EYFP-BC#A213 GTACCTATCCGTTGT 
#2197 pJW142-CMV-EYFP-BC#A214 TTCCGTGTGTTGTCT 
#2198 pJW143-CMV-EYFP-BC#A215 CCCGTATGTCGGGTA 
#2199 pJW144-CMV-EYFP-BC#A216 GAATCCATGACTTTG 
#2200 pJW145-CMV-EYFP-BC#A217 GTTCGTTGCGGGATC 
#2201 pJW146-CMV-EYFP-BC#A220 GTGCTTGTCATGCCG 
#2202 pJW147-CMV-EYFP-BC#A221 AGTTCACGACTGCGA 
#2203 pJW148-CMV-EYFP-BC#A222 GGACTCAGGCCTGGT 
#2204 pJW149-CMV-EYFP-BC#A223 TTTGGTTGGAGTCTT 
#2205 pJW150-CMV-EYFP-BC#A225 TTACGATTTATGCGC 
#2206 pJW151-CMV-EYFP-BC#A226 CAATCCGGCGCGGGT 
#2207 pJW152-CMV-EYFP-BC#A228 GTGTAGGTTATCATC 
#2208 pJW153-CMV-EYFP-BC#A229 TCGCACGCTGATGTG 
#2209 pJW154-CMV-EYFP-BC#A230 AGTTTCACATGACGG 
#2210 pJW155-CMV-EYFP-BC#A232 GTTTACGGATCTCGG 
#2211 pJW156-CMV-EYFP-BC#A233 TATATAGTCGGTTTG 
#2212 pJW157-CMV-EYFP-BC#A236 ATGTCGAACCCAATC 
#2213 pJW158-CMV-EYFP-BC#A237 TCTGTATGGGCCAGC 
#2214 pJW159-CMV-EYFP-BC#A240 TGATCTGACCGTGTG 
2.9.6 REPORTER PLASMIDS 
Table 18: Reporter plasmids 
Plasmid# Name Source 
#552 pscAAV-CMV-EYFP-BGHpolyA Eike Kienle 
#2054 pscAAV-CMV-EGFP-BGHpolyA This thesis 
#2055 pscAAV-CMV-EYFP-ccdB-
BGHpolyA 
Florian Schmidt 
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2.10 SOFTWARE 
Table 19: Software 
Name Vendor 
ApE (A Plasmid Editor) http://biologylabs.utah.edu/jorgensen/wayned/ape/ 
Gen5 2.09 BioTek Instruments, Inc. 
GraphPad Prism 7 GraphPad Software 
MendeleyDesktop Mendeley Ltd. 
NanoDrop 2000 v1.5 Thermo Fisher Scientific 
NextSeq Control 
Software  
Illumina, Inc. 
Office 2007 Microsoft Corporation 
PROSize Data Analysis 
Software 
Advanced Analytical Technologies, Inc. 
Python 2.7 Python Software Foundation 
Quantity One 4.6.9 Bio-Rad Laboratories, Inc. 
QuantStudio™ Software 
V1.3 
Thermo Fisher Scientific 
Rotor-Gene Q Series 
Software 
Qiagen N.V 
 3 METHODS 
3.1 GENERAL CLONING TECHNIQUES 
3.1.1 POLYMERASE CHAIN REACTION (PCR) 
In order to amplify DNA fragments for subsequent cloning steps, a PCR 
was performed with 10-100 ng template, 10 µl Phusion HF buffer, 1 µl dNTPs 
(10 mM), 1.5 µl forward primer (10 µM), 1.5 µl reverse primer (10 µM), 1.5 µl 
DMSO, 0.5 µl Phusion Polymerase HS and filled up to 50 µl with nuclease-free 
H2O. After mixing, PCR was run under cycling conditions listed in Table 20. 
Annealing temperature (step 3) and extension time (step 4) varied depending 
on the utilized primer combination and amplicon length respectively. 
Table 20: PCR cycling conditions 
Step Temperature [°C] Time Repetitions 
1 98 30 sec  
2 98 10 sec 
35 cycles 3 56-70 20 sec 
4 72 15 sec/kb 
5 72 5 min  
6 4 hold  
3.1.2 GEL ELECTROPHORESIS 
For a size-depended separation of a DNA sample, a 1% agarose gel 
electrophoresis was carried out by mixing a solution of 1% agarose (w/v) in 
TAE Buffer with 0.5 µg/ml of ethidium bromide. After solidification of the gel, 
Gel loading dye Purple (6X) was added to the DNA sample and mixture was 
loaded into gel pockets. Electrophoresis was performed at 120 V for ~20-
30 min. DNA bands were visualized with UV light and optionally excised for 
DNA purification. 
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3.1.3 RESTRICTION DIGEST 
To enzymatically cleave DNA fragments, restriction endonucleases were 
used (Table 10) by incubating 3 µg of plasmid DNA or 50 µl of purified PCR 
product with 1 µl of the respective restriction enzyme in its corresponding 
buffer for 3-4 h at 37 °C. Outcome was checked by gel electrophoresis as 
described in 3.1.2. 
3.1.4 DNA PURIFICATION 
Excised DNA bands from 3.1.2 were purified with QIAquick Gel Extraction 
Kit according to manufacturer’s instructions and eluted in 50 µl of nuclease-
free H2O. 
PCR amplicon purifications without gel separation were performed with 
MinElute PCR Purification Kit, DNA Clean & Concentrator™ or QIAquick 
PCR Purification Kit following manufacturer’s instructions. 
3.1.5 LIGATION 
For the ligation of a PCR-amplified insert into a restriction enzyme-digested 
plasmid backbone, 5 molar parts of the insert were combined with 1 molar part 
of the backbone (60 ng), 1 µl T4 DNA Ligase Reaction buffer, 0.5 µl T4 DNA 
Ligase and filled up to 10 µl with nuclease-free H2O. The mix was incubated 
for 30 min at RT and afterwards directly used for bacteria transformation. 
3.1.6 TRANSFORMATION 
3 µl of the ligation from 3.1.5 was mixed with 50 µl of MAX Efficiency™ 
DH5α™ Competent Cells, One Shot® ccdB Survival™ 2 T1R Competent Cells 
or 5-alpha Competent E.coli and incubated for 30 min on ice. Subsequent heat-
shock for 45 sec at 42 °C allowed plasmid uptake. Bacterial cells were placed on 
ice for 2 min before plating on LB agar dishes and incubating overnight at 
37 °C. 
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3.1.7 ELECTROPORATION 
30 µl of MegaX DH10B™ T1R Electrocomp™ Cells were mixed with 1.5 µl of 
ligation mixture from 3.2.3 or 3.1.5 and transferred to pre-cooled cuvettes. 
Electroporation was performed with GenePulser Xcell™ with the settings 
1800 V, 25 µF and 200 Ω. Immediately after completion, 1 ml of pre-warmed 
SOC medium was added to the cuvette for recovery. The solution was 
transferred to a tube and incubated at 700 rpm for 1 h at 37 °C. 100 µl of 
undiluted, 1:10 and 1:100 dilution was streaked on LB agar dishes with 
appropriate antibiotic resistance and plates were incubated overnight at 37 °C. 
3.1.8 PLASMID DNA PREPARATION 
For the preparation of plasmid DNA, 3-2000 ml of LB media, depending on 
the respective kit, with the adequate antibiotic resistance (50 µg/ml) was 
inoculated with a single colony or glycerol stock and incubated at 180 rpm 
overnight at 37 °C. Extraction of the plasmid was performed with commercial 
kits Qiaprep Spin Miniprep Kit, NucleoSpin Plasmid Miniprep Kit, Pure Yield 
Plasmid Midiprep, NucleoBond® Xtra Maxi or PureLink HiPure Plasmid 
Gigaprep Kit according to manufacturer’s instructions. 
3.2 SPECIFIC CLONING PROCEDURES 
This chapter describes the cloning of the capsid helper plasmids (Table 16) 
and the barcoded reporter constructs (Table 17). 
3.2.1 OVERLAP EXTENSION PCR 
Overlap extension PCR was used to create capsid helper plasmids for the 
published AAV variants AAV2_MTP, AAV9_K1, AAV9_K3, AAV9LD, 
AAV9K449R_PHP.eB, AAV9K449R_PHP.S and AAV9K449R_PHP.A. 
Additionally, mutations in the WH-Rep2-CapNIS plasmids of AAV1, AAV4 
and AAV12 were corrected with the same technique. The PCR reaction was set 
up as shown in 3.1.1 using the corresponding forward primer in combination 
with primer #178 and the reverse primer with #833. Upon completion of the 
cycler program (Table 20), two capsid fragments were generated for each AAV 
variant as seen by gel electrophoresis (3.1.2). Both bands were extracted and 
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purified for the following second PCR which uses the self-priming fragments 
to restore the full-length capsid gene. For that 0.5 µl 5’ fragment, 0.5 µl 3’ 
fragment, 10 µl Phusion HF buffer, 1 µl dNTPs (10 mM), 1.5 µl DMSO, 0.5 µl 
Phusion Polymerase HS and 31.2 µl nuclease-free H2O were mixed and run 
according to the cycling conditions listed in Table 21. 
Table 21: Overlap extension part 1 cycling conditions 
Step Temperature [°C] Time Repetitions 
1 98 30 sec  
2 98 10 sec 
12 cycles 
3 72 90 sec 
4 4 hold  
Afterwards 2.5 µl #178 primer as well as 2.5 µl #833 primer was added to 
the reaction and the capsid amplification was completed by starting the 
following cycler program: 
Table 22: Overlap extension part 2 cycling conditions 
Step Temperature [°C] Time Repetitions 
1 98 30 sec  
2 98 10 sec 
25 cycles 3 60 15 sec 
4 72 90 sec 
5 72 10 min  
6 4 hold  
PCR product was separated on an agarose gel (3.1.2) and appropriate band 
was purified (3.1.4) before digesting the fragment and a WH-rep2 helper 
plasmid with HindIII-HF and SpeI (3.1.3). Full-length capsid gene was 
subsequently ligated into the gel-purified plasmid backbone (3.1.5) and 
transformed (3.1.6). Outcome of the DNA preparation (3.1.8) was used for 
either virus production or peptide insertion cloning. 
3.2.2 PEPTIDE INSERTION 
To clone the missing AAV peptide insertion variants where the new 
insertion site (NIS) is utilized, the AAV serotype 1, 2, 3, 4, 4mut, 5, 6, po1 and 
12 capsid gene, in the corresponding WH-Rep2-CapNIS plasmids (Table 16), 
was digested with SfiI to enable oligonucleotide integration. Restriction digest 
and subsequent DNA purification was performed as described in chapter 3.1.3 
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and 3.1.4 respectively. DNA sequences of the peptides P2, P4, P5, A1, A2, A6 
were ordered (Merck KGaA) and double-stranded fragments with sticky 
overhangs for the SfiI-digested capsid helper plasmids were produced. For 
that, 5 µl forward and reverse peptide oligonucleotide (Table 13) as well as 5 µl 
NEBuffer 2 and 35 µl nuclease-free H2O were mixed. Cycler program listed in 
Table 23 was executed. 
Table 23: Oligonucleotide annealing cycling conditions 
Step Temperature [°C] Temperature 
decrease [°C/sec] 
Time [min] 
1 95  5 
2 75  3 
3 65 0.1 2 
4 55 0.1 2 
5 45 0.1 2 
6 4  hold 
The newly generated plasmids harboring the capsid genes with the inserted 
peptide-encoding DNA stretches are shown in Table 16. 
3.2.3 BARCODED REPORTER PLASMIDS 
For the generation of barcoded AAV reporter plasmids, an oligonucleotide 
bearing a 15 nt-long stretch of randomized nucleotides flanked by two Esp3I 
sites was ordered (Table 14, Barcode #2). A special request for a guaranteed 
1:1:1:1 ratio of the N-wobble was sent to the manufacturer (Merck KGaA). The 
synthesis of the second strand was performed by mixing 0.5 µl Barcode #2 
(100 µM), 0.5 µl Barcode #2_rv (100 µl), 10 µl Phusion HF buffer, 1 µl dNTPs 
(10 mM), 1.5 µl DMSO, 0.5 µl Phusion Polymerase HS and filled up to 50 µl 
with nuclease-free H2O. Cycler program depicted in Table 20 was used with an 
extension time of 5 sec. 
After a subsequent PCR clean-up 5 molar parts of double-stranded barcode 
oligonucleotide were mixed with 1 molar part of pscAAV-CMV-EYFP-ccdB-
BGHpolyA, 1 µl ATP (10 mM), 1 µl DTT (10 mM), 1 µl Tango Buffer (10X), 1 µl 
T4 DNA Ligase, 0.75 µl Esp3I and 1.3 µl nuclease-free H2O. Golden gate 
reaction was carried out with cycling conditions listed in Table 24. 
  
46 METHODS 
 
Table 24: Golden gate cycling conditions 
Step Temperature [°C] Time Repetitions 
1 37 5 min 
20 cycles 
2 16 5 min 
3 65 20 min  
Golden gate reaction mix was then directly used for electroporation (3.1.7). 
Individual colonies, each of them theoretically containing a unique barcode 
sequence, were picked and grown in 3 ml of LB media before extracting the 
plasmid DNA (3.1.8). All barcoded constructs were double-digested with PstI-
HF and XmaI as described in 3.1.3 to check the ITR integrity. Positive clones 
were sent for sequencing with the primer #652 (Table 14). Barcodes with a 
length of more or less than 15 and with homopolymers >3 were excluded. 
Remaining barcodes were tested for their Hamming distance to each other 
utilizing a tailored Excel sheet. To guarantee a distinct identification during 
next generation sequencing, the cutoff for the Hamming distance was set to >4. 
159 barcodes were generated matching all criteria and are depicted in Table 17. 
3.3 VIRUS PRODUCTION 
Subchapters of 3.3 comprise all necessary steps for the production of AAV 
vectors from cell seeding to determination of viral titers. 
3.3.1 HEK293T SEEDING 
Four days before transfection, 7.5x106 HEK293T cells per 175 cm2 flask were 
seeded and grown in DMEM with 10% FBS, 1% P/S. After two days, cells of 
one flask were washed with 8 ml DPBS and subsequently harvested with 2 ml 
Trypsin-EDTA (0.25%). 8 ml of DMEM with 10% FBS, 1% P/S was used to stop 
the trypsinization. Cell count was determined and 4x106 cells per 15 cm dish 
were seeded resulting in 80% confluency after two days which provided 
optimal conditions for the transfection. 
3.3.2 POLYETHYLENIMINE (PEI) TRANSFECTION 
For the triple transfection a barcoded reporter (Table 17), capsid helper 
(Table 16) and adeno helper plasmid were combined in equimolar ratios 
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adding up to 25 µg total DNA. The final concentration of NaCl in the 
transfection mix was set to 300 mM and the N/P ratio to 30. PEI was added last 
to initiate the complex formation. After vigorous vortexing, the mix was 
incubated for 10 min at RT. 2 ml were evenly distributed on a 15 cm dish and 
the plates were kept at 37 °C, 5% CO2 for three days before harvesting. 
3.3.3 HEK293T HARVEST, LYSIS AND BENZONASE 
TREATMENT 
Cells were detached with a cell scraper and the suspension was collected in 
a 500 ml conical tube. HEK293T cells were pelleted at 1000 rcf for 15 min and 
supernatant was discarded. 5 ml of Benzonase Buffer (15 ml for a large 
iodixanol gradient) were used to resuspend the pellet. Afterwards, the cells 
were lyzed by four freeze-thaw cycles to release viral particles. 75 U of 
Benzonase were added per 15 cm dish and the suspension was incubated for 
1 h at 37 °C with occasional inverting in order to break down residual plasmid 
DNA, genomic DNA and RNA. Two subsequent centrifugation steps at 
4000 rcf for 15 min at 4 °C were carried out to remove cellular debris from the 
virus-containing supernatant. 
3.3.4 AAV PURIFICATION BY IODIXANOL GRADIENT 
Iodixanol gradient was prepared by inserting a Pasteur pipette into an 
ultracentrifuge tube. Supernatant from 3.3.3 was transferred to the tube 
followed by 1.5 ml of 15%, 25%, 40% and 60% iodixanol solution in succession 
to build the gradient. For the large iodixanol gradient 7 ml, 5 ml, 4 ml and 4 ml 
were used for the phases, respectively. Afterwards, the Pasteur pipette was 
carefully removed and a 5 ml syringe with Benzonase Buffer was used to fill 
the tube to the top. Tubes were sealed with the Tube Sealer and balanced to 
each other (allowed deviation +/- 0.01 g). Ultracentrifugation was carried out in 
Rotor 70.1TI at 50000 rpm for 2 h at 4 °C (70TI at 63000 rpm for 2 h at 4 °C for 
large gradient). Upon completion, ultracentrifuge tube was punctured at the 
top with a 19 G needle to release vacuum and 3 mm below the 40%/60% barrier 
to extract ~1.2 ml of virus-containing fraction with a syringe (~2.5 ml for large 
gradients). 12 ml of DPBS was added to the purified virus solution and loaded 
on an Amicon Ultra-15 for dialyzing and concentrating by centrifuging at 
3000 rcf for 1-5 min. Centrifugation steps were carried out multiple times and 
the solution was mixed in between until ~1.5 ml residual volume. Process was 
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repeated twice by filling the Amicon tube again with DPBS to further eliminate 
the iodixanol content. Final concentrate was aimed to have 0.5-0.8 ml and 
stored at -80 °C. 
3.3.5 AAV PURIFICATION BY CESIUM CHLORIDE GRADIENT 
The supernatant from 3.3.3 was combined with 1 M CaCl2 to reach a final 
concentration of 25 mM CaCl2 and incubated for 1 h on ice to precipitate the 
proteins. Subsequent centrifugation at 10000 rcf for 15 min at 4 °C was 
performed to pellet the proteins. Supernatant was taken, mixed with ¼ 
volumes of PEG-NaCl solution and incubated overnight on ice. Solution was 
centrifuged at 2500 rcf for 30 min at 4 °C and resulting supernatant was 
discarded. Pellet was resuspended with 10 ml Na-HEPES resuspension buffer, 
followed by centrifuging at 2500 rcf for 30 min at 4 °C. Supernatant was filled 
up to 24 ml with Na-HEPES resuspension buffer and 13.2 g of CsCl was added. 
Refractive index (RI) of virus solution was determined with refractometer and 
adjusted to 1.3710 by adding CsCl or Na-HEPES resuspension buffer. After 
transferring the solution to an OptiSeal ultracentrifuge tube and filling the tube 
with Topping solution, tubes were balanced to each other (allowed deviation 
+/- 0.01 g) and centrifuged at 45000 rpm for 21-23 h at 21 °C in a 70TI rotor. To 
harvest the virus, fractions were taken by puncturing the tube at the bottom 
with a 19 G needle. 3, 3, 0.5, 0.5, 0.5, 5, 0.5, 0.5, 0.5 and 3 ml fractions are 
collected dropwise and RI-values were measured. Fractions in the range of 
1.3711-1.3766 were pooled, filled up to 9 ml with DPBS and transferred to a 
Slyde-A-Lyzer™ G2 Dialyse Cassette for dialysis against 700 ml cold DPBS. 
DPBS was replaced after 30 min without stirring. The next buffer exchanges 
were performed after 1 h, 2 h, overnight, 2 h and 2 h. Concentration of the 9 ml 
to ~1 ml was achieved by Amicon Ultra-15 centrifugation as described in 3.3.4. 
Purified virus was stored at -80 °C. 
3.3.6 AAV TITRATION BY QPCR 
For the quantification of viral titers, 10 µl of a purified virus sample from 3.3.4 
or 3.3.5 was combined with 10 µl TE Buffer and 20 µl of 2 M NaOH. Solution 
was vortexed and incubated for 30 min at 56 °C to break up the viral capsids. 
Neutralization was performed by adding 38 µl of 1 M HCl before vortexing 
again and adding 922 µl of nuclease-free H2O. The highest standard for the 
qPCR was set to 5x108 copies of double-stranded DNA and serially diluted to 
5x103 copies. 5 µl of all 6 standards and 5 µl of the alkaline lysis were combined 
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with 17.5 µl SensiMix™ II Probe No-ROX (2x), 1.4 µl qPCR_EGFP_fw (10 µM), 
1.4 µl qPCR_EGFP_rev (10 µM), 0.35 µl EGFP_Probe (10 µM) and 9.35 µl 
nuclease-free H2O, respectively. Mix was vortexed and 10 µl were pipetted in 
triplicates into Strip Tubes and run with the cycler program listed in Table 25. 
Table 25: AAV titration cycling conditions 
Step Temperature [°C] Time Repetitions 
1 95 10 min  
2 95 10 sec 
40 cycles 
3 60 20 sec 
Output values of the cycler, x, were corrected for the two dilution steps and the 
10 µl input volume to get to viral genomes per ml. 
vg/ml = x × 7 × 100 × 100 
3.4 WORKFLOW FOR VARIANT VALIDATION 
The following subchapters of 3.4 describe the full workflow for the in vivo 
validation of a barcoded AAV-library from the injection into mice to the 
analysis by next generation sequencing. 
3.4.1 IN VIVO PROCEDURES 
Seven-week-old mice ordered from Janvier Labs were i.v. injected with 
~1x1012 vg/mouse of the barcoded AAV library via the tail vein. After 1-
2 weeks abdominal aorta, thoracic aorta, brain, biceps, blood cells, colon, 
diaphragm, duodenum, eye, brown fat, white fat, heart, inner ear, kidney, 
liver, lung, ovaries, pancreas, quadriceps femoris, spleen and stomach were 
harvested and tissue pieces were submerged in RNAlater solution before 
storing at -20 °C. 
3.4.2 MACS FOR IMMUNE CELLS 
Isolation of CD3ε-, CD11b-, CD11c-, CD19-positive cells was performed by 
harvesting the mandibular, accessory mandibular, subiliac, proper axillary, 
accessory axillary and medial iliac lymph nodes as well as the spleen. Tissues 
were transferred to a 70 µm strainer and homogenized with a plunger. After 
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washing the strainer with MACS buffer, resulting cell suspension was 
centrifuged at 1000 rcf for 5 min. Supernatant was aspirated and pellet was 
resuspended in 10 ml RBC lysis solution before incubating 5 min at RT. Cells 
were centrifuged again at 1000 rcf for 5 min and resuspended in 1 ml MACS 
buffer yielding approximately 1x108 cells/ml. Cell suspension was split into 
two 500 µl fractions. 100 µl CD11c and CD11b MicroBeads were added 
respectively and following steps were carried out according to manufacturer’s 
instructions. Flow-through of both purifications was kept and used to isolate 
CD19- and CD3-positive cells respectively by following manufacturer’s 
instructions. Purified cells were counted and subsequently pelleted before 
freezing in liquid nitrogen for storage at -80 °C. 
3.4.3 TISSUE HOMOGENIZATION 
Isolated tissues were removed from RNAlater solution and weighed at RT. 
After transferring the tissue to a respective Precellys® tube, 350 µl of RLT, 1% 
β-ME was added for every 10 mg of tissue. Tubes were placed into Precellys® 
24-Dual homogenizer and homogenized by using program 1 with 5500 rpm for 
20 sec. Procedure was repeated for samples with insufficient homogenization. 
Lysates were stored at -80 °C (or at 4 °C for 1-2 h). 
Pellets of the purified cells from 3.4.2 were resuspended with 300 µl RLT, 
1% β-ME for every 1x106 cells and incubated for 5 min at RT. Lysates were 
transferred to a QiaShredder tube and centrifuged at 13000 rcf for 2 min. 
3.4.4 PHENOL-CHLOROFORM EXTRACTION 
PLG-tubes were centrifuged at 16000 rcf for 30 sec to collect the gel at the 
bottom of the tube. Afterwards 400 µl Phenol:Chloroform:Isoamylalcohol was 
added. Tissue lysates were thawed and subsequently centrifuged at 4000 rpm 
for 4 min to pellet potential debris. 400 µl of tissue lysate was transferred to a 
prepared PLG-tube and shaken vigorously for 15 sec. After centrifugation at 
16000 rcf for 5 min, 400 µl Chloroform:Isoamylalcohol was added and PLG-
tubes were again shaken vigorously for 15 sec. Tubes were incubated for 3 min 
at RT before centrifuging at 16000 rcf for 5 min. 350 µl of the aqueous phase 
was transferred to a 96-deepwell plate and stored at -80 °C (or 4 °C for 1-2 h). 
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3.4.5 DNA/RNA EXTRACTION 
For the isolation of DNA and RNA from the 350 µl aqueous phase from 
3.4.4 and the 300 µl RLT-lysate of the immune cells from 3.4.3 the Allprep 
DNA/RNA 96 Kit was used. Steps 3-10 of the manufacturer’s instructions were 
followed. Step 11 was performed with only 400 µl of RW1 and followed by a 
DNase on-column digest. DNase stock solution was prepared by adding 550 µl 
RNase-free H2O to one vial of lyophilized DNase I. DNase I incubation mix 
was prepared by adding 70 µl RDD buffer to 10 µl DNase stock solution and 
gently mixing. 80 µl of DNase I incubation mix was directly added to the 
RNeasy column in each well. Plate was sealed with a new sheet of AirPore 
Tape and incubated for 15 min at RT. Step 11 was repeated with only 400 µl 
RW1. Steps 12/16, 13/17, 14/18 and 15/19 were performed in parallel. RNA was 
eluted twice with 50 µl RNase-free H2O, DNA twice with 75 µl EB buffer. 
3.4.6 DNASE TREATMENT 
To guarantee a complete removal of remaining gDNA in RNA samples, 
212 ng of the RNA isolated in 3.4.5 was digested with DNase I. DNase I stock 
solution was prepared as described in 3.4.5. DNase I incubation mix was 
prepared by adding 1 µl DNase I stock solution and 4 µl RDD buffer to the 
212 ng RNA. Final volume was filled up to 40 µl with nuclease-free H2O. RNA 
was incubated for 15-30 min at RT and DNase I was subsequently heat-
inactivated for 10 min at 75 °C. DNase I-treated RNA was stored at -80 °C. 
3.4.7 CDNA SYNTHESIS 
DNase I-treated RNA from 3.4.6 was directly used for the High-Capacity 
cDNA Reverse Transcription Kit. Kit components were thawed on ice and 
incubation mix was prepared by adding 4 µl 10X RT buffer, 1.6 µl 25X dNTP 
Mix, 4 µl 10X RT Random Primers and 2 µl MultiScribe Reverse Transcriptase 
to 28.4 µl DNase I incubation mix from 3.4.6 containing 150 ng of RNA. PCR 
cycler was used to incubate the mix for 10 min at 25 °C, 120 min at 37 °C and 
5 min at 85 °C. Synthesized cDNA was stored at -20 °C. 
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3.4.8 AMPLIFICATION OF BARCODE REGION 
To amplify the barcode region of the viral transcripts (from 3.4.7) or 
genomes (from 3.4.5) a PCR was performed resulting in a 112 bp amplicon. For 
the reaction 10 µl 5X Phusion HF buffer, 1 µl dNTPs, 0.25 µl Fwd4 (100 µM), 
0.25 µl Rev3 (100 µM), 0.5 µl Phusion Hot Start II Polymerase and 25 ng of 
cDNA or gDNA template were mixed and filled to 50 µl with DEPC-treated 
H2O. The PCR cycler program shown in Table 26 was used. 
Table 26: Barcode region PCR cycling conditions 
Step Temperature [°C] Time Repetitions 
1 98 30 sec  
2 98 10 sec 
40 cycles 
3 72 20 sec 
4 72 5 min  
5 4 hold  
PCR reaction was subsequently cleaned up with the MagMAX Express-96 
Magnetic Particle Processor by adding 100 µl of Agencourt AMPure XP beads 
to the 50 µl of PCR reaction. Sample was mixed thoroughly by pipetting up 
and down 10 times and incubated for 10 min at RT. Two MagMAX wash plates 
were prepared with 150 µl 80% EtOH and one MagMAX plate with 25 µl 
Illumina Resuspension Buffer. MaxMAX program “AMPure_Trueseq96stan” 
was started and instructions of the machine were followed. After completion of 
the run 25 µl eluate was transferred to a 96-well plate and stored at -20 °C.  
PCR outcome and DNA concentration was analyzed by using a Fragment 
Analyzer with the Standard Sensitivity NGS Fragment Analysis Kit according 
to manufacturer’s instructions. 
3.4.9 LIBRARY PREPARATION 
In order to allow sequencing on the NextSeq500 platform a library 
preparation was performed where the PCR amplicons from 3.4.8 are ligated to 
sequencing adaptors. The Ovation Library System for Low Complexity 
Samples Kit was followed according to manufacturer’s instructions to process 
20-30 ng of amplicon DNA per sample. Result was monitored by running the 
processed samples on a Fragment Analyzer with the Standard Sensitivity NGS 
Fragment Analysis Kit according to manufacturer’s instructions. 
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3.4.10 DNA QUANTIFICATION WITH PICOGREEN 
To determine the DNA concentration of the sequencing library samples 
from 3.4.9, the Quant-iT PicoGreen dsDNA Assay Kit was used. PicoGreen was 
thawed and 1X TE buffer was prepared with the 20X TE stock solution. 1 µl of 
PicoGreen was added to 200 µl 1X TE buffer for each sample/standard to be 
analyzed. 200 µl of the mixture was transferred to a black 96-well plate for each 
sample. Eight DNA standards were prepared with a serial dilution ranging 
from 100 ng/µl to 1.56 ng/µl. 2 µl of standard or sample were added to the 
200 µl PicoGreen/TE buffer solution, mixed by vortexing and measured with a 
Cytation 5 imaging reader by using the “QuantiT_PicoGreen_dsDNA” 
program (filter settings 485/20,530/25). 
3.4.11 PREPARATION OF LIBRARY POOLS AND STARTING 
NEXTSEQ 
Based on the DNA concentrations obtained in 3.4.10, a 2 nM dilution was 
prepared for each sample with Illumina Resuspension Buffer, 0.1% Tween20. 
10 µl of every 2 nM dilution with a unique reverse adaptor which is supposed 
to be multiplexed on the flow cell were mixed and stored at -20 °C until library 
denaturation. 
For the denaturation of the library fragments 5.3-6.0 µl of the library pool 
were used and filled up to 10 µl with Illumina Resuspension Buffer, 0.1% 
Tween20. 10 µl of 0.2 M NaOH were added, vortexed and incubated for 5 min 
at RT to denature the DNA strands. For the neutralization 10 µl of 200 mM 
Tris-HCl, pH 7.0 were added and sample was vortexed. Denatured library pool 
dilution was filled to 1 ml with 970 µl of pre-chilled HT1 buffer, mixed and 
117 µl was combined with 1183 µl of pre-chilled HT1 buffer. 2 µl of 20 pM 
PhiX control was spiked in. Finished library pool dilution was vortexed 
thoroughly, spun down and loaded into a NextSeq500 cartridge. 
For starting the NextSeq500 machine, instructions on the screen were 
followed. Read 1 was set to 84 and Index 1 to 8. SampleSheet.csv which is 
needed for subsequent demultiplexing was placed in the automatically created 
run folder. 
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3.4.12 DETECTION OF VIRAL GENOMES BY QPCR 
To determine the EYFP and GAPDH copy number in the extracted DNA 
from 3.4.5, a TaqMan qPCR was performed by using 15 µl QuantiFast PCR 
Master Mix, 0.5 µl 60X Primer-Probe Mix (EYFP or GAPDH) and 14.5 µl 
sample (75 ng) or standard. Mix was vortexed and 10 µl of each sample or 
standard mix were transferred to a 384-well plate in duplicates. Plate was 
sealed and centrifuged at 800 rcf for 5 min. qPCR was started with following 
cycler program: 
Table 27: qPCR cycling conditions 
Step Temperature [°C] Time Repetitions 
1 50 2 min  
2 95 10 min  
3 95 15 sec 
40 cycles 
4 60 1 min 
Determined copy number of GAPDH was divided by two to obtain the 
number of cells. EYFP copy number was divided by the amount of cells 
resulting in viral genomes per diploid genomes (cells). Those values were used 
for data normalization. 
3.4.13 NGS DATA NORMALIZATION 
The NGS data obtained from 3.4.11 were processed by using a modified 
Python 2.7 script224 (modified by Josefine Sippel and Jonas Weinmann) which 
uses the demultiplexed reads from the sequencer and searches for the known 
15 nt-long barcode sequences. The output file lists the unknown sequences as 
well as the variant-assigned barcodes with their corresponding read counts. 
A second Python 2.7-based script (written by Sabrina Weis) utilizes the 
output files from the first script and performs a multi-step normalization 
procedure which corrects for the variations in the total read counts of each 
flow cell, unbalanced composition of the initial viral injection mixture and 
different efficiencies of the AAV library in the analyzed tissues. In the first step 
the script is normalizing the read counts R of all variants α in tissue β to the 
sum of all variants α in β to obtain the proportion Pαβ. 
Pαβ=
Rαβ
∑ Rαβα
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The second step normalizes Pαβ to the proportion of each variant α in the 
initial library Lα which corrects for the uneven composition in library. 
P*αβ=
Pαβ
Lα
 
In the third step P*αβ is normalized to the qPCR-determined vg/dg (see 
3.4.12), termed Gβ, to allow a comparison of one variant α over all analyzed 
tissues β. 
Bαβ=
Pαβ
Lα
×Gβ 
At this point Bαβ values were used and depicted directly to generate heat 
maps visualizing the differences of all variants α in all tissues β. Bαβ values can 
also be shown as proportion of the sum over α or β of Bαβ. 
Vαβ=
Bαβ
∑ Bαβα
 
Tαβ=
Bαβ
∑ Bαββ
 
Vαβ values were taken to create bar plots which demonstrate the proportion 
of all variants α in one tissue β and therefore exemplify the efficiency of the 
individual vectors. Bar plots using Tαβ values show the proportion of one 
variant α in all tissues β allowing an analysis of the tissue specificity. 
3.5 HISTOLOGY 
In order to validate promising candidates from the barcode-based in vivo 
screening, C57BL/6J mice were i.v. injected with 5x1011 vg/mouse and kept for 
2 weeks before harvesting the biceps, diaphragm, heart, liver and quadriceps 
femoris. Injected viruses carried a CMV promoter -driven egfp with a BGH 
poly-A (Table 18). Tissues were fixed in 4% PFA for 15-22 h and subsequently 
transferred to 30% sucrose solution until the tissue sinks to the bottom of the 
tube (~6 h). Afterwards, organs were embedded in TissueTek® O.C.T 
Compound, frozen on dry ice and stored at -80 °C. 12 µm sections were cut 
and embedded in ProLong™ Gold antifade reagent containing DAPI. Sections 
were scanned with Axio Scan.Z1 detecting the DAPI and GFP signal. 
 4 RESULTS 
4.1 ESTABLISHMENT OF BARCODE-BASED AAV 
CAPSID SCREENING 
The following chapter encompasses an overview of the barcode-based 
capsid screening pipeline to describe the fundamental principle of this 
workflow. Data generated by using the pipeline and more detailed information 
about the individual experimental outlines are shown in the chapters 4.3, 4.4 
and 4.5. 
In order to enable a barcode-based capsid screening in vivo, randomized 15 
nucleotide-long DNA sequences were cloned into the 3’UTR of a CMV 
promoter-driven eyfp gene by Golden Gate cloning (3.2.3). Resulting clones 
were tested for the presence of the essential ITRs by restriction digest (3.1.3) 
and the barcode region was subsequently sequenced. Barcodes with a length 
differing from 15 nucleotides or comprising homopolymers longer than 3 
nucleotides were excluded. The Hamming distance of the remaining pool was 
assessed and sequences with variations to every other barcode in at least five 
positions were kept.  
A total of 159 barcodes could be generated matching all criteria (Table 17) 
and were used for vector production. During the latter, one barcoded construct 
was transfected into HEK293T cells together with a plasmid bearing the rep 
gene of AAV2 and a cap gene of choice. Hence, a tight linkage of a barcode to 
its respective capsid was established (Figure 4A). Each variant was produced 
separately and eventually pooled to create a barcoded library. Afterwards, the 
viral library was dialyzed as well as concentrated (Figure 4B).  
For parallel validation in mice, 1x1012 vector genomes (vg) per mouse were 
injected into six C57BL/6J mice via the tail vein. Mice were kept for 1-2 weeks 
before tissues and cells of interest were harvested (Figure 4C). Steps for the 
extraction of DNA and RNA, the subsequent PCR amplification of the barcode 
region and the mandatory clean-up of the PCR product were optimized (data 
not shown). After completing the library preparation (3.4.9), the samples were 
multiplexed and processed by next generation sequencing (NGS) to identify 
the proportion of every barcode in the analyzed tissues (Figure 4D). To this 
end, a multi-layer normalization strategy was applied that corrects for the total 
read count differences of each flow cell, the variations in particle abundance in 
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the initial viral injection mixture and unequal transduction efficiencies of the 
AAV library in the tissues (3.4.13). 
 
Figure 4: Workflow for a barcode-based AAV capsid validation 
(A) Self-complementary AAV genome comprising a CMV promoter-driven eyfp transgene 
flanked by ITRs. The 3'UTR contains a 15 nucleotide-long barcode (BC) allowing capsid 
tracking on the DNA and cDNA level. During AAV production, barcoded genomes were 
paired with a cap gene of choice. (B) Each barcoded variant was produced separately and 
eventually pooled to generate a barcoded library. (C) C57BL/6J mice were i.v. injected with 
1x1012 vg/mouse and kept for 1-2 weeks before harvesting tissues and cells. (D) DNA and 
RNA were extracted from all samples and the barcode region was amplified by PCR. NGS 
was performed to determine barcode read counts of all variants in the tissues. 
To test the pipeline, 12 barcoded reporter constructs were transfected into 
HEK293T cells and barcode sequences were amplified from the cell lysate. All 
12 DNA patterns could be detected by sequencing (data not shown). To further 
evaluate if the NGS sensitivity was high enough for a barcode identification 
from in vivo samples, two barcoded vectors, AAV2wt (wild type) and AAV8wt, 
were produced and mixed, and 7.22x1011 vg/mouse were injected into two 
female C57BL/6J mice. After two weeks, liver, heart and kidney were harvested 
and barcode abundance was measured in samples from DNA (data not shown) 
and cDNA (Figure 5). 
Both barcodes could be found in the three tissues on the DNA and cDNA 
level. On the cDNA level, AAV8wt demonstrated superior efficiency in the 
liver, heart and, to a lesser extent, in the kidney compared to AAV2wt. 
Evidence is that in all cases but one, over 95% of the detected barcode 
sequences belonged to AAV8wt which is in line with expectations from the 
literature153. 
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Figure 5: Barcode abundance in a pilot run with AAV2wt and AAV8wt 
Two C57BL/6J mice were i.v. injected with 7.22x1011 vg/mouse of a mixture of AAV2wt and 
AAV8wt. Depicted is the proportion of the corresponding barcodes of the serotypes in the 
liver, heart and kidney cDNA samples. Dots represent individual mice. 
4.2 AAV VARIANTS USED IN THE SCREENINGS 
In this work, three independent library screenings were performed with 
varying vector compositions. To point out the differences between the 
individual screening rounds, this chapter provides an overview of all analyzed 
capsid variants in the three screenings and the respective library compositions 
(Table 28) as well as information about the origin of the capsids. Results 
obtained by applying these libraries in vivo are described in the chapters 4.3, 
4.4 and 4.5. 
The 1st generation library contained 91 capsids, among them 13 parental 
serotypes and 78 peptide-modified variants based on these natural AAVs. A 
highly similar panel was previously tested extensively in vitro in our laboratory 
by primarily Kathleen Börner and Eike Kienle (more information is found in 
the doctoral thesis of Eike Kienle). During this doctoral work, variants 
displaying the peptides P2, P4, P5, A1, A2 and A6 were cloned utilizing an 
alternative insertion site for the AAV serotypes 1, 2, 3, 4, 5, 6, po1 and 12 after 
amino acid position 588, 587, 588, 586, 577, 588, 569, 594, respectively. 
Structural modeling of the integration site, the variable region VIII, hinted 
towards a potential transduction improvement (unpublished data) by slightly 
shifting the peptide insertion site, aiming to better match the insertion position 
in the VRVIII loop of AAV7, AAV8, AAV9 and AAVrh10 (position 589, 590, 
588 and 590, respectively). The amino acid after which the peptide is displayed 
varies marginally due to differences in the total VP protein size of the naturally 
occurring AAV isolates.  
The first screening revealed dramatic variations in production efficiency of 
the analyzed variants (4.3). Therefore, poor producers were excluded for the 
production of the 2nd generation library but replaced with published 
benchmarks from the literature, namely, AAV2_7m8186, AAV2_BR1218, 
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AAV2_L1208, AAV2HBKO203, AAV6.2165, AAV9_PHP.B219, AAVDJ172, 
AAVLK03191 and AAVshH10179. 
Remains of the 2nd generation library were used to create the 3rd generation 
library by spiking in the benchmarks AAV2_L1mut1208, AAV2_L1mut2208, 
AAV2YF161, AAV9_K1215, AAV9_K3215, AAV9_PHP.A219, AAV9_PHP.eB220, 
AAV9_PHP.S220, AAV9LD222, AAVAnc80L65167, AAVB1190 and AAVM41189. 
Additionally, the library was enriched with 30 chimeric variants selected in 
stellate cells (work of Anne-Kathrin Herrmann) and 34 chimeras isolated from 
muscle tissue selections (work of Jihad El Andari).  
Table 28: Variants in the screenings 
Variant Source 1st library 2nd library 3rd library 
AAV1wt 43 x x x 
AAV1_A1 Our lab x x x 
AAV1_A2 Our lab x x x 
AAV1_A6 Our lab x x x 
AAV1_P2 Our lab x   
AAV1_P4 Our lab x x x 
AAV1_P5 Our lab x x x 
AAV2wt 43 x x x 
AAV2_7m8 186  x x 
AAV2_A1 Our lab x x x 
AAV2_A2 Our lab x x x 
AAV2_A6 Our lab x x x 
AAV2_BR1 218  x x 
AAV2_L1 208  x x 
AAV2_L1mut1 208   x 
AAV2_L1mut2 208   x 
AAV2_MTP 201   x 
AAV2_P2 Our lab x x x 
AAV2_P4 Our lab x x x 
AAV2_P5 Our lab x x x 
AAV2HBKO 203  x x 
AAV2YF 161   x 
AAV3bwt 46 x x x 
AAV3b_A1 Our lab x x x 
AAV3b_A2 Our lab x x x 
AAV3b_A6 Our lab x x x 
AAV3b_P2 Our lab x   
AAV3b_P4 Our lab x x x 
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AAV3b_P5 Our lab x x x 
AAV4wt 44 x x x 
AAV4_A1 Our lab x x x 
AAV4_A2 Our lab x x x 
AAV4_A6 Our lab x x x 
AAV4_L1 Our lab  x x 
AAV4_P2 Our lab x x x 
AAV4_P4 Our lab x x x 
AAV4_P5 Our lab x x x 
AAV4mutwt Our lab x   
AAV4mut_A1 Our lab x   
AAV4mut_A2 Our lab x   
AAV4mut_A6 Our lab x   
AAV4mut_P2 Our lab x   
AAV4mut_P4 Our lab x   
AAV4mut_P5 Our lab x   
AAV5wt 45 x x x 
AAV5_A1 Our lab x x x 
AAV5_A2 Our lab x x x 
AAV5_A6 Our lab x x x 
AAV5_P2 Our lab x   
AAV5_P4 Our lab x x x 
AAV5_P5 Our lab x x x 
AAV6wt 46 x x x 
AAV6_A1 Our lab x   
AAV6_A2 Our lab x   
AAV6_A6 Our lab x   
AAV6_P2 Our lab x   
AAV6_P4 Our lab x x x 
AAV6_P5 Our lab x   
AAV6.2 165  x x 
AAV7wt 47 x x x 
AAV7_A1 Our lab x x x 
AAV7_A2 Our lab x x x 
AAV7_A6 Our lab x x x 
AAV7_P2 Our lab x x x 
AAV7_P4 Our lab x x x 
AAV7_P5 Our lab x x x 
AAV8wt 47 x x x 
AAV8_A1 Our lab x x x 
AAV8_A2 Our lab x x x 
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AAV8_A6 Our lab x x x 
AAV8_P2 Our lab x x x 
AAV8_P4 Our lab x x x 
AAV8_P5 Our lab x x x 
AAV9wt 48 x x x 
AAV9_A1 Our lab x x x 
AAV9_A2 Our lab x x x 
AAV9_A6 Our lab x x x 
AAV9_BR1 Our lab  x x 
AAV9_K1 215   x 
AAV9_K3 215   x 
AAV9_P1 Our lab202  x x 
AAV9_P2 Our lab x   
AAV9_P3 Our lab   x 
AAV9_P4 Our lab x x x 
AAV9_P5 Our lab x x x 
AAV9K449R_PHP.A 219   x 
AAV9K449R_PHP.B 219  x x 
AAV9K449R_PHP.eB 220   x 
AAV9K449R_PHP.S 220   x 
AAV9BI Boehringer 
Ingelheim 
 x x 
AAV9LD 222   x 
AAVrh10wt 48 x x x 
AAVrh10_A1 Our lab x x x 
AAVrh10_A2 Our lab x x x 
AAVrh10_A6 Our lab x x x 
AAVrh10_P2 Our lab x x x 
AAVrh10_P4 Our lab x x x 
AAVrh10_P5 Our lab x x x 
AAVpo1wt 50 x x x 
AAVpo1_A1 Our lab x x x 
AAVpo1_A2 Our lab x x x 
AAVpo1_A6 Our lab x x x 
AAVpo1_P2 Our lab x   
AAVpo1_P4 Our lab x x x 
AAVpo1_P5 Our lab x x x 
AAV12wt 49 x x x 
AAV12_A1 Our lab x   
AAV12_A2 Our lab x   
AAV12_A6 Our lab x   
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AAV12_P2 Our lab x   
AAV12_P4 Our lab x   
AAV12_P5 Our lab x   
AAVAnc80L65 167   x 
AAVB1 190   x 
AAVDJ 172  x x 
AAVDJYF Our lab   x 
AAVLK03 191  x x 
AAVM41 189   x 
AAVshH10 179  x x 
AAVAH chimeras Our lab   x 
AAVJEA chimeras Our lab   x 
4.3 1ST GENERATION LIBRARY SCREENING 
The first generation library comprised a total of 91 different AAV variants 
(Table 28), each of them containing a barcode that served as unique identifier. 
To save time, two 15 cm dishes of HEK293T cells were used for the production 
of each vector. Afterwards, the cell lysates of the individual productions were 
pooled and subsequently purified by one cesium chloride gradient. The library 
was then processed on a NextSeq500 sequencer to determine the proportion of 
the variant-encoding barcodes in this mixture. This step is essential to verify 
the presence of each barcode and therefore the cognate capsid. Additionally, 
the respective proportion was used to normalize for potential variations in 
production efficiencies. Therefore, the theoretical mean proportion in case of 
an equimolar library was calculated and fold changes compared to this value 
are depicted in Figure 6. Values close to 1 or -1 reflect a production behavior 
according to the expectations. 
However, drastic differences in barcode abundance could be observed for 
the variants in the library. Peptide insertion mutants frequently demonstrated 
a proportional decrease whereas vectors from the AAV5 or AAV9 family were 
generally over-represented. The most pronounced reduction in barcode 
abundance could be detected for peptide insertion variants of AAV6 and 
AAV12, with up to 978-fold deviation from the theoretical mean proportion 
(Figure 6). Also worth noting is that P2-modified capsids typically gave the 
lowest yields within the respective family. The overall lowest amount of read 
counts was found for AAV4mut_A2 whose titer was 3600-fold decreased 
versus the mean. 
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Figure 6: Composition of 1st generation library 
Shown are fold changes to the theoretical mean proportion of each barcoded variant. A 
value close to 1 or -1 reflects the expected production behavior. Negative fold changes imply 
under-representation of the respective variant, positive values illustrate over-representation.  
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To study the library in vivo, 1x1012 vg/mouse were injected i.v. into three 
female and three male C57BL/6J mice. Mice were kept for two weeks before 
harvesting abdominal aorta, thoracic aorta, brain, colon, diaphragm, 
duodenum, eye, brown fat, white fat, heart, inner ear, kidney, liver, lung, 
pancreas, quadriceps femoris and spleen. DNA and RNA were extracted and 
the workflow described in 4.1 was followed. Sequencing data was normalized 
to the bias of the viral injection mixture (see above and Figure 6) and the 
resulting normalized proportions of each variant on the cDNA level in the 
analyzed tissues are shown as a bar plot (Figure 7). 
   
 
 
 
Figure 7: Transcriptional efficiency in various tissues 
The depicted bar plots show the transcriptional efficiency as normalized proportion of the 
top 10 AAV variants from the 1st generation library in the liver, lung, eye, diaphragm, 
quadriceps femoris and heart. The cDNA values are the average from six C57BL/6J mice 
with SD. 
In most of the studied organs, the wild type versions of AAV9, AAVrh10, 
AAV8 and AAV7 exhibited the highest efficiencies in this order, followed by 
peptide insertion variants based on these serotypes (Supplementary 
information, Figure 30). Different effects could be observed in the liver, lung, 
eye, diaphragm, quadriceps femoris and heart (Figure 7). 
In the liver, AAVrh10wt displayed the highest efficiency even displacing 
the potent AAV8wt226,227. Peptide integrations into either AAVrh10wt or 
AAV8wt could not boost their effect. A strong enrichment of AAV4 and its 
related variants was detected in the lung, with AAV4wt being the top hit. 
AAV4mutwt that differs in only one amino acid (K544E) showed a 3-fold 
reduction as compared to its unmodified counterpart.  
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In the eye and the three muscle tissues diaphragm, quadriceps femoris and 
heart, a previously barely characterized AAV isolate, AAVpo1wt50,228, appeared 
in the top 10 list of the most abundant barcodes. Furthermore, the porcine 
variant and its A1-modified version were found in the inner ear 
(Supplementary information, Figure 30). The two capsids demonstrated only 
weak efficiencies in other organs, indicating a preferential targeting of muscle. 
AAV9wt exhibits the highest normalized proportion in muscle tissues in line 
with its reputation as a gold standard for muscle transduction229. Of note, 
AAV9wt was not among the top 10 hits in the liver, potentially explaining the 
pronounced effects in several other tissues. 
4.4 2ND GENERATION LIBRARY SCREENING 
Because of the up to 3600-fold deviation from the theoretical mean 
proportion of the 1st generation library (Figure 6) and the resulting major 
implications for the normalization of the results, the production procedure was 
altered for the second library. For the first screening, two 15 cm dishes had 
been used to produce each variant, and the resulting particles had been pooled 
and concurrently purified without prior titration (4.3). However, as shown, this 
led to a heterogeneous vector abundance. Based on these findings and on 
experiences made by individually testing the production efficiencies of several 
wild type capsids (collected in a newly created internal AAV production 
database), the number of dishes required to achieve comparable yields was 
calculated for every variant and found to range from only one plate for highly 
potent producers, such as AAV5wt, to 120 plates for very poor candidates, 
such as AAV2_L1. Variants that would have required unfeasible amounts of 
plates, e.g. many P2-modified mutants or AAV6 and AAV12 with peptide 
insertions, were excluded. For each of the selected 82 vectors (Table 28), the 
aim was to reach 1.2x1011 vg after individual purification over an iodixanol 
gradient. Viral titers were determined by qPCR, and equimolar amounts were 
pooled and subsequently concentrated as well as dialyzed using Amicon Ultra-
15 tubes. This 2nd generation library was sequenced to monitor the composition 
of the mixture and to generate seminal basal values for the normalization 
strategy (Figure 8). 
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Figure 8: Composition of 2nd generation library 
Shown are the fold changes to the theoretical mean proportion of each barcoded variant. A 
value close to 1 or -1 reflects the expected production behavior. Negative fold changes imply 
under-representation of the respective variant, positive values illustrate over-representation. 
Unlike in the first library, substantial improvements could be observed for 
the second AAV pool, which showed only up to 6.4-fold under-representation 
of individual capsids (AAV3b_A6) or 5.1-fold over-representation (AAV4_P2). 
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Most others oscillated around the expected values of 1 or -1, illustrating a very 
homogenous capsid distribution and lowering the risk of normalization 
artefacts.  
After completing the quality control step, 1x1012 vg/mouse were injected i.v. 
into six female C57BL/6J mice. After one week, mice were sacrificed and 
abdominal aorta, thoracic aorta, blood cells, brain, colon, diaphragm, 
duodenum, eye, brown fat tissue, white fat tissue, heart, inner ear, kidney, 
liver, lung, ovaries, pancreas, quadriceps femoris, spleen and stomach were 
extracted. DNA and RNA were isolated for subsequent deep sequencing. 
Furthermore, a qPCR was performed to determine the viral genomes per 
diploid genome (vg/dg) in each tissue. These values are depicted in Figure 9 
and were additionally used to normalize the sequencing data. By 
implementing this step, for the first time, a comparison of one variant across all 
analyzed tissues was enabled (3.4.13), providing the opportunity to 
concurrently gather data on capsid efficiency and specificity. 
 
Figure 9: Viral DNA distribution of the 2nd generation library 
The depicted bar plot shows the viral DNA distribution from the 2nd generation library after 
systemic injection into C57BL/6J mice across abdominal aorta (Aa), thoracic aorta (At), blood 
cells (BlC), brain (B), colon (C), diaphragm (Di), duodenum (Du), eye, brown fat (FatB), 
white fat (FatW), heart (H), inner ear (I), kidney (K), liver (Li), lung (Lu), ovaries (O), 
pancreas (P), quadriceps femoris (QF), spleen (S) and stomach (St). Detected viral genomes 
(EYFP probe) were normalized to GAPDH as a housekeeper. Depicted values represent the 
average of six mice with SD. 
By determining the vg/dg values, the distribution of the 2nd generation 
library could be tracked across different tissues. As expected, the liver harbors 
the largest proportion of the viral particles with 59 vg/dg, followed by the lung 
(5.6 vg/dg) and the blood cells (4.6 vg/dg). In abdominal aorta, thoracic aorta, 
brain, diaphragm, brown fat tissue, white fat tissue, heart, inner ear, kidney, 
quadriceps femoris and spleen, roughly one viral genome was found in every 
cell (assuming a diploid genome per cell). Tissue types from the digestive tract, 
namely colon, duodenum and stomach, demonstrated very low values. In 
detail, only one viral genome could be detected in every fifth cell. The lowest 
transduction of only 0.1 vg/dg was found in the eye. 
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During processing of the NGS data, Bαβ values were calculated by a custom-
made Python script (3.4.13). These values allow the generation of a heat map 
displaying the full biodistribution of each variant in the library on the cDNA 
level (Figure 10). Thus, the transcript abundance of vectors can be compared 
either within the same organ or across all tissues. The color scheme was set to 
the highest value in the screening and a logarithmic scale was chosen to adjust 
for the over-representation in the liver. 
As already indicated above, most of the screened AAV variants showed a 
pronounced liver tropism. Nevertheless, highly interesting differences between 
the serotypes could be observed. Derivatives of AAV7, AAV8, AAV9 and 
AAVrh10 generally demonstrated a broad transcriptional activity whereas 
members of the AAV2 and AAV3b family largely remained inactive in all 
tissues. AAV4wt and related peptide insertions predominantly showed up in 
the blood cells and the lung, but avoided the liver almost entirely. An as-of-yet 
unknown tropism could be found for AAVpo1wt and AAVpo1_A1. Both 
capsids were detargeted from the liver but were transcriptionally active in 
muscle, especially in the diaphragm and the quadriceps femoris. 
Aside from the naturally occurring serotypes and their peptide-modified 
derivatives, some of the published benchmarks gave remarkable results. For 
instance, the peptide insertion variant AAV2_L1208 displayed a significantly 
higher efficiency than its parental virus AAV2wt (Figure 10). Moreover, its 
activity was limited mainly to the lung and, to a lesser extent, to the brain and 
blood cells. Another AAV2 peptide-displaying mutant, AAV2_BR1218, showed 
strong specificity for the lung and the brain. The latter was even more 
specifically targeted by the AAV9-based peptide insertion variant 
AAV9_PHP.B219, which was restricted to the brain. Of note, the well-known 
chimeric capsid AAVDJ172 was confirmed as a highly specific liver-targeting 
vector, as it barely showed any activity in off-targets. Surprisingly, the P1 
peptide-presenting variant AAV9_P1 - previously identified as lead candidate 
in cultured human astrocytes202 - could be detected mainly in the screened 
muscle tissues, namely, the diaphragm, quadriceps femoris and heart (Figure 
10). Next to this noticeable improvement in muscle specificity as compared to 
AAV9wt, an increase in efficiency was observable. 
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Figure 10: Biodistribution of all variants of the 2nd generation library 
Calculated Bαβ values are depicted as a heat map simultaneously illustrating the 
transcriptional efficiency and specificity of all variants in the 2nd generation library in the 
abdominal aorta (Aa), thoracic aorta (At), blood cells (BlC), brain (B), colon (C), diaphragm 
(Di), duodenum (Du), eye, brown fat (FatB), white fat (FatW), heart (H), inner ear (I), kidney 
(K), liver (Li), lung (Lu), ovaries (O), pancreas (P), quadriceps femoris (QF), spleen (S) and 
stomach (St). A logarithmic scale is used with blue representing the value 0, white 0.47 and 
red 4.74.  
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Although the heat map provides a comprehensive overview of the full 
dataset, subtle differences are difficult to spot. Therefore, to better illustrate 
such details, a bar plot depiction of important highlights was chosen. This 
either illustrates the efficiency of all variants within one organ, referred to as 
Vαβ values (Figure 11 and Figure 12), or the specificity of one variant across all 
tissues, termed Tαβ values (Figure 13, Figure 14 and Figure 15). A detailed 
description of how these values were generated is found in 3.4.13. 
   
   
   
Figure 11: Transcriptional efficiency in various tissues 
The depicted bar plots show the transcriptional efficiency as normalized proportion of the 
top 10 AAV variants from the 2nd generation library in the brain, liver, lung, eye, inner ear, 
blood cells, brown fat tissue and white fat tissue. The cDNA values are the average from six 
C57BL/6J mice with SD. 
In Figure 11, Vαβ values of various organs are shown to illustrate the efficiency 
of single AAV variants within the same tissue. As already visible in the heat 
map, AAV9_PHP.B showed evidence for robust brain activity as over 60% of 
all barcodes detected in this tissue belong to this capsid variant. Two AAV2wt-
based variants, AAV2_L1 and AAV2_BR1, ranked second and third, 
respectively; however, the former was 3.2-fold and the latter 12.8-fold less 
efficient than AAV9_PHP.B. Strikingly, all three variants outperformed 
AAV9wt, which is widely used for passing the blood brain barrier and 
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robustly transducing the brain. The peptide insertion mutants AAV9_P5 and 
AAV9_P4 once more demonstrated to be the most efficient in the brain of all 
vectors in the 1st generation library, replicating the result of the first screening 
(Supplementary information, Figure 30).  
Furthermore, AAVrh10wt and AAV8wt gave the highest normalized values in 
the liver (Figure 11), mirroring the effects observed for the 1st generation 
library in this tissue (Figure 7). Interestingly, AAVDJ, the chimera previously 
selected in hepatocytes, was 1.8-fold less abundant than the top hit 
AAVrh10wt.  
The collection of AAV4 capsids again exhibited a strong lung affinity, as 
evidenced by the fact that they occupied 7 out of the top 10 spots. 
Nevertheless, AAV2_L1 clearly outcompeted the AAV4 variants by at least 
34.3-fold, representing 82% of all capsids in the lung tissue. Worth noting is 
that capsids that appeared in the lung were also mostly present in blood cells.  
A new addition in the second screening, AAV9_P1, was the most efficient 
capsid in the eye and in the inner ear with 31% and 38% of all hits, 
respectively, after systemic injection (Figure 11). This particular virus could 
also be found in the brown and white fat tissue, albeit it did not reach the top 3. 
Most impressively, AAV9_P1 was the lead candidate in the diaphragm, 
quadriceps femoris and the heart, overtaking the gold standard for muscle 
transduction, AAV9wt, by 10.6-fold, 7.2-fold and 1.5-fold, respectively (Figure 
12). The promising vectors from the first screening, AAVpo1wt and 
AAVpo1_A1 further proved their muscle efficiency in diaphragm and 
quadriceps femoris but were clearly inferior to AAV9_P1. 
 
 
 
Figure 12: Transcriptional efficiency in muscle tissues 
The depicted bar plots show the transcriptional efficiency as normalized proportion of the 
top 10 AAV variants from the 2nd generation library in the diaphragm, quadriceps femoris 
and heart. The cDNA values are the average from six C57BL/6J mice with SD. 
Another possibility to interpret the screening data is to use the Bαβ values in 
order to calculate the proportion of one variant in each tissue, termed Tαβ 
value. Selected highlights of this analysis are shown in Figure 13, Figure 14 and 
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Figure 15. Importantly, these specificity values (Tαβ values) cannot be directly 
compared to the efficiency values (Vαβ values) shown above and are therefore 
herein described separately. 
   
   
   
   
Figure 13: Transcriptional specificity of common AAV serotypes 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of common serotypes from the 2nd generation library in abdominal aorta (Aa), thoracic aorta 
(At), brain (B), blood cells (BlC), colon (C), diaphragm (Di), eye, brown fat (FatB), white fat 
(FatW), heart (H), inner ear (I), kidney (K), liver (Li), lung (Lu), ovaries (O), pancreas (P), 
spleen (S), quadriceps femoris (QF) and stomach (St). Depicted is the average of cDNA 
values from six C57BL/6J mice with SD. 
Analysis of the specificity of wild type AAVs revealed a pronounced bias 
towards the liver, which typically harbored over 80% of the respective virus. 
Exceptions were AAV4wt, AAV9wt and AAVpo1wt. Instead of targeting the 
liver, AAV4wt ended up predominantly in the lung (51%) and to a lesser 
extent in blood cells (24%). The first barcode screening had already implied a 
muscle-tropic behavior of AAVpo1wt (Figure 7). The improved normalization 
strategy could now verify these data by revealing a 52% proportion of 
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AAVpo1wt in the three muscle tissues diaphragm, quadriceps femoris and 
heart, with off-targeting mainly to the brown and white fat tissue, inner ear 
and kidney (Figure 13). Of note, AAV9wt exhibited the broadest activity of all 
82 candidates in this screening and, based on the Vαβ values, also the highest 
efficiency in the majority of the organs (Figure 11 and Figure 33). However, 
most of the capsid still ended up in the liver (50%) after tail vein injection 
(Figure 13). 
Published synthetic AAV capsids included in this screening round offered 
the possibility to validate the robustness of the pipeline by attempting to 
reproduce data from the literature. For instance, in Figure 14, AAVDJ172 
showed a high specificity for the liver (97%) with negligible off-targeting to the 
diaphragm (1%) and spleen (0.7%), further improving on the already liver-
tropic competitor AAV8wt (Figure 13). A more recently published chimera that 
was selected for human hepatocyte transduction, AAVLK03191, demonstrated a 
92% proportion in the murine liver (Figure 14) but was 200-fold less efficient 
than AAV8wt (data not shown). AAV6.2165, deviating in only one amino acid 
from AAV6wt, behaved identical to its unmodified wild type parent 
concerning specificity.  
   
   
Figure 14: Transcriptional specificity of published AAV variants 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of published AAV variants from the 2nd generation library in abdominal aorta (Aa), thoracic 
aorta (At), brain (B), blood cells (BlC), colon (C), diaphragm (Di), eye, brown fat (FatB), 
white fat (FatW), heart (H), inner ear (I), kidney (K), liver (Li), lung (Lu), ovaries (O), 
pancreas (P), spleen (S), quadriceps femoris (QF) and stomach (St). Depicted is the average 
of cDNA values from six C57BL/6J mice with SD. 
Remarkably, AAV9_PHP.B219 not only proved to be a highly efficient capsid 
but furthermore excels in targeting the brain tissue (87%), with minor 
transcriptional activity in the liver (6.7%). AAV2_BR1, a peptide-displaying 
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variant selected for the brain218, could not match AAV9_PHP.B since 51% of the 
AAV2_BR1 transcripts were detected in the brain and 40% in the lung (Figure 
14). 
The highest specificity for the lung was observed for the selected 
AAV2_L1208 capsid, where it made up 71% of all hits. Of the remaining 29%, 
23% were found in blood cells as the major off-target and 4% of the capsid 
ended up in the brain. When comparing this synthetic capsid to the lung-tropic 
AAV4wt (Figure 13), superior efficiency (Figure 11) and specificity (Figure 14) 
were observed for the peptide insertion variant, exemplifying the power of 
directed evolution approaches. It was thus tempting to test whether additional 
improvements could be achieved with an AAV4-based capsid displaying the 
lung-tropic L1 peptide. The resulting rationally designed variant was called 
AAV4_L1, and the corresponding results on specificity can be seen in Figure 
15. 
   
Figure 15: Transcriptional specificity of novel AAV variants 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of novel AAV variants from the 2nd generation library in abdominal aorta (Aa), thoracic 
aorta (At), brain (B), blood cells (BlC), colon (C), diaphragm (Di), eye, brown fat (FatB), 
white fat (FatW), heart (H), inner ear (I), kidney (K), liver (Li), lung (Lu), ovaries (O), 
pancreas (P), spleen (S), quadriceps femoris (QF) and stomach (St). Depicted is the average 
of cDNA values from six C57BL/6J mice with SD. 
Curiously, AAV4_L1 showed no improvement in vector specificity; on the 
contrary, lung-targeting even decreased compared to AAV4wt. Additionally, 
the efficiency was similar to that observed for the other AAV4 peptide 
insertion variants (Figure 11).  
This rational approach was further applied by integrating the BR1 peptide into 
the most efficient wild type capsid for brain transduction, AAV9wt. However, 
the newly generated variant AAV9_BR1 was unable to selectively target the 
brain; instead, it was mainly active in the liver (Figure 15).  
Most notably, AAV9_P1 showed a marked increase in muscle specificity with a 
cumulated proportion of 75% in the three muscle tissues diaphragm, 
quadriceps femoris and heart. Identified off-targets were brown and white fat 
tissue, inner ear and the liver (Figure 15). 
76 RESULTS 
 
4.5 3RD GENERATION LIBRARY SCREENING 
For the third barcode-based variant screening, remains of the 2nd generation 
library were enriched with 64 chimeric capsids that had been independently 
generated, in vivo selected and pre-validated by two other members of the 
Grimm laboratory. Thirty of them were selected in stellate cells by Anne-
Kathrin Herrmann and the other 34 in different muscle tissues by Jihad El 
Andari. The latter were especially important for this work since the newly 
discovered benefits of AAV9_P1 in muscles should be validated against 
variants isolated from state-of-the-art selection strategies, such as DNA family 
shuffling that was used by the other two group members. Furthermore, next to 
a variety of additional published benchmarks, the most promising muscle-
tropic capsids from the literature were added, namely AAVM41189, AAVB1190 
and AAV2_MTP201. Thus, opportunities for a fair comparison to well-
established capsids were provided. On top, two more peptide insertion 
variants were added, AAV9_P3 and AAV9_K3215, comprising a peptide motif 
that is highly similar to P1 and thereby potentially helping to elucidate the role 
of the peptide itself in determining capsid tropism. Finally, to study brain 
transduction, the successors of AAV9_PHP.B219 were spiked in, referred to as 
AAV9_PHP.A219, AAV9_PHP.eB220 and AAV9_PHP.S220 (Table 28). 
All 75 additional variants were individually produced and purified, 
including the 64 extra capsids that were selected by the two colleagues (see 
above) and produced by them. After virus titration, equimolar amounts were 
pooled to create a preliminary library. This library was subsequently titrated 
together with the 2nd generation library. Based on the number of AAV variants 
in the respective libraries, molar shares for the final pooling were calculated.to 
end up with equimolar shares for each vector in the resulting 3rd generation 
library. Afterwards, the mixture was concentrated and dialyzed using an 
Amicon Ultra-15 tube.  
As before, the library composition was assessed by NGS (Supplementary 
information, Figure 36). As compared to the 2nd generation library, the 
imbalance only marginally increased, as evidenced by a 7.4-fold deviation to 
the theoretical mean proportion for one of the newly introduced chimeras, 
AAVJEA3-H4. Importantly, small composition imbalances in this range can 
readily be corrected for during the multi-step normalization procedure. 
For the in vivo screening, 1.57x1012 vg/mouse were injected i.v. into six 
female C57BL/6J mice. After one week, aorta, biceps, colon, diaphragm, 
duodenum, eye, brown fat tissue, white fat tissue, heart, inner ear, kidney, 
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liver, lung, ovaries, pancreas, quadriceps femoris and stomach were harvested. 
Additionally, lymph nodes and the spleen were extracted for subsequent 
isolation of CD3-, CD19-, CD11b- and CD11c-positive cells by MACS (in 
collaboration with Martin Busch). The brain was further dissected into the 
subventricular zone (SVZ) and the cortex (in collaboration with Sascha Dehler). 
From the SVZ, neural stem cells (NSC), neuroblasts, astrocytes and 
oligodendrocytes were extracted via FACS. Astrocytes and oligodendrocytes 
were collected from the cortex. 
In parallel, four BALB/c mice were injected via the tail vein with 
1.57x1012 vg/mouse of the same 3rd generation library. From these mice, 
hepatocytes, stellate cells, Kupffer cells and liver sinusoidal endothelial cells 
(LSECs) were isolated by MACS after perfusing the liver (in collaboration with 
the Dooley laboratory and Anne-Kathrin Herrmann). DNA and RNA were 
extracted, and qPCR-based determination of the viral genomes per diploid cell 
was performed for all samples except for the brain cells where only RNA could 
be collected. The distribution of the 3rd generation library in the comprehensive 
tissue collection from the C57BL/6J mice and the liver cells of the second mouse 
experiment can be seen in Figure 16. 
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Figure 16: Viral DNA distribution of the 3rd generation library 
(A) The depicted bar plot shows the viral DNA distribution from the 3rd generation library 
after systemic injection into six C57BL/6J mice across aorta (A), biceps (Bi), colon (C), 
diaphragm (Di), duodenum (Du), eye, brown fat (FatB), white fat (FatW), heart (H), inner 
ear (I), kidney (K), liver (Li), lung (Lu), ovaries (O), pancreas (P), quadriceps femoris (QF), 
stomach (St) and CD3-, CD19-, CD11b- as well as CD11c-positive cells. (B) Shows the 
distribution in the liver of four BALB/c mice across hepatocytes (Hep), stellate cells (HSC), 
Kupffer cells (KC) and liver sinusoidal endothelial cells (LSEC). Detected viral genomes 
(EYFP probe) were normalized to GAPDH as a housekeeper. Depicted values represent the 
average of the mice with SD. 
As previously observed for the second variant screening (Figure 9), the 
majority of AAV particles ended up in the liver (42 vg/dg) followed by CD11c 
cells (14 vg/dg), CD11b cells (3.3 vg/dg), brown fat tissue (3 vg/dg) and white 
fat tissue (2.2 vg/dg). Aorta, biceps, diaphragm, heart, kidney, lung, ovaries, 
quadriceps femoris, CD3 and CD19 cells ranged between 0.35 and 1.6 vg/dg. 
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The digestive tract including colon, duodenum and stomach as well as the eye, 
inner ear and pancreas could only be weakly transduced (0.05-0.16 vg/dg). 
Concerning the transduction of liver cell types in the separate mouse study 
(Figure 16B), hepatocytes, stellate cells and Kupffer cells demonstrated similar 
levels, while LSECs were slightly lacking behind. 
After processing the NGS data and analyzing the output files, C57BL/6J 
mouse numbers 3 and 4 were declared to be outliers due to unusually low 
AAV9_P1 abundance and therefore excluded from the analysis. The Vαβ and 
Tαβ values that are shown below hence depict the averages of mouse 1, 2, 5 and 
6 with the corresponding SD. Figure 17 shows the efficiency of the top 10 AAV 
variants in the liver, lung, eye, inner ear, brown and white fat tissue. 
   
   
Figure 17: Transcriptional efficiency in various tissues 
The depicted bar plots show the transcriptional efficiency as normalized proportion of the 
top 10 AAV variants from the 3rd generation library in the liver, lung, eye, inner ear, brown 
fat tissue and white fat tissue. The cDNA values are the average from four C57BL/6J mice 
with SD. 
A first notable result was that AAVrh10wt outcompeted the other capsids in 
the library in the liver, reproducing the results from the first (Figure 7) and 
second (Figure 11) screening. AAV8wt was found in position 7, mostly 
separated from AAVrh10wt by capsids that were newly added in the third 
screening round (Table 28). One of those, AAVB1, was originally reported to 
excel in brain, muscle and pancreas190 but turned out to be highly 
transcriptionally active in the liver. In the lung, the highly promising capsid 
AAV2_L1208 was confirmed as lead candidate displacing the rationally 
designed peptide insertion variants.  
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From the 2nd generation library, AAV9_P1 has emerged as an efficient 
vector in the muscle tissues (Figure 12) and the off-targets eye, inner ear and 
fat tissue (Figure 11). Figure 17 partially exemplifies this phenomenon again by 
verifying AAV9_P1 as the most efficient vector in the eye and inner ear. Unlike 
what was observed in the second screen, the P1-displaying variant even 
marginally overtook AAV9wt in the white fat tissue.  
More importantly, AAV9_P1 once more showed a superior efficiency 
compared to AAV9wt in the diaphragm, biceps, quadriceps femoris and heart 
where it outperformed its parent by 10.1-fold, 7.2-fold, 5.6-fold and 1.6-fold, 
respectively (Figure 18). Surprisingly, none of the published muscle 
benchmarks was able to reach the top 10 in any of the muscle tissues. 
Moreover, several of the newly generated, shuffled chimeras selected in these 
tissues were found in the top 10 albeit they remained below AAV9wt. Finally, 
an additional peptide insertion mutant from our laboratory, AAV9_P3, scored 
second to AAV9_P1 in the diaphragm, biceps and quadriceps femoris where it 
was 3- to 6-fold less efficient depending on the organ.  
  
 
   
Figure 18: Transcriptional efficiency in muscle tissues 
The depicted bar plots show the transcriptional efficiency as normalized proportion of the 
top 10 AAV variants from the 3rd generation library in the diaphragm, biceps, quadriceps 
femoris and heart. The cDNA values are the average from four C57BL/6J mice with SD. 
Another promising feature of the 3rd generation library was the presence of 
three additional brain-targeting variants next to AAV2_BR1 and AAV9_PHP.B, 
offering the opportunity for a head-to-head comparison in the clinically highly 
relevant brain tissue. However, it has to be noted that the flow cytometry 
sorting of cells from this tissue was difficult, ultimately resulting in an 
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incomplete recovery of the samples and low cellular yields ranging from 330 to 
941 cells depending on the fraction. Thus, the data must be interpreted with 
caution. Nonetheless, a trend towards AAV9_A2 could be observed 
(Supplementary information, Figure 39). Intriguingly, none of the capsids 
suggested by the literature appeared in the top 10. 
In the second mouse experiment utilizing the third barcoded library, the 
liver of four BALB/c mice was dissected into hepatocytes, Kupffer cells, stellate 
cells and LSECs in collaboration with the Dooley laboratory in Mannheim and 
Anne-Kathrin Herrmann. Samples of extracted DNA and RNA were run 
through the established pipeline and normalized as previously described 
(3.4.13). As before, Vαβ values were averaged across the mice and are depicted 
with the corresponding SD in Figure 19. 
   
   
Figure 19: Transcriptional efficiency in liver cell types 
The depicted bar plots show the transcriptional efficiency as normalized proportion of the 
top 10 AAV variants from the 3rd generation library in hepatocytes, Kupffer cells, liver 
sinusoidal endothelial cells (LSECs) and stellate cells. The cDNA values are the average 
from four BALB/c mice with SD.  
The data from the whole liver (Figure 17) had already indicated a 
pronounced liver activity of AAVB1190. Analysis of the sub-cell types revealed 
the highest AAVB1 efficiency in hepatocytes where it outperformed all other 
variants. In addition, the capsid was detected in the top 10 of the remaining 
three cell types. In Kupffer cells, an interesting effect was noted, namely the 
appearance of variants that were generally less efficient, such as AAV1_P5 and 
AAV6.2. Curiously, none of the chimeras pre-selected for stellate cells was 
preferentially detected in these cells in this screen. More information on these 
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capsids and a more detailed description and discussion of these data is found 
in the doctoral thesis of Anne-Kathrin Herrmann. 
The possibility to analyze the liver as a whole organ or divided into cell 
types massively enhances the understanding of the function of particular 
capsid variants. Accordingly, for capsids that were less frequently found in 
hepatocytes, their specificity was assessed by studying the corresponding Tαβ 
values in all 21 tissues (Figure 20). 
   
  
 
Figure 20: Transcriptional specificity of hepatocyte-detargeted variants 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of hepatocyte-detargeted AAV variants from the 3rd generation library in aorta (A), biceps 
(Bi), colon (C), CD11b-, CD11c-, CD19-, CD3-positive cells, diaphragm (Di), duodenum (Du), 
eye, brown fat tissue (FatB), white fat tissue (FatW), heart (H), inner ear (I), kidney (K), liver 
(Li), lung (Lu), ovaries (O), pancreas (P), quadriceps femoris (QF) and stomach (St). 
Depicted is the average of cDNA values from four C57BL/6J mice with SD. 
The selected candidates AAV1wt, AAV6wt, AAV6.2, AAV1_P5 and 
AAVAH3-5 demonstrated a highly similar tropism, by almost exclusively 
targeting the liver and CD11b- as well as CD11c-positive cells. Strikingly, three 
different capsid engineering approaches achieved the same result, namely 
DNA family shuffling with AAVAH3-5, peptide insertion with AAV1_P5 and 
introduction of single point mutations with AAV6.2. Even the very 
homologous, naturally occurring isolates AAV1wt and AAV6wt exhibited 
identical specificity patterns. Still, out of the five capsids, AAV1_P5 showed 
the most pronounced immune cell-targeting while its activity in the liver was 
limited to fewer than 20%. 
Concerning the specificity within the liver tissue, i.e., information provided 
by the second study in BALB/c mice, a marked hepatocyte-detargeting could 
be observed for all five variants (Figure 21). 
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Figure 21: Transcriptional specificity of hepatocyte-detargeted variants 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of hepatocyte-detargeted AAV variants from the 3rd generation library in hepatocytes (Hep), 
hepatic stellate cells (HSC), Kupffer cells (KC) and LSECs. Depicted is the average of cDNA 
values from four BALB/c mice with SD. 
In more detail, the chimera AAVAH3-5 detargeted hepatocytes almost 
entirely (0.8%), followed by the other four variants with normalized 
proportions of roughly 3%. None of the selected vectors could discriminate 
between stellate cells, Kupffer cells or LSECs, including the shuffled chimera 
selected in stellate cells, AAVAH3-5. From the three mentioned cell types, the 
mentioned vectors could be predominately found in Kupffer cells with over 
40% followed by stellate cells (~30%) and LSECs (~15%). Solely based on the 
specificity, no clear lead candidate emerged. However, AAV1_P5 was the most 
efficient in stellate cells where it marginally surpassed AAV6.2, AAV6wt, 
AAVAH3-5 and AAV1wt by 1.05-fold, 1.27-fold, 2.18-fold and 2.38-fold, 
respectively (corresponding Vαβ values are not shown). 
In the full organ biodistribution, a remarkable observation had been that 
AAV2_L1 demonstrated the highest specificity observed in all three screenings 
(Figure 22). 99% of the vector activity was measured in the lung, which is even 
higher than the 71% proportion found in the second screening round (Figure 
14). This enhancement can most likely be explained by the fact that for the 3rd 
generation library, the two major off-targets, blood cells and brain, were not 
included in the analysis. This clearly exemplifies that determination of capsid 
specificity strongly depends on the investigated organs.  
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Vice versa, an example that implementing certain tissues can also decrease 
the tropism is shown for AAVDJ (Figure 22). The dataset of the 2nd generation 
library had revealed a very pronounced 97% specificity of this capsid for the 
liver (Figure 14). However, the most recent screening showed additional 
AAVDJ activity in CD11b- and CD11c-positive cells, lowering its value in the 
liver to 58%. Anne-Kathrin Herrmann made further modifications to the 
AAVDJ capsid by mutating three tyrosine residues to phenylalanines 
(AAVDJYF), hoping to evade proteasomal degradation of the particles. 
Nevertheless, this did not result in improved efficiency in the whole liver or 
enhanced specificity. 
   
Figure 22: Transcriptional specificity of AAVDJ and AAV2_L1 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of AAVDJ, AAVDJYF and AAV2_L1 from the 3rd generation library in aorta (A), biceps (Bi), 
colon (C), CD11b-, CD11c-, CD19-, CD3-positive cells, diaphragm (Di), duodenum (Du), eye, 
brown fat tissue (FatB), white fat tissue (FatW), heart (H), inner ear (I), kidney (K), liver (Li), 
lung (Lu), ovaries (O), pancreas (P), quadriceps femoris (QF) and stomach (St). Depicted is 
the average of cDNA values from four C57BL/6J mice with SD. 
Within the liver, the chimera selected in hepatocytes, AAVDJ, was indeed 
found predominantly in hepatocytes (87%) followed by stellate cells (6.9%), 
Kupffer cells (4.3%) and LSECs (1.3%) (Figure 23). Also here, the mutations 
introduced in AAVDJYF did not alter capsid selectivity for the on-target. 
Worth noting are two peptide-modified variants, AAV5_P5 and AAV8_P5, 
that exhibited similar or even enhanced hepatocyte activity with 95% and 85%, 
respectively. Still, these vectors are slightly inferior to AAVDJ since their 
efficiency is 14-fold and 2.2-fold lower in whole liver, based on the data from 
the second screening. Finally, AAV8wt and AAVrh10wt, that were the most 
effective capsids in the liver on the cDNA level (Figure 11), showed a broad 
distribution in the four sub-cell types with minor preference to hepatocytes 
(Figure 23). 
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Figure 23: Transcriptional specificity for hepatocytes 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of hepatocyte-targeting AAV variants from the 3rd generation library in hepatocytes (Hep), 
hepatic stellate cells (HSC), Kupffer cells (KC) and LSECs. Depicted is the average of cDNA 
values from four BALB/c mice with SD. 
Next to liver, muscle is one of the preferred organs for gene therapy 
applications. The results from the 2nd generation library had already showed a 
massively improved targeting of muscle for AAV9_P1 (Figure 15). The 3rd 
generation library comprised important benchmarks from the literature, 
allowing for an extensive comparison with this lead candidate. The specificity 
values (Tαβ values) of the mentioned benchmarks are depicted in Figure 24. 
   
   
Figure 24: Transcriptional specificity of published benchmarks in muscles 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of published muscle-tropic benchmarks from the 3rd generation library in aorta (A), biceps 
(Bi), colon (C), CD11b-, CD11c-, CD19-, CD3-positive cells, diaphragm (Di), duodenum (Du), 
eye, brown fat tissue (FatB), white fat tissue (FatW), heart (H), inner ear (I), kidney (K), liver 
(Li), lung (Lu), ovaries (O), pancreas (P), quadriceps femoris (QF) and stomach (St). 
Depicted is the average of cDNA values from four C57BL/6J mice with SD. 
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The widely used and broadly transducing AAV9wt once more particularly 
targeted the liver (52%), an effect already observed in the second screening 
(Figure 13). Previously observed, AAVpo1wt exhibited a tendency for 
transduction of diaphragm and quadriceps femoris (Figure 13). In this third 
screen, this tropism could be confirmed, with brown and white fat tissue 
appearing as major off-targets (Figure 24).  
AAVB1, a chimera originally selected for the brain190, was reported to 
transduce muscle tissues more robustly than AAV9wt, a notion that could not 
be reproduced here. In fact, AAVB1 was 3-, 3.5-, 7.6- and 9.2-fold less efficient 
in the heart, diaphragm, quadriceps femoris and biceps, respectively 
(corresponding Vαβ values are not shown). Regarding specificity, the chimeric 
AAVB1 capsid was preferentially detected in the liver with 86% (Figure 24). 
Another chimera from Yang and colleagues, AAVM41, was isolated after 
two selection rounds in muscle tissue and showed a trend towards a muscle 
tropism189. Here, 16.5% of the transcriptional activity could be found in the 
diaphragm, 8.3% in the heart, 3% in the biceps and 4% in the quadriceps 
femoris. However, the capsid was roughly 10-fold less efficient than AAV9wt. 
The peptide-inserted mutant AAV9_K3 was selected in endothelial cells215 
but used in the third screening due to its peptide sequence that deviated from 
P1 in only two of the nine amino acids. Surprisingly, the variant could not 
target the muscles. Instead, 77% of the viral activity was measured in the liver. 
Two point mutations, P504A and G505A, were introduced to the AAV9wt 
capsid proteins by Adachi et al., yielding variant AAV9LD222 that was reported 
to be liver-detargeted. Indeed, the strong exclusion of the liver could be 
reproduced in this study by detecting 140-fold less viral transcripts as 
compared to AAV9wt. Interestingly, this effect resulted in a preferred targeting 
of muscle and fat tissues as depicted in Figure 24. However, the mutations 
mildly decreased the efficiency by roughly 1.5-fold in diaphragm, biceps and 
quadriceps femoris as well as, more prominently, in the heart by 3-fold 
compared to the parental virus, AAV9wt. 
So far, none of the benchmarks could reach similar levels of specificity or 
efficiency in comparison to AAV9_P1 in the second screening. New in the 
successive round were chimeric synthetic capsids selected and pre-validated in 
muscle tissues by Jihad El Andari, including an independent NGS screen. 
Thirty-four of these shuffled variants were included in the library and assessed 
for specificity, and the most promising are depicted in Figure 25. All of them 
showed a convincing detargeting from the liver while increasing the 
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proportion in muscle tissues, as hoped for. As previously observed for 
AAVM41, AAV9LD and AAV9_P1 (Figure 24 and Figure 15), off-targeting to 
the brown and white fat tissue was measured.  
   
   
Figure 25: Transcriptional specificity of novel variants in muscle tissues 
The depicted bar plots show the transcriptional specificity as normalized proportion per cell 
of novel muscle-tropic AAV variants from the 3rd generation library in aorta (A), biceps (Bi), 
colon (C), CD11b-, CD11c-, CD19-, CD3-positive cells, diaphragm (Di), duodenum (Du), eye, 
brown fat tissue (FatB), white fat tissue (FatW), heart (H), inner ear (I), kidney (K), liver (Li), 
lung (Lu), ovaries (O), pancreas (P), quadriceps femoris (QF) and stomach (St). Depicted is 
the average of cDNA values from four C57BL/6J mice with SD. 
The lead candidate of the second screening, AAV9_P1, once more exhibited 
a strong muscle tropism (66%) outcompeting all other variants in the 3rd 
generation library (Figure 25). In addition, AAV9_P1 was roughly 10-fold more 
efficient in the on-targets than the best chimeric AAVJEA vectors. Of note, 
AAV9_P3 also behaved similar to AAV9_P1 in terms of specificity, but the 
cumulative value for all muscles was lower (30%). 
4.6 VALIDATION OF AAV9_P1 
As shown above, AAV9_P1 demonstrated compelling evidence for a high 
efficiency (Figure 12 and Figure 18) and specificity (Figure 15 and Figure 25) in 
murine muscle tissues. To independently verify this novel and exciting finding, 
further validation experiments had to be performed. One particularly 
important consideration was the potential occurrence of capsid interference in 
a library context, resulting from e.g. receptor competition or particle cross-
interactions. Therefore, AAV9_P1 and the previous lead candidates from the 
first screening, AAVpo1wt and AAVpo1_A1, as well as AAV9wt as a control 
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were injected individually into three C57BL/6J mice at a dose of 
1x1011 vg/mouse. The other supposedly muscle-tropic vectors from the 
literature, AAVB1190, AAVM41189, AAV9_K3215, AAV9LD222 and AAV2_MTP201, 
were excluded from this study since none of them matched AAV9_P1 
regarding efficiency (Figure 18) and muscle-targeting (Figure 24 and Figure 
25). The two AAVpo1-based variants were included due to their roughly 50% 
proportion in the three muscle tissues (Figure 24). Intravenously injected mice 
were kept for one week before diaphragm, quadriceps femoris, heart and liver 
were harvested and analyzed by qPCR to detect the viral transcripts. The eyfp 
transgene signal was subsequently normalized to a POLR2A housekeeper. The 
values depicted in Figure 26 are eyfp relative quantities (2-ΔCt) for the mentioned 
AAVs in the respective organs. 
   
 
  
Figure 26: EYFP relative quantities of AAV9_P1 
The depicted bar plots show EYFP relative quantities of AAV9_P1, AAVpo1_A1, 
AAVpo1wt, AAV9wt and an uninjected control mouse in the diaphragm, quadriceps 
femoris, heart and liver. Relative quantities (2-ΔCt) were measured by detecting viral EYFP 
transcripts via qPCR as well as a POLR2A housekeeper. Depicted values are the average of 
three C57BL/6J mice with SD. 
AAV9_P1 exhibited a dramatically improved transcriptional activity in the 
diaphragm, quadriceps femoris and heart, exceeding its parental capsid 
AAV9wt by 55-, 17- and 11-fold, respectively. Importantly, the P1-displaying 
variant was 9-fold less abundant in the major AAV off-target, the liver. Both 
AAVpo1-based variants showed less activity than AAV9wt, which is in line 
with the barcode screening data (Figure 12). Notably, AAVpo1wt and 
AAVpo1_A1 were especially detargeted from the liver, i.e., 126-fold and 63-
fold, further improving on the already pronounced effect of AAV9_P1. 
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To study whether AAV9_P1 would exhibit additional beneficial effects on 
the protein level, the used AAV genome cassette was slightly modified by 
replacing the CMV promoter-driven eyfp gene with egfp. This guaranteed an 
optimal excitation at 488 nm for a fluorescence-based readout via histology. 
C57BL/6J mice were i.v. injected with 5x1011 vg/mouse and kept for two weeks 
before submerging organ pieces of the diaphragm, quadriceps femoris, biceps, 
heart and liver into a 4% paraformaldehyde solution for fixation. After an 
intermediate incubation in 30% sucrose, the samples were embedded and 
cryosections were generated. Both AAVpo1 variants were excluded from this 
experiment since their strong liver-detargeting did not outweigh the lower 
efficiency in the muscle tissues as compared to AAV9_P1. Next to AAV9_P1, 
AAV9wt and a PBS control, also a newly-cloned variant, AAV9LD_P1, was 
included in which the two mutations of AAV9LD222 were introduced into the 
AAV9_P1 capsid. The expectation was that this rationally designed capsid may 
display enhanced liver-detargeting while maintaining the prominent activity in 
the muscle tissues. 
During the dissection of the mice, a surprising effect observed for the 
AAV9_P1 group was that EGFP expression was visible to the naked eye. 
Images of a representative mouse in dorsal and ventral position are shown in 
Figure 27. 
 
Figure 27: Dissection of an AAV9_P1-injected mouse 
Dissection images show a representative C57BL/6J mouse in ventral and dorsal position 
from the PBS and AAV9_P1 group. Mice were injected i.v. with 5x1011 vg/mouse and kept 
for two weeks. 
Although the pictures were taken under normal light conditions, a 
pronounced EGFP signal could be detected in the skeletal muscles of the 
AAV9_P1-injected mouse. Thus far, the superior activity of AAV9_P1 in the 
muscles was determined based on cDNA data of the quadriceps femoris and 
the biceps (Figure 26). However, these images led to the assumption that the 
capsid behaved equally efficient in the other skeletal muscles. 
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From the obtained cryosections, representative images were chosen for the 
liver diaphragm, heart, biceps and quadriceps femoris and assessed directly for 
EGFP-induced fluorescence signal (Figure 28 and Figure 29). The exposure was 
normalized to the highest signal in this experiment, i.e., the diaphragm of the 
AAV9_P1-injected mouse. The dataset for the PBS and AAV9wt group can be 
seen in Figure 28. 
 
Figure 28: EGFP fluorescence of PBS and AAV9wt group 
Images show 10 µm cryosections of the liver, diaphragm, heart, biceps and quadriceps 
femoris. Representative sections were chosen from C57BL/6J mice injected with 
5x1011 vg/mouse of AAV9wt or PBS as a control. Direct EGFP fluorescence was detected 
(green) together with the DAPI signal (blue). Scale bar in the full section is 1 mm and 
100 µm for the 10x magnification. Exposure was normalized to the diaphragm of the 
AAV9_P1 group (Figure 29). 
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Figure 29: EGFP fluorescence of AAV9_P1 and AAV9LD_P1 group 
Images show 10 µm cryosections of the liver, diaphragm, heart, biceps and quadriceps 
femoris. Representative sections were chosen from C57BL/6J mice injected with 
5x1011 vg/mouse of AAV9_P1 or AAV9LD_P1. Direct EGFP fluorescence was detected 
(green) together with the DAPI signal (blue). Scale bar in the full section is 1 mm and 
100 µm for the 10x magnification. Exposure was normalized to the diaphragm of the 
AAV9_P1 group. 
As expected, no fluorescence was detected in organs of the PBS group. The 
sections of the AAV9wt-injected mice showed a faint signal in the heart and 
the liver. Strikingly, AAV9_P1 completely transduced the diaphragm and 
slightly less efficiently the biceps and quadriceps femoris (Figure 29). In the 
heart, an EGFP signal could be predominantly observed in the tissue layers 
surrounding the heart cavity, indicating that transduction in this organ is more 
heterogeneous than in the other muscles. Importantly, barely any fluorescence 
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was detected in the liver, further supporting the biodistribution illustrated in 
Figure 15 and Figure 25.  
Concurrent with the results obtained for AAV9LD (Figure 24), the modified 
P1-displaying capsid, AAV9LD_P1, showed enhanced detargeting from the 
liver albeit this is difficult to spot with the used exposure settings (Figure 29). 
Unexpectedly, the rationally designed variant mediated lower EGFP 
expression in the four muscle tissues compared to AAV9_P1, especially in the 
heart. Importantly, AAV9LD_P1 still exceeded the benchmark AAV9wt.  
Also surprising was that barely any fluorescence could be detected for 
AAV9wt in this work, at least with the exposure settings used in Figure 28 and 
Figure 29. To prove that AAV9wt was indeed above background level, the 
exposure was normalized to the EGFP signal in the liver of AAV9wt 
(Supplementary information, Figure 43). In the liver, AAV9wt demonstrated 
EGFP signals in the entire organ but preferentially surrounding the blood 
vessels. In the heart, a partial transduction was observed for AAV9wt 
supporting literature data that AAV9wt is highly efficient in this tissue230–234. It 
was already observed in Figure 13 and Figure 24 that most of the capsid ended 
up in the liver, which may contribute to the relatively weak fluorescence 
signals in the diaphragm, biceps and quadriceps femoris.  
Not surprisingly, the images for AAV9_P1 with the modified settings 
(Supplementary information, Figure 44) were massively overexposed due to 
the high activity of the mutant in these tissues. Regardless, these alternative 
settings strongly supported the conclusion that AAV9_P1 was transducing 
every cell in the muscle tissues, except for the heart where the signal was 
weaker in the outer layers. In the liver, individual cells were hit, which is in 
contrast to AAV9LD_P1 where EGFP fluorescence was almost completely 
abolished. 
 
 5 DISCUSSION 
5.1 BARCODE-BASED CAPSID SCREENING 
High-throughput capsid engineering strategies such as DNA family 
shuffling, peptide display and random mutagenesis yield thousands of 
potentially promising variants with higher efficiency and specificity. However, 
selecting the best candidate from this pool remains challenging, raising the 
demand for strategies that facilitate and accelerate the process. 
The aim of this work was to establish and apply a barcode-based AAV 
capsid screening pipeline enabling a simultaneous validation of multiple 
capsid variants in vivo. 
5.1.1 ESTABLISHMENT, LIMITATIONS AND FURTHER 
OPTIMIZATION 
Utilizing and building on the information provided in the literature222,224,225, 
the barcode was integrated into the 3’UTR of a CMV promoter-driven eyfp 
(Figure 4). Thus, barcode abundance could be monitored on the DNA and 
RNA level. However, the latter poses further challenges for the normalization 
strategy. 
First of all, a comparison of barcode-comprising viral transcripts across 
multiple organs or cells assumes equal promoter activity in all analyzed 
tissues. The CMV promoter is known for its ubiquitous expression, making it a 
suitable candidate for this screening235. Secondly, values for the activity of each 
virus in every tissue have to be determined which then allow calculating 
proportions for the individual organs, referred to as specificity. Next 
generation sequencing of the cDNA samples of each tissue reveals how much 
of all the detected barcode sequences belong to one capsid variant. However, 
this proportion alone cannot be used to predict the specificity of a given capsid 
across all tissues. For instance, a capsid could have a 20% share in the liver and 
a 20% share in the eye, but these numbers solely describe the efficiency within 
each organ compared to all other variants in the screening, while they do not 
allow a statement about the overall distribution of this variant in the body. 
This fundamental difference - efficiency within a single tissue versus specificity 
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across all studied tissues - is perhaps best illustrated by the bulk results 
depicted in Figure 9, which show that most of the library ends up in the liver. 
This implies that even if a capsid has a high efficiency in a non-liver tissue as 
compared to all other capsids in the same tissue, its actual main target in the 
whole body may still be the liver itself, which was indeed frequently in line 
with our observations. Hence, ideally the relative quantities of all viral 
transcripts have to be determined in every organ and then multiplied with the 
barcode proportion obtained from the deep sequencing, resulting in the 
relative quantities of one variant in the corresponding organ.  
Unfortunately, this strategy would introduce a bias since the RNA 
expression levels of the commonly used housekeeping genes vary across the 
tissues236,237. Due to this reason, the proportional values were normalized to the 
total viral genomes per cell in the respective organs, by making the assumption 
that the genome delivered by a particular variant always produces the same 
amount of transcripts in all analyzed tissues. As previously mentioned, this 
only applies if the promoter activity is identical in all tissues, which, however, 
cannot be guaranteed even for a ubiquitous promoter. Thus, determining the 
specificity inevitably introduces a bias either because of the heterogeneous 
housekeeper expression or tissue-specific promoter activity. However, 
assessing the relative quantities of the viral transcripts would require an 
additional qPCR step for every analyzed tissue, and the resulting values would 
moreover have to be divided by the total viral genomes (Gβ) of the same organ. 
This calculation normalizes for the potentially unequal promoter activity but 
cannot correct for the variable housekeeper expression. In conclusion, both 
approaches are appropriate, yet the strategy that multiplies the NGS 
proportions with solely the Gβ-values was chosen for this work as it saves one 
extra qPCR step. 
Importantly, the applied normalization strategy also corrects for the 
unbalanced composition of the initial library and for total read count 
differences between flow cells, ultimately leading to so-called Bαβ values 
(3.4.13) that describe the overall biodistribution of every vector in the 
screening. These values can be depicted as proportion of one variant across all 
tissues (Tαβ values) or as proportion of all variants within one tissue (Vαβ 
values). The same formulas were used to process the DNA dataset but, unlike 
the transcripts, the viral genomes are independent of the CMV promoter 
activity thus omitting this particular bias in the analysis. In summary, the 
novel normalization procedure enables, for the first time, to simultaneously 
monitor specificity and efficiency thereby yielding essential information for the 
characterization of gene therapy vectors.  
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Most crucial is the design of the barcode itself. In the first attempt to 
produce barcoded AAV genomes, an oligonucleotide with 10 random bases 
was ordered and integrated into the 3’UTR via Golden Gate cloning. After 
bacteria transformation, theoretically every individual colony should comprise 
a distinct, 10 nucleotides-long barcode. Yet, after confirming that the clones 
possessed intact ITRs, Sanger sequencing revealed truncated barcodes, 
homopolymers or even identical DNA sequences. Due to those reasons, the 
approach had to be canceled and optimized. Consequently, the barcode was 
extended to 15 bases to increase the mathematically possible unique 
combinations from 410 to 415. These second-generation barcodes exhibited a 
drastic improvement as evidenced by a reduced appearance of homopolymers 
or identical sequences. From the pool of extracted barcodes, sequences 
comprising homopolymers with more than 3 identical consecutive nucleotides 
were excluded since the NGS experiences difficulties when predicting the 
bases for such stretches. To prevent false assignment of barcodes due to 
sequencing errors, differences in at least five positions compared to all other 
barcodes in the library were required. Therefore, the Hamming distance was 
calculated, and sequences that failed to fulfill these criteria were excluded. In 
summary, 240 clones were picked, of which 11 lost their ITRs, 64 comprised 
homopolymers or truncated sequences and another six showed a Hamming 
distance below 5. Eventually, only 66% of the screened barcodes could be used 
illustrating how labor-intensive this process is.  
An alternative but inevitably more expensive approach could be to order 
pre-defined barcodes as oligonucleotides. After self-annealing, the barcodes 
can be pooled and cloned into a backbone with complementary overhangs. To 
generate a library comprising 100 unique sequences, roughly 165 colonies have 
to be analyzed and only checked for ITR integrity as determined by probability 
theory. Pre-defined barcodes could be designed without any homopolymers 
and a sufficient Hamming distance. Most importantly, the length of the 
sequences could be cut down to eight nucleotides or even lower while still 
fulfilling the mentioned prerequisites, in turn providing more freedom when 
placing the primers for amplicon generation. In the current approach the 
amplicon is slightly too long, therefore only the reverse sequencing index can 
be read with a 75 cycle Illumina kit since the required amount of nucleotides to 
cover the capsid barcode had to be 84. Consequently, this prevents sequencing 
the forward index and ultimately limits the multiplexing to 32, due to 32 
available reverse indexes in the Ovation Low Complexity kit that was used in 
this work. An optimized and therefore shorter barcode-comprising amplicon 
would offer the possibility to utilize the forward index, thus allowing to 
process substantially more samples on one flow cell. 
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Another crucial parameter during barcode-based capsid screening is the 
virus production and the resulting composition of the library. Variants for the 
1st generation library were each produced using two HEK293T plates and 
eventually purified over one cesium chloride gradient, in order to save costs 
and time. Surprisingly, pronounced discrepancies could be detected regarding 
the production efficiency of the individual variants, creating a largely 
imbalanced library composition (Figure 6). Nevertheless, the normalization 
strategy corrects for such effects by using the variant proportions in the initial 
input library (Lα) and by normalizing the NGS-determined Pαβ values to these 
ratios. Still, normalization artefacts were observed especially for capsids that 
were particularly under-represented, such as the peptide insertion mutants of 
AAV serotypes 1, 6 and 12. For instance, AAV12_P2 and AAV1_P2 were the 
fourth and ninth most efficient vector in the eye (Figure 7), but analysis of the 
raw data revealed that AAV12_P2 was only detected in four out of six mice, 
and AAV1_P2 in one out of six. Despite the minute amounts, the 77-fold and 
132-fold under-representation triggered a high multiplication of the respective 
Pαβ values during the data normalization, in turn leading to the observed 
artefacts. In fact, this phenomenon was also found in abdominal aorta, brain, 
brown and white fat tissue as well as kidney in the first screening for the 
cDNA data (Figure 30), and in abdominal aorta, thoracic aorta, brain colon, eye 
and white fat tissue for the gDNA data (Figure 31).  
In an attempt to create a more homogenous library composition, virus 
production for the variants of the 2nd generation library was performed 
individually. To this end, the amount of needed plates was adapted and the 
respective lysates were run separately over iodixanol gradients. Pooling of 
equimolar amounts as determined by qPCR led to a balanced library (Figure 8) 
unlikely to produce normalization artefacts. However, significantly more time 
and consumables, i.e., 1148 plates and 114 individual iodixanol gradients, had 
to be invested to produce the 82 variant-comprising 2nd generation AAV 
library. Still, this is worth the effort as it substantially improves library quality 
and overall robustness of the pipeline, and as it is probably the only option for 
screenings of highly diverse capsids including different serotypes, peptide 
insertions and other mutants. Of note, the production scheme of the 1st 
generation library likely remains suitable for barcode screenings of lead 
candidates from directed evolution strategies, such as DNA family shuffling or 
peptide display, since these variants have inevitably also been selected for high 
production efficiency. Therefore, the viral particle yield per plate should be 
similar among these vectors, arguably favoring the less labor-intensive process. 
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Furthermore, the detection limit of the barcode-based variant screening 
should be considered. In fact, this limit is difficult to define due to the 
multifactorial dependency on the dose per variant, homogenous intravenous 
injections, incubation time before the harvest, transducability of the analyzed 
tissues, self-complementary or single-stranded AAV genome, sequencing 
depth, cDNA or DNA detection, the variant itself and the number of potential 
competitors in the library.  
Regarding the dose, the aim was to inject 1x1010 vg per variant per mouse. 
However, the library imbalance of the first round resulted in a broad range of 
abundance between the individual variants. A good example for the detection 
limit was provided by AAV4mut_A2 which was the least abundant capsid in 
the library with 3x106 vg/mouse, with a 3600-fold deviation from the mean. 
Serotype AAV4 and its peptide-modified variants as well as AAV4mut 
exhibited a strong lung tropism, taking eight spots in the top 10 list (Figure 7). 
The remaining peptide insertion mutants of AAV4mut could all be found in 
the top 25 except for AAV4mut_A2, for which no read counts were measured 
in the six mice. Most likely, this particular capsid would have demonstrated 
the same preferred lung-targeting if equimolar titers would have been used. 
The dose of 1x1010 vg per variant in the second screening was enough to detect 
read counts in all six mice for at least two thirds of the variants, even in poorly 
transduced tissues. This is sufficient to analyze the efficiency and specificity of 
promising candidates.  
The incubation time before harvesting the organs was two weeks for the 
first screening and one week for the second and third. No noticeable difference 
could be detected when reducing the time. Further decreasing the incubation 
will eventually diminish the chance of the vectors to transduce the target 
tissues. Prolonging the time by several weeks probably enhances silencing of 
the CMV promoter238.  
Arguably the highest influence on the detection limit is exerted by the 
screened organs and variants themselves. As depicted in Figure 9, the vast 
majority of the library ended up in the liver. Organs such as the eye and the 
digestive tract were difficult to transduce and therefore required a more 
sensitive detection. Among the variants, dramatic variations in terms of 
efficiency were observed (Figure 10). For instance, vectors belonging to the 
AAV2, AAV3 and AAV5 family demonstrated a very weak in vivo activity, 
resulting in only a few barcode reads.  
Equally important is the size of the library and the associated variant 
competition. These resulting interfering effects were illustrated in the third 
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screening, where the settings were kept identical to the second round while the 
library was enriched with further 75 capsids. For each of them, 
1x1010 vg/mouse were injected intravenously. Although many results could be 
reproduced, the majority of weakly active AAVs hit the detection limit. For 
example, in the context of the 2nd generation library, AAV2wt exhibited a 
minor 0.14% share in the liver with a marginal standard deviation across the 
six mice. However, in the third screening, one out of four mice had no read 
counts even though AAV2wt preferentially targets the liver. As expected, the 
detection was even more challenging on the DNA level since only the barcodes 
on the viral genomes are measured, whereas promoter-amplified barcode-
comprising transcripts are counted on the cDNA level. In general, a deeper 
sequencing of the samples could potentially rescue some inefficient variants 
but comes with increased costs.  
In conclusion, the chosen experimental settings in this work were 
appropriate to identify highly efficient and specific AAV capsids in the mouse. 
For upcoming screenings, the parameters from the second in vivo 
characterization study should be copied and library diversities should be 
restricted to a maximum of 100 variants. 
5.1.2 COMPARISON TO PUBLISHED DATA 
After establishing the barcode-based capsid screening pipeline, the output 
values of important benchmarks can be compared to the literature to prove the 
robustness of the system. In this work, the DNA family shuffled variant 
AAVDJ demonstrated superior specificity for the liver (Figure 14) and 
efficiency scores slightly worse than AAV8wt (Figure 11). The efficiency was 
already studied in the original 2008 publication of Grimm et al. by showing 
hFIX expression levels similar to AAV8wt and AAV9wt in vivo up to a certain 
dose172. The specificity on the protein level was shown twice in 2016 by reports 
documenting highly liver-tropic detection of luciferase signals164,178. Of note, in 
all three publications and in this work, C57BL/6 mice were used supposedly 
explaining the comparable outcome. In the third barcode screening, AAVDJ 
had seemingly lost part of its liver specificity and in exchange exhibited 
activity in CD11b- and CD11c-positive cells (Figure 22). However, the applied 
normalization strategy calculates the proportion per cell, thus favoring minor 
cell populations like the mentioned immune cells. Since the liver is one of the 
largest organs, the AAVDJ proportion in this tissue greatly outweighs the off-
targets when calculating the proportion per organ. So far unpublished is the 
selective hepatocyte-targeting of the chimera in an in vivo context (Figure 23), 
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which is congruent with the fact that AAVDJ was selected in human 
hepatocytes. Next to the shuffled vector, such a specific liver sub-cell type 
tropism could only be observed for AAV5_P5 and AAV8_P5.  
Also very impressive are the results obtained for AAV2_L1. This peptide 
displaying variant showed a pronounced specificity for the lung and some off-
targeting to blood cells and the brain (Figure 14). In the original work of 
Körbelin et al.208, the blood cells were not analyzed as an off-target but several 
other tissues were assessed for luciferase expression. Strikingly, the lung/brain 
ratio of AAV2_L1 in the second barcode screening is identical to the one seen 
in Figure 4 of the original publication208. This comparison is especially 
important since both results were obtained with completely different 
techniques, further illustrating the robustness of the barcode-based system.  
Another important benchmark that has recently attracted substantial 
attention in the AAV field is AAV9_PHP.B. This variant that has been selected 
for astrocyte-targeting demonstrated superior efficiency (Figure 11) and 
specificity (Figure 14) in the whole brain where it outcompeted the commonly 
used AAV9wt. This result is consistent with published histology data 219,239–241. 
Of note, Hordeaux and colleagues showed that AAV9_PHP.B activity is 
limited to C57BL/6J mice241 that were, by coincidence, also the mouse strain of 
choice for this work, therefore delivering evidence for the comparable 
outcome. The exceptional case of AAV9_PHP.B is discussed in more detail in 
chapter 5.5. 
Next to the compelling confirmation of the benchmark results, the 
screenings additionally excelled in reproducibility between the screening 
rounds. For instance, AAVrh10wt proved to be the most efficient capsid in the 
liver in all three screens and even outperformed AAV8wt, albeit only 
marginally. In the third screening, AAV8wt was slightly separated from 
AAVrh10wt, mostly by capsids that were newly added in this round. 
Interestingly, the comparable efficiency of AAVrh10wt and AAV8wt has also 
been documented in the literature242. Nathwani et al. also showed highly 
similar vector genomes per cell for both wild types, which could be confirmed 
here in all three capsid screening rounds. Among the top 10 variants in the 
pancreas of the first and second screen, the first eight vectors were in identical 
positions when excluding the newcomers of the second round. In the same 
round, AAV9_P1 was 1.6-fold more effective than AAV9wt in the heart (Figure 
12). The successive screening once more exhibited a 1.6-fold difference between 
the two vectors (Figure 18). These findings and several further, similarly 
consistent results observed in other tissues or for other variants convincingly 
prove the robustness and reproducibility of the barcode-based variant 
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screening pipeline that was established here. This conclusion is of high 
importance since only a stable system can be used to reliably identify the most 
potent variant from a pool of potential lead candidates. 
5.2 CHALLENGES IN RATIONAL CAPSID DESIGN 
The analyzed AAV variants in this work were generated with different 
capsid engineering techniques. Next to the directed evolution approaches like 
DNA family shuffling, peptide display and error-prone PCR that were used to 
create the benchmarks in our screens, over 70 mutants based on the naturally 
occurring serotypes were used that display elsewhere-selected peptides. A 
highly similar panel of viruses was previously tested in our laboratory (work 
of primarily Kathleen Börner and Eike Kienle) and proved to be vastly effective 
in cultured cells in vitro (manuscript in preparation). Interestingly, in this work, 
the peptide-modified vectors behaved very differently as compared to the 
respective wild type versions in mice, clearly exemplifying the very restricted 
transferability between in vitro and in vivo systems. The same effect was also 
observed for commonly used AAV serotypes by exhibiting diverging 
transduction profiles in cell lines243 as compared to the in vivo situation in 
mice153. Plausible explanations are the additional barriers in a living organism 
including the more challenging accessibility of the target tissue and potential 
interactions with the host immune system. Moreover, it has to be noted that a 
direct comparison is difficult since the in vitro screenings were performed in 
one particular cell line whereas mostly whole organs were analyzed in the 
barcode-based screenings.  
Further interesting and useful observations were made when attempting to 
rationally improve capsids by transferring peptides isolated through directed 
AAV evolution between two different capsids. In detail, the natural isolate 
AAV4wt and the previously selected peptide display mutant AAV2_L1208 were 
detected preferentially in the lungs. The fact that AAV2wt itself predominantly 
targets the liver suggested that it is the L1 peptide that mediates the lung 
tropism and thus pointed towards the possibility to further improve AAV4's 
activity in the lung by integrating the L1 peptide into AAV4wt. Curiously, 
though, the resulting AAV4_L1 variant exhibited equal efficiencies as the other 
AAV4-based peptide insertion mutants but remained below that of the 
parental AAV2_L1. This is a very important result as it highlights the 
synergism between capsid backbone and inserted peptide that ultimately 
governs the properties of the resulting synthetic viral particle.  
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A second example supporting this seminal conclusion is AAV9_BR1 that 
was designed here to combine the most potent serotype for brain-targeting, 
AAV9wt, with the brain-homing peptide BR1 from the directed evolution 
variant AAV2_BR1218. Also here, it was observed that the identical peptide led 
to strikingly different particle phenotypes depending on the capsid backbone it 
was presented in, again illustrating the complexity of AAV biology and the 
challenges in rational AAV capsid design.  
A third consistent example from the literature is AAV2_MTP, a variant 
displaying a putative muscle-targeting peptide MTP that was isolated by 
phage display in muscle tissue. The paper reported an enhancement in the 
diaphragm, heart and gastrocnemius after systemic delivery in mice over 
AAV2wt, which is very inefficient in these tissues in vivo 201. While these effects 
could be confirmed for all the muscle tissues in this doctoral work, 90% of 
vector activity was actually measured in the liver. This highlights the 
importance of performing comprehensive screens in a wide variety of tissues, 
as a prerequisite for drawing fair and unbiased conclusions about in vivo 
capsid efficiency and/or specificity.  
Strikingly, we found that even single point mutations can significantly 
change the behavior of AAVs in the complex setting of a mouse. The first 
barcoded variant screening comprised capsids based on AAV4 with a K544E 
mutation, herein referred to as AAV4mut. All members of this family were less 
active in the lung in direct comparison to their wild type parent, AAV4wt. An 
example that the influence of a few mutations can also be negligible was 
AAVDJYF that was introduced to the 3rd generation library and bears three 
tyrosine-to-phenylalanine exchanges that could potentially improve particle 
stability by preventing proteasomal degradation. The beneficial effects of such 
tyrosine mutants was demonstrated previously159,161–163,244 and now applied 
here by mimicking the respective residue alterations of an AAV2 triple 
mutant161 in AAVDJ. Interestingly, the resulting mutant showed the same 
specificity (Figure 22 and Figure 23) and efficiency as AAVDJ, once more 
illustrating the complex interplay of capsid backbone and ectopic 
modifications, such as point mutations here or peptide insertions above. Last 
but not least, AAV9LD_P1 was generated to further enhance the effects of 
AAV9_P1, by including two point mutations P504A and G505A that led to a 
massive detargeting of the liver when integrated into AAV9wt222. This 
published mutant, AAV9LD, was already more specific for the muscle in 
comparison to its parental virus, implying that transfer of these two point 
mutations may improve our own variant. Remarkably, even though only 
minimal changes were made to AAV9_P1, its high efficiency in muscle was 
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actually decreased in exchange for a better liver-detargeting, as seen in the 
histology sections of the analyzed tissues (Figure 29). 
In summary, rationally designing AAV capsids by transferring peptides or 
mutations between two capsids is challenging since the assembled AAV 
particle can be highly sensitive to even minimal variations, ultimately resulting 
in unpredictable phenotypes. This is perhaps best exemplified by our capsids 
resulting from the transfer of peptides that were pre-selected via random 
peptide display in AAV2, such as the P2, P4, P5, A1, A2 and A6, into another 
AAV serotype. In most cases, this integration into a slightly different AAV 
context largely changed particle behavior, most likely due to different steric 
requirements in the exposed capsid regions of closely-related serotypes. Even 
when in vivo selected peptides such as L1 and BR1 were transferred to the same 
integration site of another isolate, this typically yielded a phenotype that 
differed from the parental peptide-modified capsid. Still, two notable 
exceptions were observed in this work, namely AAV9_P1 and AAV9_P3, that 
both use peptides isolated through AAV2 peptide display. Both mutants 
exhibit a remarkable muscle-targeting that most likely results from the 
synergistic action of the capsid backbone and the peptide. Hence, they serve as 
very encouraging examples for how transfer of a given peptide between two 
serotypes can in fact create entirely novel and beneficial capsid features. 
Taken together, the data presented here and literature findings show that 
AAV is a tremendously versatile and promising scaffold for the design of 
synthetic capsids and vectors with original features in vitro and in vivo. 
Concurrently, the presented results also support the notion that additional 
work and knowledge on AAV capsid biology are urgently needed in order to 
realize the potential of rational design, whereby the outcome of a capsid 
modulation including particle stability or receptor interaction can be fully 
predicted in advance. 
5.3 DIRECTED EVOLUTION – THE HOLY GRAIL IN 
CAPSID ENGINEERING? 
Until the field possesses sufficient knowledge to realize rational design of 
AAV capsids, two major capsid engineering techniques, DNA family shuffling 
and random peptide display, showed great promise for the identification of 
more efficient or specific vectors. Both strategies rely on the generation of AAV 
libraries with diversities of around 1x107 novel synthetic variants that are 
subsequently used for transducing cells or animals. Viral genomes are then in 
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most cases PCR-rescued from successfully penetrated cells or organs of 
interest, therefore excluding variants incapable of reaching the target tissue. By 
repeating this procedure for several rounds, candidates are enriched that 
outperform their competitors in terms of e.g. efficiency. In this work, several 
capsids resulting from such a directed evolution scheme were included, either 
from the literature and then serving as benchmarks, or novel variants 
independently isolated by the group members Anne-Kathrin Herrmann and 
Jihad El Andari, which allowed us to assess the potency of these techniques.  
The DNA family shuffled chimera AAVDJ is a very good example for a 
successful selection. The vector reported in 2008 by Grimm and colleagues was 
isolated from human hepatocytes after five consecutive rounds of screening of 
a shuffled capsid library in the presence of intravenous immunoglobulin and 
found to restrict the biodistribution to the liver172. Indeed, these data could be 
verified in the second and third barcode screening where AAVDJ 
demonstrated strong liver-targeting (Figure 14 and Figure 22). Concurrent with 
the original publication, AAVDJ was less efficient than AAV8wt in this organ 
(Figure 11) which is worth noting since directed evolution in theory mainly 
selects for a higher efficiency or in the case of AAVDJ in addition for antibody-
evading features. Most impressively, within the liver the chimera was found 
almost exclusively in hepatocytes, reflecting the selection strategy used for its 
isolation (Figure 23). AAVLK03191, AAVM41189 and the lead candidates of the 
muscle selection (work of Jihad El Andari), AAVJEA3-S1, AAVJEA3-S10, 
AAVJEA3-H15 and AAVJEA3-D20 furthermore support the hypothesis that 
DNA family shuffling is oftentimes yielding vectors with an increased 
specificity. However, none of the mentioned chimeras demonstrated a higher 
efficiency compared to their parental counterparts. The fact that only wild type 
AAV isolates are used for shuffling can potentially explain the phenomenon 
since the resulting chimeras are restricted to the provided sequences of the 
parents. Hence, the chimeric sequences presumably possess a lesser chance to 
form motifs needed for a complete retargeting.  
On the contrary, in random peptide display approaches, novel motifs are 
integrated into the capsids, thus offering the possibility to utilize a different 
entry mechanism. For instance, variants such as AAV9_PHP.B, AAV2_BR1 and 
AAV2_L1 were extracted from peptide displays and show a concurrent 
increase in specificity and efficiency (Figure 11 and Figure 14). Interestingly, 
the potency of the parental backbone for the insertion seems to play a minor 
role as illustrated by AAV2_L1 and AAV2_BR1. AAV2wt itself demonstrated a 
high liver specificity (Figure 13) and in general a weak efficiency in all tissues 
(Figure 10). Nevertheless, the incorporation of nine additional amino acids 
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converted the capsid to a particularly effective and specific mutant. Once more, 
the less important native activity of the parental wild type capsid for peptide 
display is in contrast to DNA family shuffling where enriched chimeras are 
oftentimes comprised of sequences from efficient serotypes in the respective 
organ or cells where they were selected in. For example, AAVDJ is a mixture of 
AAV2wt, AAV8wt and AAV9wt from which especially AAV8wt exhibited 
high efficiency in the liver (Figure 11). However, the chimera has the highest 
homology to AAV2wt, deviating in 60 amino acids. AAV2wt proved to be 
vastly effective in vitro, especially in the human hepatoma cell lines Huh7 and 
HepG2 (doctoral thesis of Eike Kienle), the cells AAVDJ was isolated from. 
Another example are the muscle-tropic chimeras of Jihad El Andari that 
comprise long stretches of the most potent wild type in the muscle, AAV9wt, 
at the C-terminus (data not shown). Finally, the shuffled variant AAVAH3-5, 
selected in stellate cells, consists of mainly AAV1wt (doctoral thesis of Anne-
Kathrin Herrmann), a serotype demonstrating a surprisingly similar efficiency 
(4.5) and specificity (Figure 20 and Figure 21) in the on-target further 
supporting the abovementioned theory. 
One very important aspect when choosing one of the two directed evolution 
approaches for the development of a tailored variant is the monitoring of the 
library during the selection. During every round, the library composition will 
change, which yields vital information about the enrichment of certain motifs. 
However, tracking a library created through DNA family shuffling is 
challenging since the whole 2.2 kb-long capsid gene undergoes alterations. 
Traditional Illumina sequencing cannot resolve these changes since 
homologous sequences are needed for the required alignment. Recently, 
another sequencing technology became available, namely PacBio sequencing221. 
The advantages are the particularly long read lengths covering the 2.2 kb with 
ease. Regardless, the system requires improvements since the total number of 
reads, roughly 50.000-100.000, cannot cover typical library diversities of up to 
1x107. In addition, the system is more expensive than traditional sequencing 
and, in its current iteration, introduces many insertions and deletions to the 
sequences based on our own experiences, which complicates the analysis. 
Random peptide libraries pose an advantage as one can readily exploit 
Illumina sequencing due to the only ~30 bp-long peptide-encoding DNA 
stretch that has to be resolved. Thereby, up to 450 million reads per sample can 
be generated when using the NextSeq500, which exceedingly covers a typical 
library. Accordingly, monitoring of every selection round can identify peptides 
with increasing abundance, as was perfectly exemplified in the original 
publication of AAV2_BR1218. By concomitantly also sequencing off-targets, the 
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collective information can be utilized to calculate the enrichment scores in the 
on-target while simultaneously determining tissue specificity208.  
In general, to obtain organ-specific variants, the number of selection rounds 
is crucial for both mentioned directed evolution strategies. Most tissue-specific 
published vectors resulted from five iterative rounds and therefore had to 
survive a strong selection pressure. Attempts to save time by lowering the 
repetitions increases the riskto obtain sub-optimal progeny, as exemplified by 
the chimera AAVB1, a variant that was selected for central nervous system-
targeting after only one selection round190. Instead, the variant possesses a 
pronounced liver specificity (Figure 24). A second example are the chimeric 
muscle-tropic vectors from our laboratory that underwent either two or three 
selection rounds. All chimeras experiencing only two cycles were 
predominantly found in the liver followed by CD11b- and CD11c-positive cells 
as well as fat tissue. Notably, the four lead candidates with increased muscle-
targeting, AAVJEA3-S1, AAVJEA3-S10, AAVJEA3-H15 and AAVJEA3-D20, 
were all extracted after three rounds. One exception is the brain-specific 
peptide display mutant, AAV9_PHP.B, that was isolated after the second 
round of selection. The fact that this relatively short selection scheme was still 
successful is perhaps explained by the use of the novel CREATE system, in 
which only those viral genomes that had undergone Cre-mediated 
recombination in astrocytes can be rescued, which substantially raised the 
stringency of the system219. 
In conclusion, directed evolution is currently arguably the most promising 
method to identify highly selective and effective capsids, especially after 
several selection rounds. Clearly and not surprisingly, a major challenge is to 
selectively and robustly target individual cells types. Although AAVDJ 
managed to preferentially hit hepatocytes, the lead candidate of our laboratory 
from a stellate cell selection, AAVAH3-5, additionally transduced Kupffer cells 
and LSECs (Figure 21) indicating a limit for a highly specific tissue-targeting 
when solely relying on the capsid. Nevertheless, specificity can be enhanced by 
combining a beneficial capsid with tissue-specific promoters or cis-acting 
elements for the transcriptional regulation with endogenous mRNAs. Last but 
not least, synthetic AAVs generated by directed evolution strategies are 
simultaneously selected for a potent production efficiency (experiences made 
in our laboratory), which is essential considering the immense manufacturing 
effort to yield high titers for clinical trials245. 
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5.4 AAV9_P1 – AN UNEXPECTED NEWCOMER FOR 
MUSCLE GENE THERAPY 
Genetic disorders leading to muscle diseases are ideal targets for an AAV-
based gene therapy. In order to reach every affected muscle tissue in the whole 
body, an intravenous administration is required creating challenges concerning 
immune responses and off-targeting effects. To date, AAV9wt proved to be the 
most efficient wild type AAV in multiple animals229 therefore qualifying it for 
the use in clinical trials. However, this work revealed a strong bias towards the 
liver for the naturally occurring isolate (Figure 13 and Figure 24), illustrating 
the existing room for improvement and the urgent need in the AAV field of 
new, potent and muscle-tropic vectors that could foster the implementation of 
gene therapies for many muscle diseases.  
Surprisingly, a capsid added in the second barcode library, AAV9_P1, 
showed superior efficiency in the diaphragm, heart, biceps and quadriceps 
femoris (Figure 12 and Figure 18). In addition, it also exhibited a greatly 
improved specificity as compared to AAV9wt (Figure 15 and Figure 25). 
Importantly, separate validation of this capsid out of the library context could 
confirm the results on the cDNA (Figure 26) and protein level (Figure 29). In 
strong contrast to AAV9wt, the P1-displaying variant detargets the liver and 
many other organs, restricting ~70% of its activity to the muscles. These 
striking effects are caused by integrating the nine amino acid-long peptide 
GRGDLGLSA into the AAV9 capsid protein after position 588 (in VP1). The 
peptide, herein referred to as P1, was originally discovered during the 
screening of a random peptide display library based on AAV2wt inmurine 
breast cancer PymT cells213. In the course of his doctoral work in the Grimm 
laboratory, Eike Kienle had incorporated promising peptides from the 
literature, including P1, into AAV9 and 11 other AAV serotypes, with the aim 
to study the interplay of capsid and peptide concerning particle efficiency and 
specificity.  
Indeed, this prior work resulted in the identification of numerous 
combinations of capsid and peptide that often surpassed the parental wild type 
in a vast collection of cell types in culture. This comprises AAV9_P1 which 
clearly outperformed AAV9wt and many other capsids in cultured human 
astrocytes where it was the lead candidate202, as found and published together 
with a collaboration partner (Ruth Brack-Werner) at the Helmholtz Center in 
Munich. Intriguingly, the same capsid as well as the closely related AAV9_P3 
behaved very differently in this work in peripherally injected mice, as 
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discussed above. Interestingly, P1 (GRGDLGLSA) and P3 (GRGDAVGVA) 
both comprise an RGD motif that was shown to interact with integrins196,246,247 
suggesting an alternative entry mechanism potentially independent of the used 
N-linked galactose101,102, AAVR87 or LamR90. Of note, P2 (GCDCRGDCFCA) 
displayed by AAV9wt was markedly less efficient than its parent and not 
found in the top 10 in the analyzed muscle tissues (Figure 7), despite 
containing an RGD motif. In contrast to P1 and P3, the motif starts three amino 
acids later potentially explaining the differences. This hypothesis is 
furthermore backed up by AAV9_K3 which comprises a peptide 
(GRGDLRVSA) that is highly similar to P1, deviating in only two amino acids. 
Stunningly, AAV9_K3 was predominantly detected in the liver (Figure 24) and 
demonstrated a ~20-fold reduction in efficiency as compared to AAV9_P1 in 
the skeletal muscles and 6-fold in the heart. Importantly, K3 was integrated 
after amino acid 589 thereby marginally altering the position of the RGD motif. 
In conclusion, the exact position of the motif seems to be of high importance 
whereas the successive amino acids can tolerate more changes without losing 
the beneficial effects, as exemplified by AAV9_P3. The exact role of the RGD-
comprising peptide in the context of AAV9 and related capsids for muscle and 
astrocyte transduction is a matter of ongoing investigation in our group and 
the collaboration partner in Munich. By integrating P1, a ~10-fold reduction in 
the liver was observed in comparison to AAV9wt, indicating that fewer virus 
particles are trapped in the liver, which may add to the observed pronounced 
muscle activity. In fact, a double point mutation variant published by Adachi et 
al., AAV9LD222, largely detargets the liver by ~100-fold and concurrently 
showed higher specificity for the muscle tissues (Figure 24). However, 
transferring these two mutations to AAV9_P1 greatly diminished the 
expression of EGFP in the muscle sections (Figure 29), suggesting an even 
more complex correlation. 
In summary, based on the information provided by this work, the question 
remains whether the peptide-induced beneficial effects in the muscles are due 
to an improved muscle homing, the detargeting from the liver or a 
combination of both factors. Regardless of mechanism, the tremendous 
potential of AAV9_P1 as a candidate for muscle-directed gene therapy is 
obvious and undisputed. Currently, extremely high doses exceeding 
1x1014 vg/kg are injected into animals in order to reach curative effects with the 
best vector on the market, AAV9wt (American Society of Gene and Cell 
Therapy, ASGCT 2018). By using AAV9_P1, the vector load could be reduced 
by at least 10-fold while maintaining high levels of transgene expression and 
additionally limiting the transcriptional activity predominantly to the muscle 
tissues, thus preventing unwanted off-targeting effects. Furthermore, since 
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AAV9_P1 produces as efficiently as AAV9wt, injecting lower doses would 
significantly decrease manufacturing costs and ultimately lower the prize for a 
related gene therapy product. 
5.5 RESTRICTED TRANSFERABILITY – YOU GET 
WHAT YOU SCREEN FOR 
Many synthetic AAV variants have been generated over the last 15 years by 
directed evolution approaches, trying to develop more efficient vectors for the 
transduction of cells or organs. This work showed that results obtained from 
published variants can indeed be reproduced when recapitulating the same 
experimental outlines. For instance, AAV2_L1 was selected for the murine lung 
after intravenous injection and demonstrated a drastically increased efficiency 
and specificity208. This could be confirmed after intravenously injecting the 
barcoded AAV library comprising AAV2_L1 into C57BL/6J mice. However, 
changing the injection route most likely alters the properties of a selected 
variant, as exemplified by AAV2_7m8186. Dalkara et al. intravitreally injected an 
AAV library in search of a lead candidate for the outer retina. The resulting hit, 
AAV2_7m8, was able to rescue two retinal diseases in mouse models186. Here, 
the peptide display mutant was added to the 2nd generation library. Notably, it 
showed a 90% specificity for the liver after systemic application, supporting 
the theory that the injection route should be kept constant to achieve the same 
result.  
Another crucial aspect is the target tissue that was used for the selection. 
The shuffled chimera AAVLK03 was extracted from human hepatocytes in a 
xenograft mouse model and showed high efficiency in the human cells, in 
contrast to poor transduction of murine hepatocytes191. In this doctoral work, 
this variant was tested in a murine liver and exhibited a 200-fold lower activity 
than AAV8wt albeit 91% of LK03 targeted the liver. Hence, in the absence of its 
on-target (human hepatocytes), AAVLK03 exhibited a unique behavior. The 
same applies for the variants AAV9_K1 and AAV9_K3 that were selected on 
human coronary artery endothelial cells215. Both vectors were predominantly 
liver-tropic in the present work, barely showing any specificity for the heart in 
vivo.  
Arguably the most important factor is the transferability of a selected AAV 
variant to clinically relevant animal models such as non-human primates and 
eventually to humans. The challenges are best exemplified by the brain-
targeting peptide display mutant AAV9_PHP.B. Deverman and colleagues 
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isolated the capsid after two selection rounds in C57BL/6J mice utilizing their 
novel CREATE system and demonstrated superior efficiency and specificity 
compared to AAV9wt219. These effects could be fully confirmed in this work 
(Figure 11 and Figure 14). However, follow-up publications by Matsuzaki et al. 
and Hordeaux et al. could not prove the superiority of AAV9_PHP.B in the 
marmoset239 and rhesus macaques241 brain, respectively. Furthermore, 
unpublished work from the groups of Gray-Edwards and Sena-Esteves 
presented at the ASGCT conference in 2018 showed no transduction increase in 
the sheep and cat brain. Most strikingly, the abovementioned publication by 
Hordeaux et al. in addition demonstrated a discrepancy between the mouse 
strains C57BL/6J and BALB/cJ. The impressive features of AAV9_PHP.B were 
entirely absent in BALB/cJ mice, indicating a lack of transferability even within 
the same species. Nevertheless, it has to be noted that, for example, AAV2_L1 
and AAV2_BR1 were selected in FVB/N mice and validated in this work in 
C57BL/6J mice, suggesting that AAV9_PHP.B may represent an exceptional 
case. 
In summary, isolating and characterizing a variant for a specific application 
does not guarantee similar results when altering the injection route or the 
animal model, or when switching from in vitro to in vivo. Thus, the notable 
effects observed for AAV9_P1 in mice should be considered with caution. 
Nonetheless, it is certain that AAV9_P1 is a superior variant for muscle-
targeting in C57BL/6J mice after intravenous injection. However, the 
transferability to higher animal models has to be elucidated first prior to 
considering AAV9_P1 as a potential vector for clinical trials. Generally, to 
increase chances to obtain capsids that are relevant for use in humans, it seems 
advisable to perform library selections directly in non-human primates. 
Although the initial costs would be significantly higher and ethical 
considerations will have to be made, costs may be saved in the long run since 
fewer validations have to be performed due to the increased chance for 
enhanced transferability of resulting lead candidates. 
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5.6 CONCLUSIONS AND PERSPECTIVES 
In the course of this doctoral work, a barcode-based AAV capsid screening 
pipeline was established allowing the simultaneous tracking of over 100 
variants in the context of a living organism. The applied comprehensive 
normalization strategy produces essential values denoting the specificity and 
efficiency of every analyzed barcoded AAV. The system turned out to be 
highly robust and especially helpful for the characterization of lead candidates 
after directed evolution approaches, consequently reducing animal numbers 
and downstream processing. These benefits not only promote a barcode-based 
capsid screening in higher animals such as non-human primates, but 
furthermore allow applying the pipeline to answer capsid-unrelated questions. 
For instance, different doses of the same vector, represented by corresponding 
barcodes, can be tested in one organism, once more omitting high animal 
numbers. Even the transduction differences143,144 between barcode-labeled self-
complementary and single-stranded AAV genomes could be assessed in more 
detail exemplifying the enormous potential of this technology. 
The P1-displaying variant AAV9_P1 was an unexpected discovery of the 
herein used barcode-based capsid screenings, demonstrating superior 
efficiency in the muscle tissues and increased muscle-targeting on the 
transcript and protein level. The question remains how AAV9_P1 mediates the 
improved effects and how crucial the placement of the RGD motif is. One 
simple experiment might be to generate mutants comprising a slightly shifted 
P1 peptide by one amino acid upstream or downstream. Additionally, an 
alanine walk should elucidate the importance of each position. Although P1 
was originally extracted by Michelfelder et al.213 and found once more in 2016 
by Körbelin et al.208, the peptide was selected in the context of AAV2 and 
therefore not optimized for AAV9. Hence, based on the information provided 
by altering the RGD position and the alanine walk, amino acids that are 
essential for the improvements in the muscle tissues can be fixed while the 
remaining ones offer the possibility to be randomized. The resulting peptide-
displaying AAV library can subsequently be screened in muscles tissues for 
new mutants with an improved P1 peptide. In conclusion, despite the already 
great promise of AAV9_P1, the development of an optimized muscle-tropic 
gene therapy vector will continue, raising hopes to eventually be able to cure 
patients with severe muscle diseases. 
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Figure 30: Transcriptional efficiency in various tissues 
Bar plots show the transcriptional efficiency as normalized proportion of the top 10 AAV 
variants of the 1st generation library in the abdominal aorta, thoracic aorta, brain, colon, 
duodenum, brown fat, white fat, inner ear, kidney, pancreas and spleen. The cDNA values 
are the average from six C57BL/6J mice with SD. 
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Figure 31: Transduction efficiency in various tissues 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 1st generation library in the abdominal aorta, thoracic aorta, brain, colon, 
diaphragm, duodenum, eye, brown fat and white fat. The gDNA values are the average 
from six C57BL/6J mice with SD. 
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Figure 32: Transduction efficiency in various tissues 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 1st generation library in the heart, inner ear, kidney, liver, lung, pancreas, 
quadriceps femoris and spleen. The gDNA values are the average from six C57BL/6J mice 
with SD. 
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Figure 33: Transcriptional efficiency in various tissues 
Bar plots show the transcriptional efficiency as normalized proportion of the top 10 AAV 
variants of the 2nd generation library in the abdominal aorta, thoracic aorta, brain, colon, 
duodenum, brown fat, white fat, inner ear, kidney, pancreas and spleen. The cDNA values 
are the average from six C57BL/6J mice with SD. 
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Figure 34: Transduction efficiency in various tissues 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 2nd generation library in the abdominal aorta, thoracic aorta, blood cells, 
brain, colon, diaphragm, duodenum, eye, brown fat, white fat, heart and inner ear. The 
gDNA values are the average from six C57BL/6J mice with SD. 
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Figure 35: Transduction efficiency in various tissues 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 2nd generation library in the kidney, liver, lung, ovaries, pancreas, quadriceps 
femoris, spleen, stomach. The gDNA values are the average from six C57BL/6J mice with 
SD. 
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Figure 36: Composition of 3rd generation library 
134 SUPPLEMENTARY INFORMATION 
 
 
Figure 37: Biodistribution of all variants of the 3rd generation library 
Calculated Bαβ values are depicted as a heat map simultaneously illustrating the 
transcriptional efficiency and specificity of all variants in the 3rd generation library in the 
aorta (A), biceps (Bi), colon (C), diaphragm (Di), duodenum (Du), eye, brown fat (FatB), 
white fat (FatW), heart (H), inner ear (I), kidney (K), liver (Li), lung (Lu), ovaries (O), 
pancreas (P), quadriceps femoris (QF), stomach (St) and CD3-, CD19-, CD11b- as well as 
CD11c-positive cells. A logarithmic scale is used with blue representing the value 0, white 
0.37 and red 3.71. 
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Figure 38: Transcriptional efficiency in various tissues 
Bar plots show the transcriptional efficiency as normalized proportion of the top 10 AAV 
variants of the 3rd generation library in the aorta, colon, duodenum, kidney, ovaries, 
pancreas and stomach. The cDNA values are the average from four C57BL/6J mice with SD. 
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Figure 39: Transcriptional efficiency in brain cells 
Bar plots show the transcriptional efficiency as normalized proportion of the top 10 AAV 
variants of the 3rd generation library in the astrocytes and oligodendrocytes of the cortex as 
well as the neuroblasts and oligodendrocytes in the subventricular zone (SVZ). The cDNA 
values are the average from six C57BL/6J mice with SD. 
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Figure 40: Transduction efficiency in various tissues 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 3rd generation library in the aorta, biceps, colon, diaphragm, duodenum, eye, 
brown fat, white fat and heart. The gDNA values are the average from four C57BL/6J mice 
with SD. 
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Figure 41: Transduction efficiency in various tissues 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 3rd generation library in the inner ear, kidney, liver, lung, ovaries, pancreas, 
quadriceps femoris and stomach. The gDNA values are the average from four C57BL/6J 
mice with SD. 
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Figure 42: Transduction efficiency in liver cell types 
Bar plots show the transduction efficiency as normalized proportion of the top 10 AAV 
variants of the 3rd generation library in hepatocytes, Kupffer cells, liver sinusoidal 
endothelial cells (LSECs) and stellate cells. The gDNA values are the average from four 
BALB/c mice with SD. 
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Figure 43: EGFP fluorescence of PBS and AAV9wt group 
Images show 10 µm cryosections of the liver, diaphragm, heart, biceps and quadriceps 
femoris. Representative sections were chosen from C57BL/6J mice injected with 
5x1011 vg/mouse of AAV9wt or PBS as a control. Direct EGFP fluorescence was detected 
(green) together with the DAPI signal (blue). Scale bar in the full section is 1 mm and 
100 µm for the 10x magnification. Exposure was normalized to the liver of the AAV9wt 
group. 
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Figure 44: EGFP fluorescence of AAV9_P1 and AAV9LD_P1 group 
Images show 10 µm cryosections of the liver, diaphragm, heart, biceps and quadriceps 
femoris. Representative sections were chosen from C57BL/6J mice injected with 
5x1011 vg/mouse of AAV9_P1 or AAV9LD_P1. Direct EGFP fluorescence was detected 
(green) together with the DAPI signal (blue). Scale bar in the full section is 1 mm and 
100 µm for the 10x magnification. Exposure was normalized to the liver of the AAV9wt 
group (Figure 43). 
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